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Abstract 
 
Successful haemodialysis depends on the availability of safe, efficient, and durable 
access to the vascular tree.  This can be provided by creation of an arteriovenous 
fistula, insertion of a synthetic vascular graft or insertion of a central venous catheter. 
Established haemodialysis vascular access is associated with a number of important 
complications which can impact significantly on both the quality of life and survival 
of haemodialysis patients. 
 
The primary aim of this thesis was to perform a detailed evaluation of the risks to 
health conferred by haemodialysis vascular access and its maintenance in patients 
with advanced renal failure.   
 
The work described in this thesis describes the relative strength and independence of 
association  between  haemodialysis  vascular  access  type  and  risk  of  mortality, 
bacteraemia and catheter thrombosis.  Greater clarity is demonstrated on the relative 
effect of heparin-based haemodialysis catheter lock solutions on markers of systemic 
coagulation in vivo, whilst the in-vitro variability of antimicrobial activity  against 
planktonic and biofilm-embedded staphylococci achieved with catheter lock solutions 
containing heparin and vancomycin, alone and in combination, is clearly shown. 
 
New insights are gained into the benefits of contrast magnetic resonance venography 
as  a  tool  for  demonstrating  thrombosis  and  stenosis  of  the  central  veins  in  the 
assessment of vascular access in haemodialysis patients.  Similarly, the emergence of   3 
a  new  disease,  nephrogenic  systemic  fibrosis  was  found  and  its  association  with 
gadolinium-enhanced magnetic resonance imaging was explored in detail.   
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Summary 
 
The aim of this thesis was to perform a detailed evaluation of the risks to health 
conferred by haemodialysis vascular access and its maintenance. 
  
The first part of this thesis examines the relationship between haemodialysis vascular 
access, bacteraemia and mortality.  A retrospective analysis of vascular access type 
and  subsequent  outcome  in  all  265  prevalent  haemodialysis  patients  attending 
Glasgow Royal Infirmary Renal Unit on a given date was conducted.  Multivariate 
analyses  of  clinical  and  laboratory  variables  demonstrated  an  especially  strong, 
independent relationship between the type of haemodialysis vascular access in use 
and risk of bacteraemia and death.  When considering bacteraemia tunnelled catheters 
and  non-tunnelled  catheters  were  each  independently  associated  with  adverse 
outcome  compared  to  arteriovenous  fistulae  (tunnelled  HR  5.43  (p<0.001);  non-
tunnelled HR 3.14 (p=0.01)).  When considering mortality tunnelled catheters and 
non-tunnelled  catheters  were  each  independently  associated  with  adverse  outcome 
compared to arteriovenous fistulae (tunnelled HR 2.75 (p=0.012); non-tunnelled HR 
3.39 (p=0.001)). 
 
The role of the central venous catheter in determining outcome was then explored in 
greater  detail  by  a  two-year  prospective  analysis  of  all  patients  undergoing 
haemodialysis catheter insertion in Glasgow Royal Infirmary.  This study evaluated 
independent risk association between clinical and laboratory variables and instances 
of  catheter-related  bacteraemia  and  catheter  thrombosis  for  each  catheter  type  by 
univariate  and  multivariate  analysis.    Over  the  period  of  observation  823  central   23 
venous  catheter  insertion  procedures  were  conducted.    Tunnelled  central  venous 
catheters (TCVCs) were associated with lower rates of bacteraemia and thrombosis 
than  non-tunnelled  central  venous  catheters  (NTCVCs),  independent  of  whether 
patients have acute or chronic renal failure, high levels of comorbidity and levels of 
routinely recorded biochemical and haematological parameters.  Using TCVCs as a 
comparator, a hierarchy of risk association within the NTCVC insertion procedures 
was found with catheterisation of the internal jugular veins to be the best NTCVC 
insertion  procedure  (bacteraemia  HR  =  2.93,  p<0.001  /  thrombosis  HR  =  4.65, 
p<0.001), followed by insertion of a femoral venous catheter (bacteraemia HR 5.97, 
p<0.001 / thrombosis HR = 9.23, p<0.001).  Catheter-exchange over a guidewire was 
associated  with  especially  high  risks  of  bacteraemia  and  thrombosis  (femoral 
exchanges,  bacteraemia  HR  =  9.84,  p=0.002  /  thrombosis  HR  =  11.73,  p<0.001; 
internal jugular exchanges, bacteraemia HR = 6.42, p<0.001 / thrombosis HR = 5.26, 
p<0.001). 
  
The second part of this thesis evaluates the performance of catheter lock solutions. 
This  was  explored  by  a  prospective,  randomised,  controlled  comparison  of 
heparinised catheter lock solutions in 28 consecutive patients undergoing NTCVC 
insertion.  Heparin 1000iu/mL incurred less disruption of systemic coagulation than 
heparin 5000iu/mL, without an obvious loss in clinical utility.  When expressed as the 
percentage rise in activated partial thromboplastin time (APTT) at 10 minutes post 
catheter locking, the difference between groups amounted to a rise in APTT of 22.2% 
(range 0, 210) in the heparin 1000iu/mL group compared with 373.7% (range 133, 
800) in the heparin 5000iu/mL group (p<0.001).  
   24 
An  in-vitro  assessment  of  combined  anti-microbial/anticoagulant  catheter  lock 
solutions was then conducted.  This studied six isolates of staphylococcus aureus in 
planktonic and biofilm models with regard to their response when exposed to heparin 
and vancomycin solutions alone and in combination.  Heparin had the capacity to 
enhance  and  suppress  staphylococcal  growth,  depending  upon  the  strain  studied.  
When combined with vancomycin heparin appeared to increase its potency although 
not  in  a  dose-dependent  way.    The  relative  resilience  of  biofilm-embedded 
staphylococci  to  vancomycin  compared  with  planktonic  staphylococci  was 
demonstrated. 
 
The third part of the thesis begins with a retrospective evaluation of 78 consecutive 
magnetic  resonance  venograms  conducted  in  haemodialysis  patients  with  poorly 
functioning  vascular  access.    A  significant  association  was  found  between  the 
frequency  of  vascular  access  procedures  and  the  frequency  of  acquired  structural 
abnormalities of the central venous system seen on magnetic resonance venography 
(central venous stenosis on imaging; arteriovenous fistulae or grafts p=0.04, central 
venous  catheters  p=0.034).    It  was  noted  that  within  this  cohort  a  significant 
proportion  of  patients  were  found  to  have  developed  the  relatively  new  disease 
nephrogenic systemic fibrosis (NSF).   
 
The next chapter describes a case-control analysis of NSF cases in all 1826 patients 
who underwent renal replacement therapy over a six and a half year period in North 
Glasgow.  This demonstrated a significant association between gadolinium-enhanced 
magnetic resonance imaging (MRI) and development of NSF (proportion of patients 
exposed to MRI, non-NSF 408/1812, 22.5% v NSF 13/14, 92.9%, p<0.001).  Patients   25 
with NSF were exposed to a significantly higher total dose of gadodiamide than their 
non-NSF counterparts (median 45ml v 30ml, p<0.001), indicating dose-dependency.  
This  was  further  supported  by  weight-adjusted  data  (median  0.39mmol/kg  v 
0.23mmol/kg, p=0.008). 
 
In conclusion, the work described in this thesis demonstrates the relative strength and 
independence of association between haemodialysis vascular access type and risk of 
mortality,  bacteraemia  and  catheter  thrombosis.    Greater  clarity  has  been 
demonstrated  on  the  relative  effect  of  heparin-based  haemodialysis  catheter  lock 
solutions on markers of systemic coagulation in vivo, whilst the in-vitro variability of 
antimicrobial  activity  against  planktonic  and  biofilm-embedded  staphylococci  with 
heparin and vancomycin, alone and in combination, has demonstrated the need for 
more  rigorous  evaluation  and  selection  of  potential  haemodialysis  catheter  lock 
solutions.  New insights were gained into the risks and benefits of contrast magnetic 
resonance venography in the assessment of vascular access in haemodialysis patients.   
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Chapter 1 
 
Introduction 
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1.1 Chronic Kidney Disease 
 
Chronic kidney disease  (CKD) is an important condition with considerable public 
health implications.  It affects a significant proportion of the general population and, 
when progressive, has an increasing impact on morbidity and mortality.  CKD is an 
independent risk factor for cardiovascular disease and the development of established 
renal  failure  (ERF).    Once  a  patient  reaches  ERF,  quality  of  life  has  become 
invariably poor and life expectancy considerably shortened.  Through the provision of 
renal replacement therapy (RRT) survival and quality of life of ERF patients can be 
markedly improved.   
 
CKD places a considerable demand on medical resources around the  world.  The 
United States Renal Data System (USRDS) report of 2008 describes  expenditures 
associated with CKD as having more than doubled over the past 10 years, from 11.3% 
of the total Medicare budget in 1996 to 24.5% in 2006.  Costs for Medicare patients 
with CKD exceeded $49 billion in 2006.  The increasing cost of CKD to the US 
population is demonstrated in figure 1.1. 
 
When considering the cost of providing RRT to the ERF population, the cost per 
patient rises significantly.  In 2006 the prevalence of ERF patients maintained on RRT 
in the United States was 506,256.  In that year total Medicare spending on patients 
with ERF rose to $23 billion which accounted for 6.4% of the entire Medicare budget 
(1).   
 
   28 
 
 
Figure 1.1 - Expenditure in the Medicare (1993-2006) and Medstat (2000-2006) populations of the 
United States.  (Adapted, with permission, from the USRDS Annual Report, 2008). 
 
In order to understand the resource implications of CKD and ERF, there is a pressing 
need  to  develop  our  understanding  of  their  epidemiology.    Historically,  many 
estimates  of  CKD  incidence  were  drawn  from  population  studies  using  varied, 
arbitrary definitions of renal impairment.  In one such study in 2003, by defining 
CKD as a serum creatinine level of ≥150µmol/L for 6 months, the annual incidence of 
detected CKD was determined as 1,701 per million population (2).  An earlier study 
of advanced renal failure used a cut off of >500µmol/L and reported an incidence of 
148 patients per million population (3).  Whilst these data were of significant interest, 
their clinical applicability was undermined by the use of serum creatinine as opposed 
to  glomerular  filtration  rate  when  wishing  to  consider  the  absolute  level  of  renal 
function. 
 
The publication of the NKF/DOQI clinical guidelines in 2002 greatly improved our 
ability  to  study  the  epidemiology  of  CKD.    These  guidelines  gave  a  universally 
applicable definition of CKD as either kidney damage for >3months accompanied by   29 
pathological or functional abnormalities of the kidney or a glomerular filtration rate of 
<60mL/min/1.73m
2  for  >3  months.    This  definition  was  further  refined  by  sub-
division  into  a  5-stage  CKD  classification.    Stage  1  was  defined  as  an  estimated 
glomerular filtration rate (eGFR) of >90 mL/min and either >20 mg/dL of albumin in 
the urine, an albumin/creatinine ratio ≥30 mg/g, or other evidence of structural kidney 
damage.  A similar definition was applied to stage 2 although with an eGFR range of 
60–89.  Stages 3, 4, and 5 were defined solely by eGFR ranges of 30–59, 15–29, and 
less than 15, respectively (4).  By applying this structure to US data from the National 
Health and Nutrition Examination Survey (NHANES), the prevalence of CKD stages 
1, 2, 3 and 4/5 was determined as 3.2%, 4.1%, 7.8% and 0.5% respectively.  Recent 
USRDS data from 1999-2004 suggest an overall CKD prevalence of 16.8% in the 
U.S. population aged  20 years (5).  This relatively high prevalence translates into a 
significant lifetime risk of developing ERF.  In the US in 2002, Kiberd and Clase 
determined cumulative lifetime risk of ERF for a 20-yr-old
 black female, black male, 
white male and white female as 7.8%, 7.3%,
 2.5%, and 1.8% respectively.  These 
risks equated to the lifetime risks of breast, prostate and colorectal malignancies in the 
same population (6). 
 
There is a relative wealth of data on the epidemiology of ERF compared with that of 
CKD.    This  is  due  to  many  countries  with  established  RRT  services  engaging  in 
comprehensive data collection programs overseen by national registries.  These data 
have  proven  an  invaluable  resource  in  assessing  service  provision,  establishing 
clinical standards and providing reproducible audit measures.  Such data, collected 
year on year, have provided an insight into recent and expected trends within the RRT 
population.     30 
1.2 Current Trends in Renal Replacement Therapy  
 
The provision of renal replacement therapy (RRT) prolongs survival in patients with 
established renal failure (ERF) and in most cases improves quality of life.  RRT may 
be  provided  by  renal  transplantation,  haemodialysis  or  peritoneal  dialysis.    Over 
recent years the prevalent number of patients on RRT in the UK and around the world 
has been rising (figure 1.2) (7). 
 
 
 
 
 
 
 
 
Figure 1.2 – Growth in prevalent UK patients by treatment modality at the end of each year 1982-2006 
(Adapted, with permission, from the UK Renal Registry Tenth Annual Report, 2007).  
 
At the end of 2006, the UK Renal Registry reported the prevalence of adult patients 
receiving renal replacement therapy in the UK as 43,901.  This amounts to a UK 
prevalence of 725 per million population (7).  Over recent decades the UK population 
prevalence of RRT has risen steadily in line with other developed countries within 
Europe, Australasia and the Americas (1, 8, 9).  This is predominately due to a trend 
of  rising  incidence  of  starting  RRT  over  recent  decades  (figure  1.3)  and  slowly 
increasing survival (figure 1.4) (10). 
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Figure 1.3 - Incident rates of RRT uptake in the countries of the UK: 1990-2006.  (Adapted, with 
permission, from the UK Renal Registry Tenth Annual Report, 2007). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Change in one-year, after 90 day, adjusted (age 60) survival, 1999-2005 within the UK 
Renal Registry participating centres from 1999 only (left) and all centres over time within the UK 
(right).  (Adapted, with permission, from the UK Renal Registry Tenth Annual Report, 2007). 
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In 2006 the incidence of starting RRT in the UK was 113 per million population, a 
rise from 110 per million population in 2005.  The age adjusted (60 years) one-year 
survival for the prevalent RRT population was 87.7% in 2006 compared with 84.9% 
in 2000 (7).  The rise in RRT incidence over recent decades is predominately due to 
an  increase  in  the  availability  of  renal  replacement  therapy  programs  around  the 
world.    This  has  led  to  more  inclusive  RRT  acceptance  policies  with  a  resultant 
expansion  in  the  numbers  of  elderly  patients  and  those  with  comorbidity  such  as 
diabetes and vascular disease.  This phenomenon is demonstrated in figure 1.5 below. 
 
 
Figure 1.5 – Primary renal diagnosis of patients aged 75 years and older starting RRT in Scotland 
1980-2004. (Adapted, with permission, from the Scottish Renal Registry Report 2002-2004). 
  
The elderly now represent the fastest growing group of prevalent patients on RRT.  
An analysis of age ranges within the Scottish RRT population over the past 50 years 
is demonstrated in figure 1.6.  This shows a steady expansion in the proportion of 
patients aged between 65 and 74 years of age, and those greater than 75 years of age.  
In 2004 the median age of patients starting RRT in Scotland was 65.3 years compared   33 
with a median age of 60.9 years in 1995 (11).  These findings are similarly reflected 
in data recently reported by the UK Renal Registry, European Renal Registry and 
USRDS (1, 7, 9). 
 
 
Figure 1.6 – Age distribution of patients when starting RRT 1960-2004. (Adapted, with permission, 
from the Scottish Renal Registry Report 2002-2004). 
 
It also appears that as the RRT population ages, the burden of comorbidity within the 
population  increases.    The  UK  Renal  Registry  publishes  a  standardised  list  of 
accepted  comorbid  conditions.    This  contains  a  range  of  diagnoses  covering 
cardiovascular  diseases,  diabetes,  chronic  obstructive  pulmonary  disease,  liver 
disease, malignancy and smoking.  From this list, the degree of comorbidity expressed 
within the UK RRT population has been found to vary between ethnic groups, with 
white patients tending to exhibit a higher prevalence of comorbid illness than those 
patients  from  Black,  Asian,  Chinese  or  other  ethnic  populations.    Throughout  all 
ethnicities, however, the burden of comorbidity has been shown to steadily increase   34 
with age.  This is demonstrated in figure 1.7 which displays the proportion of patients 
with a comorbid illness within differing age ranges.  These data suggest that over two-
thirds of the RRT population over 65 years of age will have at least one comorbid 
illness compared with one-third of the RRT population less than 44 years of age.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 - Presence or absence of co-morbid conditions at the start of RRT amongst patients of White 
origin  starting  RRT  (2001-2006).    (Adapted,  with  permission,  from  the  UK  Renal  Registry  Tenth 
Annual Report, 2007). 
  
The implications of an aging, more comorbid RRT population are significant.  Data 
from  the  Scottish  Renal  Registry  supports  the  association  between  age  and 
comorbidity with adverse clinical outcome (12, 13).  Whilst overall survival on RRT 
has increased, considerable variability in survival rates may be seen within the RRT 
population when considering the different age groups and the different primary renal 
diagnosis groups contained within.  Data from the Scottish Renal Registry describe a 
median survival of 27.5 yrs in those patients under 20 years of age, falling to a median 
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survival of 1.3 years in those over 75 years of age.  When considering primary renal 
diagnosis,  patients  with  interstitial  renal  disease  or  glomerulonephritis  may  be 
expected to have a median survival of 9.3 years compared with 2.2 years in those with 
a multisystem disease (11).  Consequently, as the age and proportions of constituent 
primary renal disease within the RRT population evolve, it can be anticipated that 
expected survival will change accordingly.   
 
The  dramatic  difference  in  survival  between  the  RRT  population  and  the  general 
population  is  illustrated  below  in  figure  1.8.    This  figure  demonstrates  the 
considerable burden of cardiovascular disease within the ERF population and how it 
translates into heightened rates of mortality (14).   
 
 
 
Figure 1.8 - Cardiovascular mortality in the US general population (GP) and in ERF treated by dialysis.  
(Recreated with permission). 
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This  pattern  has  been  elicited  in  several  other  studies  of  RRT  populations  in  the 
developed  world  (8,  15).    These  findings  not  only  reflect  the  high  prevalence  of 
traditional  cardiovascular  risk  factors  within  the  ERF  population  such  as 
hypertension, left ventricular hypertrophy (16, 17) diabetes and proteinuria, but also 
the presence of risk factors generally specific to ERF such as vascular endothelial 
dysfunction  (18-20),  the  development  of  atherogenic  lipid  profiles  (21,  22)  and 
vascular calcification (23).  Many of these acquired risk factors have been found to 
develop early in the development in chronic kidney disease, and are associated with 
escalating cardiovascular risk as ERF approaches. 
 
As  the  demographics  of  the  RRT  population  change,  dependence  on  the  different 
modes  of  RRT  provision  also  appears  to  be  changing.    When  considering  the 
prevalent UK RRT population, on the 31
st December 2006, 44.9% were maintained 
on  a  functioning  transplant,  44.3%  maintained  on  haemodialysis  and  10.6% 
maintained on peritoneal dialysis.  Whilst the proportion of patients maintained on a 
functioning  renal  transplant  appears  to  have  been  stable  over  recent  years,  the 
proportion of patients on haemodialysis appears to be increasing with a concurrent 
decrease in the proportion maintained on peritoneal dialysis.  This trend may be partly 
explained  by  the  increasing  age  and  comorbidity  of  the  RRT  population  limiting 
patients’ ability to meet the physical demands that peritoneal dialysis incur.   
 
Registry  data  have  demonstrated  an  increasing  trend  in  the  overall  frequency  of 
haemodialysis as the first modality of RRT.  In the UK in 2006, haemodialysis was 
the first modality of RRT in 76.6% of ERF patients compared with 58% in 1998.  Of   37 
the remainder 20.0% started RRT on peritoneal dialysis and 3.4% with a pre-emptive 
renal transplant.  Increasing age is also associated with a greater likelihood of starting 
RRT on haemodialysis.  When considering incident dialysis patients 90 days after 
starting RRT, 83% of patients over 65 years of age were started on haemodialysis 
compared with 70% of those less than 65 years of age (7).   
 
In summary, the registry data accrued for the UK and other developed countries are 
suggestive of an RRT population that is increasing in size, age, comorbidity and its 
reliance on haemodialysis as the predominant means of delivering RRT. 
 
 
1.3 Renal Replacement Therapy with Haemodialysis 
 
RRT  with  haemodialysis  does  not  provide  true  replacement  of  renal  function.  
However by removing waste solutes, excess body water and restoring biochemical 
and acid-base balance, haemodialysis has considerably improved the morbidity and 
mortality of ERF patients.   
 
The first description of dialysis was made by Thomas Graham of Glasgow in 1854.  
In his pursuit of the study of colloids, Graham was able to demonstrate a method of 
separating a mixture of colloids and crystalloids using a “dialyser”, a wooden hoop 
covered  on  one  end  by  a  selectively  permeable  membrane  which  floated  on  the 
surface of a mixed solution of crystalloid and colloid (24).   
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By  applying  Graham’s  principles  Abel,  Rountree  and  Turner  developed  the  first 
artificial kidney in 1913 when they published on the removal of diffusible substances 
from circulating blood in living animals by dialysis.  This was conducted in dogs and 
rabbits,  and  described  the  first  successful  in-vivo  haemodialysis  (25).    The  first 
occasion haemodialysis was performed in a human was by Haas in 1924, however it 
was  another  20  years  before  Willem  Kolff  overcame  the  difficulties  of  providing 
adequate  vascular  access,  establishing  safe  and  effective  anticoagulation  and 
producing reliable equipment for widespread use when he created the rotating drum 
kidney in 1943 (26). 
  
Kolff’s original design was further refined in the early 1950s with the emergence of 
the stainless steel Kolff-Brigham dialysis machine.  This was used for the treatment of 
acute renal failure as sustainable vascular access for repeated dialysis treatments was 
still difficult to obtain and effectively prevented its use as a long-term treatment for 
ERF.  Further refinement of the Kolff dialysis machine and improvement in methods 
of  establishing  vascular  access  were  led  by  Nils  Alwall  in  Sweden  and  Belding 
Scribner in the US.  Their work led to increasing numbers of patients with acute renal 
failure being treated by haemodialysis from the mid 1940s to the 1960s.  By then 
many other centres were improving both the design of the haemodialysis machine and 
methods  of  establishing  sustainable  vascular  access.    In  1962  the  world’s  first 
outpatient  dialysis  facility  was  opened  in  Seattle  by  Scribner  and  from  then  on 
demand for provision of RRT by haemodialysis facilities spread around the world. 
  
The current haemodialysis machine bears little resemblance to that devised by Kolff 
in 1943 although the design adheres to similar principles.  These centre on removing   39 
blood from the intravascular compartment, passing it through an extracorporeal circuit 
into a dialyser and removing waste solutes and excess water by exposure to conditions 
that promote diffusion, convection and movement in response to hydrostatic pressure 
gradients.  Dialysed blood is then returned to the patient via the venous system. 
 
The volume of plasma cleared of solute per unit time by dialysis is expressed as the 
solute clearance.  Diffusion is the predominant method by  which solute clearance 
from plasma is achieved by haemodialysis.  The process of diffusion is dependent 
upon blood from the extracorporeal circuit flowing through the dialyser, a collection 
of  microfilament  fibres  bathed  in  dialysate  fluid  which  circulates  in  the  opposing 
direction to blood flow.  These conditions are favourable to the rapid diffusion of 
solutes through pores within the microfilament fibres, down a concentration gradient 
from blood to dialysate or vice-versa.  The rate of diffusion varies with the degree of 
concentration gradient between compartments, the surface area of the microfilament 
membrane, the number and size of pores within the membrane, the molecular size of 
the  solute  and  the  relative  flow  rates  of  both  extracorporeal  blood  and  dialysate.  
These factors determine the capacity of a dialyser and are collectively described as the 
mass  transfer  coefficient  (KoA)  of  the  dialyser,  a  quantitative  measure  of  the 
dialyser's efficiency of clearance.   
 
Convection  describes  the  movement  of  fluid  between  blood  and  dialysate 
compartments where, with increasing volumes of fluid movement from extracorporeal 
to dialysate circuits some solute may be concurrently dragged across the membrane 
and thus may contribute to the overall solute clearance achieved.  Such movement is a 
key  contributor  in  expressing  the  degree  of  flux  exhibited  by  the  microfilament   40 
membrane  in  the  dialyser.    The  concept  of  flux  has  arisen  from  a  greater 
understanding  of  the  clearance  of  small,  medium  and  large  molecular  weight 
molecules.  High-flux membranes have characteristically high permeability for water, 
low and middle molecular weight
 solutes and most are made from materials of high 
biocompatibility.  While transport
 of solutes through low-flux membranes is mainly 
achieved  by
  diffusion,  convection  plays  an  especially  important  role  in  the 
performance of high-flux membranes. 
 
Fluid  is  predominately  removed  by  the  production  of  a  transmembrane  pressure 
gradient across the microfilament membrane.  This causes fluid to cross from the 
relatively high pressure within the extracorporeal circuit to the relatively low pressure 
created on the dialysate side of the membrane.  This process of fluid removal from the 
extracorporeal circuit is termed ultrafiltration.  The degree of ultrafiltration achieved 
across a membrane is a function of its permeability, surface area and the size of the 
transmembrane  pressure  gradient  and  may  be  expressed  as  the  ultrafiltration 
coefficient. 
 
It  can  be  seen  that  a  key  determinant  in  the  success  of  haemodialysis  are  the 
characteristics  of  the  selectively  permeable  membranes  used  to  form  the 
microfilament tubes within dialyser units.  Membranes may now be classified by the 
type of material used in their manufacture (synthetic, cellulose, substituted cellulose), 
their capacity, surface area, ultrafiltration coefficient, flux and, in some cases, their 
ability to be reused.   
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The prescription of haemodialysis therefore requires consideration of its constituent 
components.  Alteration of the KoA, ultrafiltration coefficient and flux all have the 
ability to affect the amount of dialysis delivered and the relative clearances of small, 
medium and large molecular solutes.  Despite greater understanding of haemodialysis 
method  and  significant  advances  in  haemodialysis  technology,  the  morbidity
  and 
mortality of dialysis patients has remained disproportionately high.  Whilst it has been 
demonstrated that low doses of delivered haemodialysis are associated with adverse 
outcome  (27)  the  precise  components  of  the  optimal  haemodialysis  prescription 
remain controversial and have yet to be fully determined by randomised controlled 
trials (28-30). 
 
One  component,  however,  has  consistently  been  shown  to  be  fundamental  to  the 
effective delivery of haemodialysis – the successful provision of functioning vascular 
access.  Without effective and sustainable methods of establishing and maintaining 
vascular access, haemodialysis, irrespective of modality, cannot be provided. 
 
 
1.4 Methods of Haemodialysis Vascular Access  
 
Successful  haemodialysis  depends  on  the  provision  of  safe,  efficient  and  durable 
vascular  access.    Establishing  and  maintaining  effective  vascular  access  is  a 
demanding process for both patients and renal services.  These demands are set to 
increase in response to an RRT population that is becoming increasingly reliant on 
haemodialysis whilst also increasing in size, age and comorbidity. 
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Initially, vascular access methods relied on repeated peripheral cannulation to deliver 
arterial blood to the dialysis machine and return it to an accompanying vein.  In 1949, 
Alwall  from  Lund,  Sweden,  made  the  first  attempt  to  make  a  direct  connection 
between an artery and  a vein, using glass cannulae and rubber tubing (26).  This 
device would allow blood to be diverted onto an extracorporeal circuit for dialysis 
when required.  His attempt was unsuccessful although it provided the template for 
the arteriovenous Teflon Shunt developed by Quinton, Dillard and Scribner in the US 
in 1960 (31).  Their device consisted of two Teflon cannulae inserted into the wrist, 
one in the radial artery and one in accompanying cephalic vein.  The external ends of 
the  cannulae  were  connected  by  flexible  tubing  from  which  connection  to  an 
extracorporeal  circuit  could  be  made.    This  provided  nephrologists  with  the  first 
permanent vascular access device and was a decisive breakthrough in the provision of 
haemodialysis to the ERF population.  The ‘Scribner’ shunt, as it became known, 
underwent many refinements before being ultimately superseded by the successful 
development  of  arteriovenous  fistulae,  arteriovenous  grafts  and  central  venous 
catheters.  Nonetheless, the Scribner shunt played a key role in the development of 
permanent vascular access devices. 
 
The Arteriovenous Fistula 
 
In  1962,  Cimino  and  Brescia  described  a  technique  where  haemodialysis  was 
conducted through a simple puncture of the most accessible forearm vein.  Patency of 
the vein was assured by the use of an inflatable tourniquet.  This allowed needles of 
varying  sizes  to  be  used  with  resultant  haemodialysis  flows  of  150-400mL/min.  
Whilst successful, this technique was limited by the poor longevity of peripheral veins   43 
in  comparison  with  that  of  Scribner’s  external  arteriovenous  shunt.    Logical 
development  of  this  technique,  however,  led  to  the  creation  of  the  first  internal 
arteriovenous fistula (AVF).  The successful use of the new technique was reported in 
a landmark paper published by Brescia et al in 1966.  They reported 12 cases in which 
successful primary function of an AVF had been achieved by creating a side-to-side 
anastamosis between the radial artery and the cephalic vein at the wrist.  Exposure to 
high-pressure arterial flow was found to promote enlargement and thickening of the 
venous  wall.    After  approximately  six  weeks  maturation  a  robust  vessel  wall  had 
developed that could sustain repeated cannulation and allow regular haemodialysis to 
take place (32).   
 
A year later the technique had been amended to allow successful creation of an end-
to-end  anastamosis  between  radial  artery  and  cephalic  antebrachial  vein  in  the 
forearm (33).  This technique restricted arterial inflow into the AVF to that delivered 
by the feeding radial artery and thus led to a high risk of developing steal syndrome.  
Consequently the technique latterly became regarded as a secondary option available 
to surgeons when considering surgical revision of a failed AVF.   
 
The technique was further refined in 1968 by Rohl, who devised the radial artery-
side-to-vein-end anastamosis, with or without ligation of the radial artery distal to the 
anastamosis.  This allowed a more suitable positioning of the AVF with excellent 
subsequent flows.  It is this technique that has become the standard AVF creation 
procedure of choice and has allowed AVF creation surgery to evolve and successfully 
provide a range of potential sites for AVF creation, predominately within the upper   44 
limbs (26).  A diagrammatic representation of an upper limb AVF is demonstrated in 
figure 1.9. 
 
 
       
Figure 1.9 – A typical radiocephalic arteriovenous fistula with cannulation points for attachment to the 
extracorporeal haemodialysis circuit. 
 
For practical purposes AVF creation is best conducted on the non-dominant arm with 
use  of  distal  sites  where  possible;  preserving  the  proximal  vascular  tree  should 
vascular  access  surgery  be  required  in  the  future.    The  longevity,  durability  and 
favourable complication rate of the AVF have established it as the leading method of 
establishing  permanent  haemodialysis  vascular  access.    Approximately  68%  of 
haemodialysis patients in the UK dialyse via an AVF at present (34). 
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Synthetic Arteriovenous Grafts 
 
An  alternative  to  the  AVF  is  the  synthetic  arteriovenous  graft  (AVG).    This  was 
devised following the introduction of the Scribner shunt, which was noted to employ a 
length of flexible tubing to connect the arterial and venous cannulae.  In 1969 George 
Thomas  developed  this  principle  by  replacing  the  cannulae  with  Dacron  patches 
sutured into the vessel wall and bringing out a loop of connecting silastic material to 
the skin surface.  By avoiding the use of intraluminal cannulae, this device was less 
prone to thrombosis (35).   Meanwhile Buselmeier et al had adapted the Scribner 
shunt by using a silastic material which could be tunnelled subcutaneously to connect 
the two cannulae.  During the same period the first vein graft had been performed 
using  a  length  of  excised  saphenous  vein  to  connect  the  brachial  arterial  to  its 
accompanying vein.  By combining each of these three principles – direct anastamosis 
of  vessels  to  tubing,  looping  a  section  of  tubing  to  connect  artery  to  vein  and 
subcutaneous tunnelling of the connecting loop, the modern AVG was created (26). 
  
Whilst initially Dacron was the most commonly used graft material, the emergence of 
the  synthetic  material  polytetrafluoroethylene  (PTFE)  as  a  pliable,  biocompatible 
material that may be repeatedly cannulated yet maintain its structural integrity, led to 
significant improvement in the durability of the AVG.  First described by Soyer in 
1972  PTFE  has  since  become  the  most  commonly  used  graft  material  for 
haemodialysis vascular access worldwide (36).    A diagrammatic representation of an 
upper limb AVG is demonstrated in figure 1.10 
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Figure  1.10  -  A  typical  looped  brachiocephalic  arteriovenous  graft  used  for  attachment  to  the 
extracorporeal haemodialysis circuit. 
 
Commonly an AVG is used to connect the brachial artery to the basilic vein, although 
grafts between the radial artery and basilic vein and the brachial artery and axillary 
vein are also regularly used.  When vascular access in the upper limbs is exhausted, 
synthetic  grafts  can  be  used  to  establish  vascular  access  using  the  subclavian  or 
axillary vessels, femoral vessels, or even may be anastamosed between the arterial 
system and the right atrium.  Approximately 3% of haemodialysis patients in the UK 
dialyse via an AVG at present (34). 
 
Central Venous Catheters 
 
In the early years of haemodialysis the demand for experienced surgeons to create 
arteriovenous shunts, fistulae and grafts outstripped supply.  The paucity of vascular 
surgeons  prepared  to  perform  these  procedures  provoked  one  UK  nephrologist, 
Stanley Shaldon, to develop hand-made cannulae that could undergo insertion into the 
femoral artery and accompanying vein to permit immediate haemodialysis access.  He 
made use of the Seldinger insertion technique - a method that enables safe catheter   47 
placement  into  the  vascular  tree  introduced  by  Sven-Ivar  Seldinger  in  1953  (37).  
Arterial cannulation was soon abandoned after it was found to be associated with an 
unacceptably high risk of bleeding compared to veno-venous cannulation.  Gradually 
different insertion sites were used including the jugular and subclavian veins.  These 
had the advantage of allowing central venous pressures to be estimated in patients 
with extracellular fluid depletion (38), a common occurrence in many patients with 
acute renal failure requiring dialysis.  Cannulation of the subclavian vein became the 
favoured approach for central venous catheter (CVC) insertion until the early 1990s 
when angiographic data demonstrated a significantly increased risk of central venous 
stenosis at the site of cannulation.  This predisposed patients to a high risk of limb 
oedema which could impair the ability to create and maintain a functioning AVF (39).  
Insertion into the internal jugular veins is now regarded as standard practice although 
femoral venous cannulation is also performed. 
 
CVCs are frequently used temporarily to provide vascular access for haemodialysis 
whilst the patient awaits creation or maturation of an AVF or AVG or because they 
have run out of suitable options for permanent vascular access.  Some CVCs may be 
tunnelled subcutaneously en-route to entering the vein with a securing cuff to stabilise 
the position of the catheter and reduce periluminal infection.  Direct transcutaneous 
cannulation  of  the  vein  is  often  performed  acutely  and  tends  not  to  involve 
subcutaneous tunnelling or use of a securing cuff.  Polyurethane and silicone are the 
two materials most commonly used in the manufacture of haemodialysis catheters 
although polymers such as carbothane are increasingly  common.  These materials 
provide  sufficient  flexibility,  durability  and  biocompatibility  for  intravascular  use.  
Approximately 29% of haemodialysis patients in the UK dialyse via a CVC (34).     48 
 
These different methods of obtaining vascular access allow haemodialysis to be a 
viable treatment for the majority of patients with ERF.  The diversity of vascular 
access options available can help nephrologists address a range of clinical scenarios 
more effectively.  Late presentation of ERF is one frequently experienced scenario 
that may have a significant impact on vascular access provision.  In this setting the 
time in which RRT is required to start may arrive before the patient can undergo 
vascular assessment, surgery and successful maturation of their fistula or graft.  This 
phenomenon is often used to explain the relatively high prevalence of ERF patients 
using CVCs as their first haemodialysis access modality.   In the UKRR vascular 
access survey of 2006, 66% of patients started haemodialysis on a CVC compared 
with 34% using an AVF or AVG.  By 12 months 28% of prevalent patients were 
using a CVC compared with 71% using an AVF or AVG (34).  Similarly when an 
AVF or AVG fails, CVCs are a rapid means of establishing vascular access and thus 
have an important role in the emergency provision of vascular access.  
 
Whilst each access type has its relative attributes, it is vitally important to consider the 
differing  degrees  of  reliability,  durability  and  complications  associated  with  each 
approach.    Whether  considering  an  individual  patient’s  circumstances  or  planning 
vascular  access  provision  at  a  population  level,  understanding  the  range  of 
complications expressed by each access type and which factors predispose to these 
complications  is  of  fundamental  importance  in  deriving  maximum  benefit  with 
minimal risk. 
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1.5 The Complications of Haemodialysis Vascular Access 
 
Each vascular access method has associated complications that may arise immediately 
following creation or later during  regular use.   Failure of vascular  access is most 
frequently due to thrombosis occurring within or around the AVF, AVG or catheter 
however  other  significant  problems  such  as  infection,  aneurysm  formation,  heart 
failure and ischaemia distal to the site of access creation may occur. 
 
Establishing and maintaining vascular access in the face of these complications is 
costly.  USRDS data suggest that the total annual cost of establishing and maintaining 
haemodialysis vascular access is approximately one billion dollars.  The recent trend 
of increasing expenditure on dialysis access reported to the USRDS is demonstrated 
in figure 1.11 below. 
 
 
 
Figure 1.11 - Per person per year access costs, by type of access, in the USRDS ERF population (1999-
2005).  (Adapted, with permission, from the USRDS Annual Report, 2008).   50 
 
Within  these  figures  there  has  been  a  notable  rise  in  the  amount  spent  on 
interventional radiology services and a relative fall in the amount spent on vascular 
surgery and thus access creation costs have remained relatively static.  The main rise 
in  expenditure  relates  to  vascular  access  maintenance  with  access-related 
complications  accounting  for  nearly  a  quarter  of  hospitalisations  in  the  RRT 
population (1).   
 
Thrombosis 
 
Over 80% of vascular access loss is due to local vascular thrombosis.  In the case of 
arteriovenous  fistulae  or  grafts,  this  is  mostly  due  to  intravascular  stenosis  from 
anatomical defects arising within venous drainage from the access site although rarely 
from the arterial inflow.  The rate of AVF thrombosis is estimated as 0.2-0.4 episodes 
per patient year compared with 0.8-1.2 episodes per patient year for AVGs (40).   
 
The main substrate for venous stenosis is endothelial cell injury, most commonly at 
the site of the anastamosis.  This results in the up regulation of a pro-inflamatory 
cascade which promotes smooth muscle cell accumulation at the site of injury (41).  
This process may be escalated in response to shear stress arising from turbulent flow 
(42), repeated cannulation and the relative difference in vascular elasticity either side 
of the anastamosis (43).  Other contributing factors include compression of the fistula 
or graft between dialysis sessions, hypotension, hypovolaemia and hypercoagulable 
states (44).   
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Primary prevention of AVF or AVG stenosis has focussed on selecting an appropriate 
site for vascular access creation, as determined by vascular imaging, and monitoring 
fistula or graft performance.  Monitoring relies on assessment of access structure, 
assessment  of  access  blood  flow,  measurement  of  delivered  dialysis  dose  and 
assessment of the resistance to blood flow on return to the venous tree.  These features 
may all contribute towards determining whether an AVF or AVG is at risk of failure.    
Where venous stenosis of >50% is discovered, percutaneous angioplasty or surgical 
revision may improve AVF or AVG longevity.  Intervention on a thrombosed AVF, 
however, is not likely to lead to restoration of long-term patency unless an acute, 
unexpected  deterioration  in  AVF  performance  occurs  and  patency  is  restored 
promptly.  Monitoring may occur routinely as part of a regulated screening program 
or be undertaken in response to clinical deterioration in a previously functioning AVF 
or  AVG.    Best  practice  remains  uncertain.    Whilst  many  of  the  methods  used  in 
detecting  venous  stenosis  and  thrombosis  are  effective,  routine  screening  with 
subsequent intervention has not yet been proven to reproducibly increase the long-
term survival of AVFs and AVGs.  Prospective monitoring thus remains controversial 
(45,  46).    Some  guideline  groups  are  recommending  some  form  of  prospective 
monitoring for all AVFs and AVGs (47) whilst others recommend restricting detailed 
AVF  and  AVG  assessment  to  those  with  clinical  signs  of  deterioration  such  as  a 
decrease in intradialytic blood flows (48).   
 
The  issue  of  antiplatelet  agent  use  in  preventing  AVF  or  AVG  thrombosis  is 
unresolved.  Several antiplatelet agents including aspirin, dipyridamole, clopidogrel, 
sulfinpyrazone and ticlopidine have been studied in the past.  Many of the studies 
were conducted in the 1970s and 1980s where dialysis populations and treatments   52 
were very different to those seen today (49).  Recent studies have focussed primarily 
on  primary  patency  in  arteriovenous  grafts.    One  more  recent  trial  compared 
dipyridamole and/or aspirin in PTFE AVGs.  Neither treatment approach appeared to 
be  effective  as  a  secondary  preventative  measure  although  primary  prevention  of 
thrombosis was demonstrated with dipyridamole (50).  A randomised controlled trial 
evaluated use of aspirin and clopidogrel although was stopped early because of a 
significantly elevated risk of bleeding among those receiving antiplatelets (51).  More 
recently  a  randomised  controlled  trial  of  649  patients  with  a  new  AVG  assessed 
dipyridamole (200 mg twice daily) plus aspirin (25 mg twice daily) or placebo.  The 
intervention group demonstrated greater rates of primary patency with a similar rate 
of adverse events, including bleeding, albeit in a population designed to be of low 
bleeding risk and with relatively short exposure to the antiplatelets on trial (52).  Use 
of anticoagulants such as warfarin has not been proven to reduce thrombosis and has 
been associated with an increased risk of bleeding (53). 
 
When considering CVCs, thrombosis is a common problem that frequently results in 
catheter loss.  Two types of thrombosis may occur with central venous catheterisation 
– extrinsic venous thrombosis and intrinsic catheter thrombosis.  Extrinsic venous 
thrombus  arises  in  lumen  of  the  vein  in  which  the  catheter  has  been  inserted, 
invariably around the outside of the catheter and thus impairing blood flow past the 
device.  Whilst not necessarily attached to the catheter surface, the catheter or its tip 
may be embedded within the thrombus, further exacerbating abnormal venous flow 
patterns.  Intrinsic thrombus arises from within the catheter lumen and may extend 
from the  catheter tip outwards, reflecting back  over the  catheter  as a surrounding 
sheath.  Up to 70% of CVCs may develop a fibrin sheath soon after insertion.     53 
 
Both extrinsic and intrinsic catheter thrombosis may arise from (i) abnormalities of 
blood flow such as turbulence and low venous flow rates; (ii) abnormalities of the 
vessel wall such as local vascular endothelial damage following catheter insertion and 
the presence of a foreign body within the venous lumen; and (iii) a local or systemic 
pro-coagulant  state  such  as  that  mediated  by  the  release  of  pro-inflammatory 
cytokines  from  the  damaged  venous  endothelium  or  the  presence  of  a  systemic 
coagulopathy.    Once  local  thrombosis  occurs,  venous  flow  is  disturbed  and  an 
escalating cascade of thrombus formation may perpetuate. 
 
Primary prevention of catheter thrombosis focuses on selection of an appropriate site 
for CVC insertion and  adequate heparinisation  of the catheter in between dialysis 
sessions.  The internal jugular vein is favoured over the sub-clavian vein due to its 
lower  risk  of  subsequent  venous  stenosis  that  could  impair  the  function  of  future 
AVFs  or  AVGs.    Many  patients  who  have  undergone  previous  vascular  access 
procedures  may  benefit  from  imaging  of  target  sites  –  a  practice  increasing  in 
frequency with the development of interventional radiology services.  Controversy 
exists as to the best means of assessing the central veins in complex patients, with 
ultrasound, radiocontrast venography and magnetic resonance venography all being 
available methods.  Use of contrast enhanced magnetic resonance venography (CE-
MRV)  had  increased  over  recent  years  due  to  its  proven  speed,  accuracy  and 
reproducibility  in  the  detection  and  evaluation  of  central  venous  thrombus  and 
stenosis (54).  Recently, however, use of CE-MRV has come under close scrutiny 
following reports indicating an association between the administration of gadolinium-
based contrast agents and the development of the rare condition nephrogenic systemic   54 
fibrosis (NSF) (55).  This has limited the use of CE-MRV in these patients and placed 
renewed focus on imaging practices in ERF patients. 
   
The routine practice of filling the internal lumen of CVCs with heparin solution is 
almost universal in haemodialysis catheter use due to the clear benefit in preventing 
intraluminal thrombosis.  The concentration and volume of heparin solution instilled 
into  catheters  may  vary  greatly  between  renal  units.  The  benefits  of  maintaining 
catheter  patency  with  heparin-locking  are  balanced  against  the  risk  of  systemic 
heparinisation and subsequent bleeding.  In a Canadian longitudinal study of 6940 
haemodialysis  sessions  the  use  of  a  1000iU/mL  heparin  lock  solution  in  central 
venous  haemodialysis  catheters  was  not  associated  with  higher  rates  of  catheter 
malfunction  compared  with  the  use  of  10,000iU/mL  heparin  solution  but  the 
1000iu/ml group did require greater anti-thrombotic intervention with thrombolytic 
drugs (56).   Concentrations of heparin up to 5,000iU/mL are regularly used yet no 
prospective  studies  have  been  performed  to  examine  the  effects  of  higher 
concentrations of heparin solution. 
  
Several  measures  may  be  used  to  treat  established  catheter  thrombosis.    Catheter 
salvage may be attempted by infusion of saline flushes which are easily performed, 
economical,  safe  and  frequently  effective  (57).    Intraluminal  thrombolytic  or  a 
systemic infusion of thrombolytic may also restore catheter patency.  Historically this 
was conducted with urokinase however tissue plasminogen activator (tPA) has been 
demonstrated as providing better long-term patency without any additional risk of 
bleeding or other adverse events (58).  Despite this, one prospective study found tPA 
infusion to allow for a median of only five to seven additional haemodialysis sessions   55 
before  needing  repeated  or  the  catheter  needing  exchanged.    The  overall  clinical 
benefit and cost-effectiveness of tPA treatment thus remains doubtful (59).   
 
Anticoagulation with warfarin as a means of preventing catheter thrombosis remains 
controversial.  Sub-therapeutic warfarinisation has been found to be of no benefit to 
catheter patency in patients on haemodialysis (60).  Warfarinisation to an INR range 
of 1.5 to 2.5 has been found to be of some benefit in patients deemed at high risk of 
thrombosis  (61,  62).    Recent  USRDS  data,  however,  have  found  the  rate  of 
development of subdural haematomas in long-term
 dialysis patients is 10 times higher 
than that of the general
 population and cite a concurrent increase in warfarin usage as 
being a possible contributant (63).  Further data has also demonstrated an association 
between warfarin use and heightened risk of stroke in haemodialysis patients (64).  
Consensus opinion is therefore that anticoagulation with warfarin only  be used in 
long-term
  haemodialysis  patients  when  deemed  absolutely  necessary  and  when 
justified by
 published evidence. 
 
Another option is catheter replacement over a guidewire with or without stripping of 
the fibrin sheath (65, 66).  This approach allows optimal preservation of the venous 
anatomy with a significant rate of success.  Doubts exist, however, when considering 
the  likelihood  of  recurrent  thrombosis  and  the  prospect  of  introducing  infection 
through the subcutaneous tunnel during catheter exchange.  One small study of 42 
catheter  exchange  procedures  found  comparable  rates  of  subsequent  infection  and 
failure to de novo catheter insertions (67) however others have suggested an increase 
in  complication  rates  (68).    How  the  complication  rate  of  catheter  exchange   56 
procedures compares with other catheter insertion procedures is unclear and remains 
an area of controversy. 
 
Infection 
 
Infection is a common problem in haemodialysis patients and accounts for increasing 
rates of hospitalisation, comorbidity and mortality.  Figure 1.12 demonstrates recent 
trends in admissions for principle diagnoses of infection and bacteraemia/septicaemia 
in  the  USRDS  ERF  population.      It  has  been  found  that  approximately  20%  of 
vascular access loss is due to the development of infection.   
 
           
 
Figure 1.12 – USRDS 2008 report, adjusted admissions for principle diagnoses, by modality from 1993 
to 2005.  (Adapted, with permission, from the USRDS Annual Report, 2008). 
 
Vascular access is the source of the majority of infections within haemodialysis units.  
The  predominance  of  skin  commensals  as  pathogenic  organisms  in  bacteraemic 
patients suggests that inoculation during vascular cannulation is the main mechanism 
by which infection arises (69).  Once inoculated, synthetic materials such as those   57 
used in AVGs and CVCs have a tendency towards chronic infection due to their lack 
of  innate  immune  defence  mechanisms  and  their  propensity  to  develop  biofilm 
compared with autologous AVFs.  Biofilm is a complex community of sessile cells 
that attach to a substratum and to each other.  Bacteria may form biofilm through the 
production  of  a  matrix  of  glycoprotein  polymers  that  act  as  both  a  physical  and 
chemical barrier to the immune response.  These properties allow biofilms to develop 
resistance to biocides, phagocytes and antimicrobials with the degree of resistance 
correlating with the maturity of the biofilm (70).  Biofilm formation is a key substrate 
in  the  development  of  chronic  infection  in  vascular  access  devices.    A  scanning 
electron  microscopic  image  of  a  staphylococcal  biofilm  is  demonstrated  below  in 
figure 1.13. 
 
       
Figure 1.13 – A scanning electron microscopic image of a staphylococcal biofilm formed on a 96-peg 
lid plate. 
 
Prevention and treatment of vascular access infection is a major component in the safe 
delivery of haemodialysis.  When considering arteriovenous fistulae and grafts, sterile   58 
cannulation is fundamentally important.  Poor cannulation technique, often due to 
relative inexperience of dialysis personnel, may lead to pseudoaneurysm formation or 
the  development  of  perifistular  haematomas  and  is  significantly  associated  with 
subsequent infection (71).   
 
Routine antibiotic prophylaxis is controversial.  Topical antibiotic use has not been 
found to be effective with benefits in reducing nasal staphylococcus aureus carriage 
by topical mupirocin treatment being found to be associated with the development of 
resistant pathogens (72).  Consequently most primary prevention strategies focus on 
the  ability  to  ensure  aseptic  technique  when  inserting  or  handling  vascular  access 
devices. 
 
Practices such as sterile barrier nursing, hand hygiene, use of antiseptic solutions such 
as chlorhexidine and removal of the catheter at the earliest point possible are widely 
established and reflected in national guidelines (48).  
 
When considering CVCs the location and type of catheter used have an important 
association with subsequent rates of infection.  Infection is more commonly seen in 
patients  who  have  undergone  catheterisation  of  the  femoral  veins  compared  with 
those in whom catheterisation is undertaken in the internal jugular veins.  Catheters 
tunnelled subcutaneously prior to entry into the vein are associated with lower rates of 
infection.    Whether  these  associations  arise  due  to  the  location  and  method  of 
catheterisation in distinct sites or as a function of the characteristics of the types of 
patients who undergo different catheterisation procedures remains unclear.   
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New methods for the primary and secondary prevention of CVC infection have been 
devised over recent years with a growing evidence base detailing their applicability. 
Catheter materials coated or impregnated with anticoagulants, antibiotics, and silver 
ions have been studied with conflicting results.  One meta-analysis of 11 randomised 
trials demonstrated significant reductions in catheter colonisation and catheter-related 
bacteraemia  with  antiseptic-impregnated  catheters  compared  to  standard  non-
impregnated catheters.  These conclusions were disputed in a second meta-analysis 
which highlighted inconsistencies in key definitions, failures in determining clinically 
important end points and the neglect of potential confounding variables in many of 
the study populations examined (73).  Despite these uncertainties such catheters are 
often found in routine use within dialysis centres. 
 
Another area of increasing interest is the development of combined anticoagulant-
antimicrobial catheter lock solutions.  Known as the antibiotic lock technique, this 
method is targeted at preventing and eradicating biofilm on the endoluminal surface 
of haemodialysis catheters.  An antibiotic-anticoagulant solution is instilled into the 
catheter  lumen  and  left  to  dwell  between  haemodialysis  sessions.    This  method 
delivers a small absolute amount
 of antibiotic to the patient but achieves a high local 
concentration
  in  the  catheter  lumen  that  is  100 to  5,000 times  higher  than  the 
minimum  inhibitory  concentration  (MIC)  for  the  infecting  bacterium.    Use  of 
antibiotic  lock  solutions  as  a  primary  prevention  strategy  has  raised  concerns 
regarding  the  risks  of  developing  antimicrobial  resistance  with  leakage  of  the 
antibiotic-lock  solution  into  the  circulation.    Using  antibiotic-lock  solution  as  a 
secondary adjunctive measure to systemic antibiotics in treating CRB is, however, 
less contentious.     60 
 
A recent meta-analysis of the antibiotic lock technique was reported by Jaffer et al in 
2008.  This reported the relative success of antibiotic lock solutions in haemodialysis 
cohorts with a significant reduction in the frequency of catheter-related infection (74).  
A  further  meta-analysis  using  different  inclusion  criteria  arrived  at  the  same 
conclusions  with  the  techniques  appearing  to  offer  significant  improvements  in 
bacteraemia rates (75).  In both studies the authors, however, cited major limitations 
incurred due to the  relatively short duration of  follow-up and thus an inability to 
assess the risk of antibiotic resistance.   
 
Other reported barriers to the use of these solutions are concerns of systemic leakage 
of the lock solutions, a finding demonstrated by one of the randomised controlled 
trials which used gentamicin
 40mg/ml in combination with citrate where basal levels 
of gentamicin were detected in the systemic circulation (76).  This may result in a 
cumulative increase in risk of toxicity/adverse effects.  The potential economic costs 
of these solutions are also yet to be fully evaluated.  Whilst this area continues to 
evolve, our understanding of how combinations of anticoagulant and antimicrobial 
interact is limited and remains an area of considerable interest.   
 
 
1.6 Summary 
 
It can be seen that when considering the complications of haemodialysis vascular 
access, many areas of controversy and uncertainty persist.  This thesis consists of   61 
several studies which aim to bring clarity and certainty to specific areas of vascular 
access practice and thus enhance clinical judgement and decision making. 
 
The first part of this thesis scrutinises the hierarchy of complications seen across the 
range of haemodialysis access types.  In particular the complication rates associated 
with  different  types  of  vascular  access  catheter  insertion  procedure  are  examined.  
The prevalence of maintenance procedures, thrombotic complications and infectious 
complications reported by each vascular access population in the USRDS 2008 survey 
are demonstrated in table 1.1 below. 
 
Complication  AVF (%)  AVG (%)  CVC (%) 
Removal  0.7  1.1  13.3 
Replacement  0.7  1.3  25.4 
Declotting  3.3  14.4  1.5 
Mechanical Complication  0.5  0.8  1.6 
Infection  1.1  2.6  10.2 
Sepsis  4.2  4.8  15.7 
 
Table  1.1  –  A  comparison  of  prevalent  maintenance  procedures,  thrombotic  complications  and 
infectious complications reported by each vascular access population reported in the USRDS 2008 
Data Report.   
 
AVFs  have  the  lowest  complication  rates  followed  by  AVGs  and  then  CVCs.  
Consensus opinion thus suggests that AVF creation should be sought where possible 
(47).  Clearly there are logistical hurdles to this – late presentation to renal services, 
fitness for surgery, suitable peripheral vascular anatomy, delays due to primary or 
secondary  access  failure  and  slow  rates  of  AVF  maturation.    Consequently  there   62 
remain situations, especially when starting RRT, where use of an AVG or CVC may 
be  required.    This  is  demonstrated  by  the  relative  preponderance  of  CVC  use  in 
patients starting RRT around the world.  Similarly CVC insertion is the mainstay of 
vascular  access  provision  to  the  acute  renal  failure  population  who  require 
haemodialysis.    CVCs  therefore  have  an  important  role  in  haemodialysis  vascular 
access provision although do so at a cost.   
 
USRDS  data  from  2007  suggest  that  expenditure  on  catheter  placement  is 
approximately 2.5 to 2.8 times higher than on AVF and AVG surgery.  It is suggested 
that  these  figures  reflect  the  excess  costs  the  catheter  group  incur  by  being  a 
predominately  in-patient  comorbid  population  compared  to  the  population  who 
undergo elective AVF and AVG surgery (1).   
 
The association between catheter use, comorbidity and in-patient care is strong.  The 
question  of  whether  the  adverse  features  related  to  catheter  use,  such  as  catheter 
thrombosis and bacteraemia, are specifically related to use of a catheter or are simply 
related to the greater level of comorbidity expressed by the population who require 
catheter  insertion  has  been  subject  to  controversy.    This  question  is  addressed  in 
chapters 2 and 3 of this thesis where prevalent and incident RRT populations are 
studied by detailed univariate and multivariate analyses in an effort to determine the 
relative strength of independent association between clinical, laboratory and vascular 
access variables and the outcomes of catheter-related bacteraemia and thrombosis. 
 
Methods of preventing and treating CVC related bacteraemia and thrombosis have 
come under close scrutiny.  Numerous strategies targeting these problems have been   63 
examined  however  the  introduction  of  anticoagulant-antimicrobial  catheter  lock 
solutions  into  clinical  practice  appears  to  have  been  successful  despite  many 
uncertainties  remaining.    In  this  thesis  the  contentious  issue  of  heparin  and  also 
antibiotic-lock solution leakage into the circulation is addressed by the work detailed 
in  Chapter  4.    This  work  describes  a  randomised  controlled  study  of  heparinised 
catheter lock solutions and their relative effects on systemic markers of coagulation.  
Secondly, the uncertain issue of how the combination of an antimicrobial with an 
anticoagulant may affect the antimicrobial performance of the antibiotic lock solution 
is addressed in the studies detailed in Chapter 5.  This work describes an in-vitro 
assessment of the properties exhibited by heparin and vancomycin against planktonic 
and biofilm embedded staphylococci. 
 
Many  of  the  complications  of  vascular  access,  however,  can  only  be  definitively 
addressed by removal or replacement of the vascular access device.  As noted earlier, 
significant controversy exists as to the best means of assessing the central veins in 
complex  patients.    In  recent  years  the  development  of  contrast-enhanced  MRV 
imaging had become a favoured approach.  The work detailed in Chapter 6 describes 
a retrospective assessment of all CE-MRV examinations undertaken in haemodialysis 
patients within the renal unit of Glasgow Royal Infirmary.  This work describes the 
abnormalities found on CE-MRV and the subsequent clinical course followed by the 
patients in whom CE-MRV imaging was undertaken.  It was during this study that a 
relatively high prevalence of the serious condition nephrogenic systemic fibrosis was 
noted.    During  this  period  the  first  published  association  between  NSF  and 
gadolinium-enhanced  MRV  was  made  (77).    Consequently  a  large  retrospective 
analysis of all RRT patients in the West of Scotland was made to assess whether an   64 
association between gadolinium contrast agents and NSF existed in our population.  
This work is presented in Chapter 7. 
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Chapter 2  
 
A Retrospective Study of Vascular Access in Haemodialysis 
Patients and Risk of Bacteraemia and Death 
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2.1 Background 
 
Haemodialysis patients have high rates of morbidity and mortality of which infection 
makes a significant contribution (7, 78).  The immunosuppressive effects of advanced 
renal failure, concurrent co-morbid disease and associated malnourishment combine 
with the repeated intravascular intervention required for haemodialysis to provide an 
environment conducive to the development of bacteraemia and sepsis syndrome (79).   
 
The effect of sepsis can be profound.  The financial cost of treating dialysis patients 
with septicaemia is high with estimates of up to $32,000 per patient hospitalised with 
bacteraemia in the United States (80-84).  Septicaemia in  a haemodialysis patient 
confers a relative risk for mortality of 2.8 with relative risks of subsequent myocardial 
infarction,  cardiac  failure  and  stroke  of  4.1,  5.5  and  4.1  respectively.    The 
development  of  sepsis  syndrome  is  now  classed  as  second  only  to  cardiovascular 
disease as the leading cause of death in patients on renal replacement therapy (RRT) 
(78).    These  implications  have  become  increasingly  recognised  and  recent  reports 
have suggested methods such as cohort surveillance and bacteraemia monitoring to 
help define at risk groups before targeting resources to prevent and treat bacteraemia 
(85, 86).  
 
Vascular access is an established risk factor for sepsis in patients on RRT.  Different 
types  of  haemodialysis  vascular  access  are  associated  with  differing  rates  of 
bacteraemia (87-91).  Patients using different types of vascular access, however, tend 
to  have  different  clinical  characteristics.    Indeed,  the  true  independence  of  the 
association  between  vascular  access  and  bacteraemia  in  comparison  with  other   67 
clinical and laboratory risk factors has yet to be clearly established.  This study was 
designed  to  determine  which  routinely  recorded  clinical  variables,  laboratory 
variables and vascular access types are independently associated with bacteraemia and 
death in haemodialysis patients.  
 
 
2.2 Methods 
 
A retrospective analysis of all patients in our renal unit who were on haemodialysis on 
the  1st  of  January  2004  was  performed.    Clinical,  demographic  and  laboratory 
variables for each patient were retrieved from the unitary electronic patient record.  
Where multiple measurements of a single variable had been recorded, the first value 
after 1
st January 2004 was used.   
 
Clinical variables collected were age, gender, primary renal diagnosis, the presence or 
absence of diabetes, length of time on renal replacement therapy, vascular access flow 
rate on haemodialysis and urea reduction ratio (a standard measure of haemodialysis 
adequacy).  The dialysis access in use at the time of study initiation was recorded as 
one  of  four  categories:  native  arteriovenous  fistula  (AVF)  –  a  surgically  created 
anastamosis  between  artery  and  vein  to  create  a  robust  port  of  access  for 
haemodialysis,  synthetic  vascular  access  graft,  tunnelled  central  venous  catheter 
(TCVC) and non-tunnelled central venous catheter (NTCVC).  
 
Laboratory  variables collected at study  entry were haemoglobin, serum C-reactive 
protein (CRP), serum ferritin, serum albumin, serum adjusted calcium and phosphate   68 
product, serum alkaline phosphatase, serum parathyroid hormone concentration and 
total serum cholesterol to high-density lipoprotein (HDL) cholesterol ratio.   
 
Outcomes 
 
Outcomes were ascertained over an 18-month period of follow up terminating on 1
st 
of July 2005.   Bacteraemia events were determined by analysis of all positive in-
patient  and  out-patient  blood  culture  results  from  the  renal  unit  reported  by  the 
bacteriology laboratory during the period of study in conjunction with analysis of the 
patient’s clinical notes and electronic patient record.  Bacteraemia was regarded as 
significant  if  positive  blood  cultures  were  associated  with  a  raised  systemic 
inflammatory  response  (e.g.  pyrexia,  raised  CRP,  raised  white-cell  count).    Sub-
clinical  bacteraemia  was  not  evaluated.    This  approach  is  in  keeping  with  the 
consensus definition of clinically significant bacteraemia and consistent with that used 
in  routine  clinical  practice.    Where  patients  were  found  to  have  developed  a 
significant bacteraemia, the date of the first positive blood culture result was entered 
as the event date and the time to event subsequently calculated.  The patient was then 
removed from further bacteraemia  analysis.  This study did not  examine cases of 
recurrent bacteraemia and thus was a ‘time to first bacteraemia’ analysis.  In all cases 
of confirmed bacteraemia the causative organism was recorded and sensitivity profiles 
examined.    Patients  who  remained  on  haemodialysis  throughout  the  observation 
period and did not develop bacteraemia had a census date of 1
st July 2005 recorded.   
 
All patients who died during the follow up period had the date of death recorded as an 
endpoint.    All  patients  who  were  discharged,  were  transferred  to  another   69 
haemodialysis  unit  or  who  switched  renal  replacement  modality  were  assigned  a 
census date corresponding to the date of discharge from the haemodialysis cohort. 
 
Our  standard  unitary  protocol  for  catheter  care  was  employed  throughout  the 
observation period.  Specifically, this demanded complete sterile barrier precautions 
during  catheter  insertion  and  when  manipulating  the  catheter  hub.    Following 
catheter-hub manipulation, the skin surrounding the insertion site was soaked with 
chlorhexidine  solution  prior  to  a  sterile  dressing  being  applied.  All  haemodialysis 
patients were on a standard regimen of 3 haemodialysis sessions per week, each of 
minimum 4 hours per session with subsequent increases in session length up to 5 
hours in order to achieve a target urea-reduction ratio of 70%.  This conforms to UK 
Renal  Association  Guidelines.    Water  quality  in  the  haemodialysis  facilities  was 
quantified on a pass/fail basis using a failure threshold of 0.25 endotoxin units per mL 
with pass rates for all reverse osmosis units in the unit typically averaging 98% with 
total viability counts averaging <10 cfu/ml. 
 
Analysis 
  
Sample  size  was  determined  by  the  size  of  the  haemodialysis  population  within 
Glasgow  Royal  Infirmary  Renal  Unit  on  01/01/2004.    No  other  similar  patient 
populations  were  available  for  study  in  whom  reliable  data  retrieval  could  be 
achieved.  Statistical analysis was performed by SPSS
TM version 14.0 (SPSS Inc, IL, 
USA).  Normality testing was performed on all of the recorded continuous variables.  
Student’s t-testing and Mann-Whitney U testing were then used to assess differences 
between TCVC and NTCVC groups with AVF as a comparator.     70 
  
Bacteraemia  free  survival  and  mortality  rates  for  each  access  type  was  subject  to 
Kaplan-Meier survival analysis and Log Rank testing with p<0.05 being regarded as 
statistically significant.  The remaining variables were subject to univariate analysis 
with  Students  t-testing  and  Mann-Whitney  U  testing  as  appropriate  to  test  for 
associations  between  characteristics  at  study  entry  and  the  development  of 
bacteraemia  and  mortality.  The  relationship  between  bacteraemia  and  subsequent 
mortality  was  subject  to  Pearson  Chi-square  testing.    After  application  of  the 
bonferroni correction a p-value of <0.0025 was regarded as statistically significant in 
these  univariate  analyses.    Multivariate  analysis  was  performed  using  a  Cox 
proportional hazards model with a stepwise conditional method of analysis to test for: 
1)  an  independent  association  with  the  development  of  bacteraemia  and  2)  an 
independent  association  with  mortality.    To  avoid  over  fitting  of  the  multivariate 
models the convention of limiting the number of independent variables entered to 
approximately 10% of the number of outcome events was followed.  In our analysis 
independent variables for entry into the models were selected according to their p-
values on univariate testing. On multivariate analysis all reported p-values <0.05 were 
regarded as significant. 
 
 
2.3 Results 
 
A  search  of  the  renal  unit  electronic  patient  record  was  conducted  to  identify  all 
patients who underwent haemodialysis between 1
st and 3
rd of January 2004.  A total of 
265 patients were identified of whom 136/265 (51.3%) were male.  Mean age was   71 
63.5 years (SD 14.6) whilst median duration of renal replacement therapy prior to 1
st 
of January 2004 was 1076 days (range 7-12,829).  All patients were found to have 
established renal failure with none of the cohort on dialysis for acute renal failure.  
59/265 (22.3%) of the cohort had a diagnosis of diabetes mellitus.  At study entry 
206/265  (77.7%)  were  dialysing  via  native  AVF,  31/265  (11.7%)  were  dialysing 
through a TCVC, 26/265 (9.8%) were dialysing through a NTCVC and 2/265 (0.8%) 
were dialysing through a synthetic vascular graft.  As only two patients were dialysing 
through a synthetic graft, they were not subject to further analysis.  Table 2.1 displays 
the  characteristics  of  the  full  cohort  whilst  table  2.2  compares  the  clinical  and 
laboratory characteristics for each vascular access type. 
  
Variable  Data Values 
 
Age (years) 
 
 
63.5 (14.6)* 
Male   136/265 (51.3%)  
 
Female 
 
129/265 (48.7%) 
 
Diabetes 
 
59/265 (22.3%) 
Duration of RRT (days) 
 
1076 (376, 2095)** 
Haemoglobin (g/dL) 
 
11.3 (1.8)* 
Ferritin (ng/ml) 
 
356 (196, 568)** 
Albumin (g/L) 
 
37.5 (4.8)* 
C-reactive protein (mg/L) 
 
17.4 (2.9)* 
Alkaline phosphatase (U/L) 
 
203 (156, 304)** 
Parathyroid Hormone (pmol/L)                                            
 
22.0 (11.0, 40.0)** 
Calcium x phosphate product 
 
4.08 (1.34)* 
Cholesterol:HDL 
 
3.39 (1.24)* 
Haemodialysis blood flow (mL/min) 
 
300.0 (59.4)* 
Urea reduction ratio (%) 
 
71.3 (8.9)* 
 
Table 2.1 – Data values and descriptive statistics for the laboratory variables studied in the full cohort.  
Data values are expressed as value (%), *mean (SD) or **median (Q1, Q3).   72 
 
 
Table 2.2 - Characteristics for each of the main vascular access groups.  All statistical testing of the tunnelled 
and non-tunnelled catheter groups was carried out in comparison with the characteristics of the arteriovenous 
fistula group.  Data values are expressed as value (%), *mean (SD) or **median (Q1, Q3). 
  Arteriovenous 
Fistula (n=206) 
Tunnelled Catheter  
(n=31)   
Non-Tunnelled 
Catheter (n=26) 
 
 
 
Clinical Features 
 
Age (years) 
 
 
 
 
 
63.8 (14.4)* 
 
 
 
 
63.5 (15.2)* 
 
 
 
 
p = 0.90 
 
 
 
 
62.8 (17.0)* 
 
 
 
 
p = 0.75 
Male  111 (53.9%)  10 (32.3%)  p = 0.03  14 (53.8%)  p = 0.99 
 
Female 
 
95 (46.1%)  21 (67.7%)  p = 0.03  12 (46.2%)  p = 0.99 
Diabetes 
 
43/206 (20.9%)  8/31 (25.8%)  p = 0.49  7/26 (26.9%)  p = 0.46 
Duration on RRT 
 
1138 (412, 2048)**  1511 (765, 5288)**  p = 0.01  278 (55, 903)**  p<0.001 
Haemodialysis blood flow 
(ml/min) 
309 (56.5)*  267 (60.9)*  p<0.001  268.8 (58.6)*  p = 0.001 
Urea reduction ratio (%) 
 
71.9 (8.9)*  70.45 (8.04)*  p = 0.27  66.7 (8.73)*  p = 0.01 
 
Primary Renal Diagnosis 
 
         
Primary Glomerulonephritis 
 
39/206 (18.9%)  6/31 (19.4%)  p = 0.96  6/26 (23.1%)  p = 0.61 
Interstitial Nephropathies 
 
57/206 (27.7%)  10/31 (32.2%)  p = 0.60  5/26 (19.2%)  p = 0.36 
Multisystem Disease 
 
28/206 (13.6%)  2/31 (6.5%)  p = 0.27  2/26 (7.7%)  p = 0.40 
Diabetic Nephropathy 
 
33/206 (16.0%)  4/31 (12.9%)  p = 0.66  8/26 (30.8%)  p = 0.06 
Laboratory Variables     
 
   
Haemoglobin (g/dL) 
 
11.4 (1.7)*  11.6 (1.98)*  p = 0.74  10.2 (1.56)*  p = 0.001 
Ferritin (ng/ml) 
 
357 (200.0, 578.0)**  467 (192, 575)**  p = 0.94  253 (88.5, 432.5)**  p = 0.06 
Albumin (g/L) 
 
37.9 (5.0)*  36.6 (3.13)*  p=0.007  35.7 (4.1)*  p= 0.005 
C-reactive protein (mg/L) 
 
15.7 (2.9)*  23.9 (3.0)*  p = 0.06  24.5 (2.7)*  p = 0.03 
Calcium x phosphate  
 
4.13 (1.36)*  4.03 (1.18)*  p = 0.87  3.8 (1.5)*  p = 0.20 
Alkaline phosphatase (U/ml) 
  
196 (156, 297)**  220 (154.5, 333.0)**  p = 0.43  239 (153.0, 466.0)**  p = 0.41 
Parathyroid hormone (pmol/L) 
 
35.5 (38.7)*  29.7 (29.8)*  p = 0.37  24.7 (22.4)*  p = 0.23 
Chol:HDL 
 
3.5 (1.3)*  2.73 (0.58)*  p = 0.03  3.2 (1.0)*  p = 0.34   73 
As expected, patients dialysing through a TCVC had a significantly lower haemodialysis 
blood flow rate when compared to those dialysing through an AVF.  Otherwise, those using 
a TCVC demonstrated trends towards lower serum albumin, lower serum cholesterol to 
HDL ratios and longer median duration on RRT in comparison to those dialysing through 
an AVF.  26/31 patients were dependent on their TCVC as their only remaining option for 
vascular access whilst 5/31 patients were using a TCVC prior to definitive vascular access 
being created.   
 
Patients  dialysing  through  a  NTCVC  had  significantly  lower  haemoglobin  and  lower 
haemodialysis blood flow rates than those dialysing through either a TCVC or AVF.  14/26 
(53.7%) patients had been on dialysis for >3 months and had temporary vascular access 
problems  that  had  required  NTCVC  insertion.    12/26  (46.2%)  had  started  RRT  for 
established renal failure within 3 months of study entry.  This proportion accounts for the 
significantly  shorter  duration  on  RRT  in  the  NTCVC  group  when  compared  with  the 
TCVC and AVF groups (p=0.001).  None of these patients had acute renal failure (i.e. 
recovered renal function within a 3 month period).  Patients dialysing through a NTCVC 
had  trends  towards  lower  albumin  and  urea-reduction  ratios  as  well  as  higher  CRP 
compared to the AVF group.   
 
During the observation period, 15 patients underwent renal transplantation, 5 transferred to 
other renal units, 2 patients switched to continuous ambulatory peritoneal dialysis (CAPD) 
and 1 patient recovered renal function and was subsequently discharged.   
   74 
Bacteraemia  
 
45/263 (17.1%) patients developed at least one episode of bacteraemia over the 18-month 
period.  39/45 (86.7%) of cases were secondary to staphylococci of which 15/45 (33.3%) 
cases were due to coagulase-negative staphylococci and 5/45 (11.1%) cases were due to 
methicillin-resistant staphylococcus aureus (MRSA) infection.  3/45 (6.7%) cases were due 
to  gram-stain  negative  bacteria  and  3/45  (6.7%)  were  secondary  to  other  bacterial 
subspecies.  The relative frequencies of cases of catheter-related bacteraemia from each 
pathogenic group are demonstrated in figure 2.1.   
 
Figure  2.1  –  Frequency  plot  of  the  types  of  pathogenic  organisms  in  cases  of  clinically  significant 
bacteraemia demonstrated over the 18-month period of observation. 
 
Analysis  of  bacterial  resistance  profiles  demonstrated  that  9/13  (69%)  cases  of  the 
coagulase-negative  staphylococci  where  antibiotic  sensitivities  were  available,  were 
resistant to the antibiotic flucloxacillin.  Of the 45 patients who developed bacteraemia 17 
patients (37.8%) died during the 18-month observation period.   75 
Univariate analysis was performed on the laboratory and clinical variables recorded at the 
start of the study period to examine whether there was an association with the development 
of bacteraemia.   The actuarial 18 month bacteraemia-free survival in the cohort dialysing 
via AVF at study entry was significantly higher than the cohorts dialysing through TCVC 
or  NTCVC  (88.8%  v  54.8%  v  69.2%  respectively;  p<0.001).    This  is  demonstrated 
graphically as a Kaplan-Meier plot in figure 2.2.   
 
 
 
 
 
 
 
 
 
 
Figure 2.2 – Kaplan-Meier plot of time to bacteraemia per haemodialysis vascular access type. ‘AVF’ = 
arteriovenous fistula, ‘Tunnelled CVC’ = tunnelled central venous catheter, ‘Non-tunnelled CVC’  = non-
tunnelled central venous catheter.  
 
No significant difference in bacteraemia event rates was found when directly comparing 
TCVCs with NTCVCs (p=0.29). Patients who developed bacteraemia were found to have 
trends towards higher CRP levels and lower serum albumin levels at study entry than their 
bacteraemia free counterparts but this did not reach the bonferroni corrected significance 
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level.  Age (bacteraemia 62.9yrs v no-bacteraemia 63.8yrs, p=0.74) and the presence of 
diabetes (bacteraemia 8/45 (17.8%) % v no-bacteraemia 34/218 (15.6%), p=0.66) were not 
associated with bacteraemia. 
 
Multivariate analysis demonstrated hazard ratios (HR) for the development of bacteraemia 
in patients dialysing with TCVCs and NTCVCs of 5.43 (95% CI 2.67-11.0, p<0.001) and 
3.14 (95% CI 1.32-7.48, p=0.01) respectively compared to those patients dialysing through 
an AVF.  There was also an independent association between elevated CRP at study entry 
and the risk of developing bacteraemia over an 18-month period with a HR of 1.49 (95% 
CI 1.12-1.98, p=0.006).  The results of the univariate and multivariate analyses for the 
outcome of bacteraemia are demonstrated in table 2.3.   
 
 
Table 2.3 – Factors that underwent both univariate and multivariate analysis and their association with the 
incidence of bacteraemia.  Data values are expressed as value (%) or *mean (SD) where appropriate.  ‘CRP’ 
= C-reactive protein, ‘HD’ = haemodialysis,
 a Pearson Chi-Square testing, 
b Student's t-test. 
 
Variable at Study Entry  
 
Univariate Analysis   Multivariate Analysis  
  Data Values   p-value  Hazard Ratio 
(95% CI) 
 
p-value 
 
 
Tunnelled Catheter       Bacteraemia 
(n=31)                           No Bacteraemia 
 
 
14 (45.2%)   
17 (54.8%) 
 
P<0.001
a 
 
5.43 (2.67, 11.0) 
 
p<0.001 
Non-tunnelled Catheter Bacteraemia 
(n=26)                           No Bacteraemia 
 
8   (30.8%)   
18 (69.2%) 
P=0.006
a  3.14 (1.32, 7.48)  p=0.01 
CRP                               Bacteraemia 
(mg/L)                            No Bacteraemia 
 
25.3 (2.9)*   
16.0 (2.9)* 
P=0.015
b  1.49 (1.12, 1.98)  p=0.006 
Albumin                         Bacteraemia 
(g/L)                               No Bacteraemia 
 
36.0 (4.9)*   
37.9 (4.7)* 
P=0.021
b  -  - 
HD Flow                        Bacteraemia 
(ml/min)                         No Bacteraemia 
 
283 (56)*      
303 (60)* 
P=0.036
b  -  -   77 
Mortality 
 
65/263  (24.7%)  patients  died  during  the  follow-up  period  and  were  found  to  have 
significantly elevated serum CRP, low serum albumin and increased age at study entry 
compared with those who survived.  The actuarial 18 month patient survival in the cohort 
dialysing via AVF at study entry was better than the cohorts dialysing through TCVC or 
NTCVC  (79.1%  v  64.5%  v  57.7%  respectively;  p<0.019).    This  is  demonstrated 
graphically as a Kaplan-Meier plot in figure 2.3.  
 
 
 
 
 
 
 
 
 
 
 
Figure  2.3  –  Kaplan-Meier  survival  plot  of  mortality  per  haemodialysis  vascular  access  type.  ‘AVF’  = 
arteriovenous fistula, ‘Tunnelled CVC’ = tunnelled central venous catheter, ‘Non-tunnelled CVC’  = non-
tunnelled central venous catheter. 
 
Trends of association with mortality by univariate analysis were seen with elevated serum 
alkaline phosphatase levels and lower levels of haemoglobin and the product of serum 
calcium and phosphate at study entry.  A diagnosis of diabetes mellitus was found to be 
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associated with mortality (death occurring in 21/58 (36.2%) diabetics and 44/205 (21.5%) 
of  non-diabetics,  p=0.02)  as  was  a  diagnosis  of  dialysis  related  bacteraemia  (death 
occurring  in  17/45  (37.8%)  bacteraemics  and  48/218  (22.0%)  of  non-bacteraemics, 
p=0.026). 
 
Multivariate analysis demonstrated an independent association with death with the use of 
TCVCs and NTCVCs (HR 2.75; p=0.012 and HR 3.39; p=0.001 respectively) compared 
with AVFs, low serum albumin (HR 0.92, 95% CI 0.87-0.97, p=0.003), elevated alkaline 
phosphatase (HR 1.002, 95% CI 1.000-1.003, p=0.011) and increasing age (HR 1.04, 95% 
CI 1.02-1.07, p<0.001).  The results of the univariate and multivariate analyses for the 
outcome of mortality are demonstrated in table 2.4.   
 
Variable at Study Entry 
 
Univariate Analysis   Multivariate Analysis  
  Mean (SD)   p-value  Hazard Ratio 
(95% CI) 
 
p-value 
Non-tunnelled     Dead 
Catheter                                                
 
11/26 (42%)  p=0.015
a  3.39 (1.67, 6.87)  p=0.001 
Tunnelled            Dead 
Catheter                                                
 
11/31 (35%)  p=0.016
a  2.75 (1.25, 6.04)  p=0.012 
Age                     Dead 
(Years)                Alive 
 
68.6 (13.2)* 
62.0 (14.7)* 
p=0.001
b  1.04 (1.02, 1.07)  p<0.001 
Alk phos              Dead 
(U/L)                    Alive 
 
221 (107, 976)** 
192 (58, 943)** 
p=0.003
c  1.002 (1.000, 1.003)  p=0.011 
Albumin              Dead 
(g/L)                    Alive 
 
35.8 (4.8)* 
38.1 (4.6)* 
p<0.001
b  0.92 (0.87, 0.97)  p=0.003 
CRP                    Dead 
(mg/L)                 Alive 
  
27.2 (2.8)** 
14.6 (2.8)** 
p<0.001
b  -  - 
Table 2.4 – Factors that underwent both univariate and multivariate analysis and their association with the 
incidence of mortality.  Data values are expressed as value (%), *mean (SD) or **median (Q1, Q3). ‘Alk 
Phos’ = Alkaline Phosphatase, *Median (Q1, Q3), **Geometric Mean (SD),
 a Pearson Chi-Square testing, 
b 
Student's t-test, 
c Mann-Whitney U test.   79 
2.4 Discussion 
 
This study examined bacteraemia and mortality in a cohort of haemodialysis patients with 
established renal failure that had a pattern of vascular access which was representative of a 
typical  UK  chronic  haemodialysis  population.    The  rates  of  bacteraemia  (17.1%)  and 
mortality (24.7%) over the 18-month period of observation equate to those described in the 
literature to date (91).  Through a retrospective methodology an independent association 
between  several  commonly  recorded  clinical  and  laboratory  variables  and  subsequent 
outcome was demonstrated. 
  
Of particular note was the finding that use of synthetic vascular access catheters had an 
especially  strong  association  with  risk  of  bacteraemia  and  death,  an  effect  that  was 
independent of known adverse factors such as age, sex, diabetes, anaemia, and the other 
clinical and laboratory variables that were studied and found to be not to be significantly 
associated with outcome on univariate testing (92).  Whilst tunnelled catheters were found 
to be used in patients who had been on dialysis longer, we found this to be a product of 
patients  whose  peripheral  vasculature  had  been  exhausted  of  attempts  to  create  an 
arteriovenous fistula or graft.  None of the TCVC group had been exposed to bacteraemia 
in,  at  least,  the  period  3  months  prior  to  commencement  of  the  study.    Indeed,  the 
demographics and co-morbidities of the tunnelled catheter group and arteriovenous fistula 
group were very similar and thus the conclusion that adverse outcomes are independently 
associated  TCVC  use  when  compared  to  AVFs  would  appear  to  be  accurate.    When 
considering the NTCVC group, it was evident that this consisted of a higher proportion of 
patients who had commenced RRT for established renal failure within three months of 
study entry and in this setting the co-morbidities that often arise during this period may   80 
contribute to the difference in clinical outcomes seen in this particular group compared to 
the others.  No difference in bacteraemia rates was seen between NTCVCs and TCVCs 
although higher mortality rates were seen in the NTCVC group.  It is difficult to draw any 
meaningful conclusions when comparing these groups due to the inherent limitations of the 
methodology employed. 
  
The limitations incurred by the retrospective study design and subsequent extrapolation of 
a ‘snapshot’ of vascular access related to long-term outcome have to be acknowledged.  In 
particular, this method of analysis was not sensitive to potential changes in vascular access 
type over the period of observation.  Many patients using NTCVCs would be reasonably 
expected to migrate onto TCVCs and then AVFs as they progress through the early months 
following  commencement  on  RRT.    One  would,  however,  expect  that  this  potential 
confounding would weaken any association between vascular access and clinical outcome 
since  risks  presumably  lower  when  patients  convert  from  central  venous  catheter  to 
arteriovenous fistulae.  Nonetheless, in such an observational study it must be remembered 
that the primary drive behind access choice was from the clinician responsible for each 
patient’s care.  Therefore, whilst access type has been associated with adverse events it 
should be assumed that each patient was on the optimal vascular access possible within 
their clinical situation.  Another limitation was the lack of detailed data on comorbidity, 
other than the data we included regarding age, duration on RRT and diabetes.  Whilst these 
variables will account for some of the main comorbidites experienced in this population, 
prospective  study  incorporating  comorbidity-scored  data  would  be  of  great  benefit  in 
bringing clarity to this perpetual confounder of vascular access studies. 
   81 
Sample size was also a significant limitation in this study, especially when attempting to 
relate these results to the haemodialysis population within the UK.  As an example, the 
current UK haemodialysis population is approximately 20,000 patients.  To determine a 
hazard ratio with 95% confidence interval of 1.00 to 1.05 and significance level of p<0.05 
in such a large population size would require a sample size of over 8000 patients.  Clearly 
the sample size in this study falls short of such levels and this is reflected in the wide 
confidence intervals demonstrated when considering the hazard ratios in each of the access 
groups with both outcome measures. 
 
The  significant  role  of  transcutaneous  vascular  access  devices  in  increasing  risk  of 
bacteraemia  was  further  implicated  by  the  finding  that  86.7%  of  bacteraemia  was 
secondary to staphylococci.  Within this cohort methicillin-resistant staphylococcus aureus 
(MRSA) accounted for 11.1% of all bacteraemia.  These rates are consistent with those 
published in the current literature where the vast majority of clinically significant infection 
in dialysis patients has been found to be secondary to staphylococcal sub-species derived 
from the surface of the skin (92-96).   
 
Not only is the identity of the causative organisms important, but the spectrum of antibiotic 
resistance is also of importance when determining appropriate first line antibiotic treatment 
(96).  Sub-analysis of the cohort demonstrated that two-thirds of all coagulase negative 
staphylococci isolated on blood cultures were flucloxacillin resistant.  This, in conjunction 
with an 11.1% prevalence of MRSA would suggest that current antibiotic protocols that use 
flucloxacillin as first line therapy may require re-consideration with regards local patterns 
of anti-microbial resistance.  
   82 
The  finding  of  an  independent  association  between  CRP  at  study  entry  and  the 
development of subsequent bacteraemia, an association that remained after adjusting for 
several potential confounders on multivariate testing, was also of interest.  The exact nature 
of the relationship between infection, inflammation and outcome remains to be clarified.  
When considering inflammatory burden and mortality, several studies have demonstrated a 
significant association between increased inflammatory indices and heightened mortality 
rates,  possibly  through  a  process  of  vascular  endothelial  dysfunction,  subsequent 
atherogenesis and a resultant tendency towards cardiovascular events (89, 97-100).  Other 
potential  drivers  of  CRP  release  in  haemodialysis  patients  include  pre-existent,  latent 
infection, underlying inflammatory conditions such as connective tissue disease, vasculitis 
and  glomerulonephritis,  and  exposure  to  inflammatory  triggers  inherent  with  the 
haemodialysis  process.    These  include  exposure  to  invasive  procedures  to  assess  the 
vasculature and establish vascular access, repeated exposure of blood to the extracorporeal 
circuit  and  exposure  to  low  levels  of  endotoxin  through  dialysis  water.    Such  is  the 
prevalence of vascular disease in the haemodialysis population, however, the link between 
CRP and underlying vascular endothelial damage is an attractive target to those keen to 
explore  how  CRP  levels  translate  into  increased  numbers  of  cardiovascular  and  other 
adverse events.  Not all cardiovascular mortality in dialysis patients can be explained by 
traditional risk factors (97) and indeed sepsis and inflammatory burden could be plausible 
pre-disposing factors in many cardiovascular deaths (96).  Proving causation is, however, 
difficult given the wide variety of confounders that would need accounted for. 
 
In summary, this work demonstrates the prevalence of bacteraemia and mortality in a UK 
haemodialysis  unit  and  provides  an  assessment  of  potential  risk  association  across  a 
spectrum  of  laboratory  and  clinical  variables  that  is  broader  than  most  similar  studies.    83 
Many previous studies have been conducted in US populations which are demographically 
different and function through a different system of health care delivery to that of the UK 
population.  What this study therefore adds to the field is the demonstration of similar rates 
of bacteraemia and mortality alongside a similar profile of vascular access risk association 
in  a  UK  population.    Similarly,  the  strength  of  association  found  with  haemodialysis 
vascular access type compared to other routinely recorded clinical and laboratory variables 
is clearly demonstrated and comparable to that of other studies in different populations.  Of 
additional relevance and interest is the degree to which vascular access type translates into 
adverse risk compared with other variables, as is the finding of an association between 
baseline CRP and subsequent bacteraemia risk.  Whilst of interest, all these findings must 
be tempered by the inherent limitations of the study design, as noted above.  
 
 
2.5 Conclusion 
 
These data found that use of synthetic vascular access catheters had an especially strong 
association with risk of bacteraemia and death in a typical haemodialysis cohort, an effect 
that was independent of age, sex, diabetes, anaemia, and the other clinical and laboratory 
variables that were studied.    84 
 
 
 
 
 
 
Chapter 3 
 
A Prospective Observational Study of Catheter-related 
Bacteraemia and Thrombosis in a Haemodialysis Cohort: 
Univariate and Multivariate Analyses of Risk Association 
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3.1 Background 
 
The work detailed in Chapter 2 demonstrated that central venous catheters compare poorly 
with  arteriovenous  fistulae  when  considering  bacteraemia  and  mortality  in  patients  on 
haemodialysis.  A strong, independent association with poor outcome was demonstrated 
after accounting for several known markers of comorbidity despite the limitations inferred 
by a retrospective study design not sensitive to changes in vascular access.  
 
Central  venous  catheters  are,  however,  a  fundamental  component  in  delivering 
haemodialysis.  They may be inserted quickly and without use of surgical support.  Central 
venous catheters are thus especially useful when patients require dialysis urgently and have 
no  pre-existent  functioning  vascular  access.    Alternatively,  catheters  may  be  used  in 
patients in whom sites for establishing arteriovenous fistulae or grafts have been exhausted.  
 
The  two  most  common  complications  of  catheterisation  are  catheter  thrombosis  and 
catheter-related  bacteraemia  (101).    Developing  either  of  these  complications  incurs 
significant impact on both the functionality and lifespan of the catheter and confers high 
rates of morbidity and mortality notwithstanding considerable cost (82-84, 102).  The work 
in Chapter 2 highlighted some of the different demographics between patients using each 
of the vascular access types, differences that may change further when patients with acute 
renal failure are included.  Whether the complication profile seen in patients using catheters 
is a result of a higher burden of comorbidity seen in selected groups of complex patients is 
yet to be conclusively demonstrated.     86 
To  test  this  hypothesis  in  more  detail,  the  work  in  this  chapter  examines  rates  of 
bacteraemia and thrombosis experienced with all types of vascular access catheter insertion 
conducted in an incident renal replacement therapy (RRT) cohort over a 2-year period of 
prospective observation.  Univariate and multivariate analyses were undertaken to identify 
and quantify independent risk association between clinical variables, laboratory variables 
and measures of comorbidity, with regard to both catheter thrombosis and catheter-related 
bacteraemia. 
 
3.2 Methods 
 
A  prospective  analysis  of  all  incident  vascular  access  haemodialysis  catheter  insertions 
over the period starting 05/08/2005 and ending 05/08/2007 was performed.  The date of 
each  catheter  insertion  was  recorded  along  with  the  type  of  catheter  inserted,  the 
anatomical location of catheter insertion and whether the catheter insertion was conducted 
as a catheter-exchange procedure over a guidewire.  Clinical casenotes and our unitary 
electronic patient record were used to obtain details of a number of clinical and laboratory 
variables that were routinely collected as part of our standard care, on the date of catheter 
insertion. 
  
Clinical  variables  including  age,  sex  and  concurrent  antibiotic,  anticoagulant, 
immunosuppressive  and  statin  therapy  were  recorded.    Modified  Charlson  comorbidity 
scores (103-105), a diagnosis of diabetes, cause and duration of renal failure, body mass 
index, systolic blood pressure, diastolic blood pressure and haemodialysis blood flow on 
dialysis immediately following catheter insertion (as determined by dialysis machine blood   87 
pump speed) were also  obtained.   Laboratory variables including haemoglobin, platelet 
count, neutrophil count, lymphocyte count, CRP, albumin, adjusted calcium, phosphate and 
urea reduction ratio prior to catheter insertion were recorded. 
 
Outcomes 
 
Patients were prospectively followed up to the point of catheter removal or the cessation of 
the  study.    During  this  period  two  main  outcomes  were  assessed:  catheter-related 
bacteraemia (CRB) and catheter failure with removal due to poor haemodialysis blood flow 
as a surrogate of catheter thrombosis.  All patients who died or were discharged to another 
renal unit with a central venous catheter in-situ were assigned a census date corresponding 
to the date of discharge from the renal unit.  Patients who remained on haemodialysis at the 
end of the observation period with a central venous catheter in-situ had a census date of 5
th 
August 2007 recorded.   
 
CRB events were sought through analysis of all positive blood culture results from the 
renal  patient  population  as  reported  by  the  bacteriology  laboratory  in  conjunction  with 
analysis of the patient’s clinical notes and electronic patient record.  CRB was defined as 
the  presence  of  positive  blood  cultures  associated  with  a  raised  systemic  inflammatory 
response (e.g. pyrexia, raised CRP, raised white-cell count) and the absence of clinical or 
radiological signs of a non-catheter related source of infection.  Sub-clinical bacteraemia 
was not evaluated.  This approach is in keeping with the definition of CRB commonly 
reported in the literature and consistent with that used in routine clinical practice.  Where 
patients were found to have developed CRB, the date of the first positive blood culture   88 
result was entered as the event date and the time to event subsequently calculated.  Catheter 
removal due to poor flow was defined as removal of a central venous catheter in response 
to  low  haemodialysis  blood  flows  that  consistently  impaired  effective  haemodialysis 
delivery despite optimal anticoagulation and/or thrombolytic intervention.  This reflected 
routine clinical practice in the participating renal unit.  All decisions regarding catheter 
removal were made by the clinical team responsible for each patient’s care and were made 
independently from the investigator.  The standard unitary protocol for catheter care was 
employed throughout the observation period.  Specifically, this demanded complete sterile 
barrier  precautions  during  catheter  insertion  and  when  manipulating  the  catheter  hub.  
Following catheter-hub manipulation, the skin surrounding the insertion site was soaked 
with  chlorhexidine  solution  prior  to  a  sterile  dressing  being  applied.    Between 
haemodialysis  sessions  all  catheters  were  ‘locked’  with  5000iu/mL  heparin  of  volume 
consistent with the manufacturer’s stated catheter luminal volume. 
  
All haemodialysis patients were on a standard regimen of 3 haemodialysis sessions per 
week, each of minimum 4 hours per session with subsequent increases in session length up 
to 5 hours in order to achieve a target urea-reduction ratio of >65%.   
 
Analysis 
 
Statistical  analysis  was  performed  using  SPSS
TM  version  14.0  (SPSS  Inc,  IL,  USA).  
Parametric testing with student’s t-test and non-parametric testing with the Wilcoxon-sign 
rank  test  were  used  in  the  assessment  of  continuous  variables  where  appropriate.  
Categorical  variables  were  assessed  using  Pearson  Chi-square  testing.    Rates  of   89 
bacteraemia  free  survival  and  catheter  removal  due  to  poor  haemodialysis  flow  were 
compared  by  Kaplan-Meier  survival  analysis  with  log-rank  testing  with  event  rates 
expressed per 1000 catheter days.  When performing the univariate analyses, in view of the 
large number of variables assessed, Bonferroni’s correction was applied with a significance 
level of α < 0.0025. 
 
Multivariate  analysis  was  performed  using  a  Cox  proportional  hazards  model  with  a 
stepwise conditional method of analysis to test for: 1) an independent association with the 
development  of  catheter-related  bacteraemia  and  2)  an  independent  association  with 
catheter  failure  due  to  poor  haemodialysis  blood  flow.    To  avoid  over  fitting  of  the 
multivariate models the convention of limiting the number of independent variables entered 
to approximately 10% of the number of outcome events was followed.  In our analysis 
independent variables for entry into the models were selected according to their p-values on 
univariate testing.  On multivariate analysis p-values <0.05 were regarded as significant. 
 
3.3 Results 
 
Over  the  2-year  period  a  total  of  365  patients  underwent  823  central  venous  catheter 
insertions.    Patients  were  of  median  age  66.4yrs  (range  19.8,  87.1yrs)  with  203/365 
(55.6%) male.  130/365 (35.6%) patients were found to have acute renal failure (ARF) 
defined as a recovery of renal function with cessation of dialysis within 90 days.  60/365 
(16.4%)  patients  underwent  catheter  insertion  in  the  context  of  acute  on  chronic  renal 
failure  (A/CRF)  whilst  175/365  (47.9%)  patients  underwent  catheter  insertion  in  the 
context of chronic renal failure (CRF).  Clinical and laboratory variables recorded at the 
point of catheter insertion are detailed in table 3.1.   90 
Variable 
 
TCVC  NTCVC IJug  NTCVC Fem  NTCVC IJug (G)  NTCVC Fem (G) 
Patients 
 
N=301  N=313  N=136  N=60  N=13 
CRB events 
 
N=72  N=25  N=8  N=8  N=2 
Poor Flow events 
 
N=40  N=49  N=27  N=12  N=3 
ARF  
 
20 (6.6%)  109 (34.8%)  47 (34.6%)  35 (58.3%)  3 (23.1%) 
A/CRF  
 
21 (7.0%)  63 (20.1%)  23 (16.9%)  10 (16.7%)  1 (7.7%) 
CRF  
 
260 (86.4%)  141 (45.0%)  66 (48.5%)  15 (25.0%)  9 (69.2%) 
Diabetes   
 
129/301 (42.9%)  116/313 (37.1%)  48/136 (28.9%)  22/60 (36.7%)  5/13 (38.5%) 
Statin  
 
183/301 (60.8%)  150/313 (47.9%)  61/136 (44.6%)  22/60 (36.7%)  7/13 (53.8%) 
Anticoagulation 
 
231/301 (76.7%)  182/313 (58.1%)  83/136 (61.0%)  36/60 (60.0%)  10/13 (76.9%) 
Immunosuppression  
 
32/301 (10.6%)  35/313 (11.2%)  11/136 (8.1%)  7/60 (11.7%)  1/13 (7.7%) 
Antibiotic  
 
294/301 (97.7%)  128/313 (40.9%)  62/136 (45.6%)  32/60 (53.3%)  7/13 (53.8%) 
Modified Charlson  
score 
2 (0,13) **  2 (0,8) **  2 (0,9) **  1 (0,4) **  1.5 (0,8) ** 
Days on RRT 
 
531 (0,14061) **  9 (0,13690) **  4 (0,8653) **  5 (0,3484) **  482 (0,2551) ** 
Catheter days 
 
92 (1,692) **  9 (0,200) **  5 (0,34) **  7 (0,97) **  6 (0,32) ** 
Urea reduction ratio 
 
66.1 (11.5) *  68.4 (9.9) *  67.2 (7.2) *  65.4 (5.4) *  62.6 (10.0) * 
Dialysis blood flow 
(mls/min) 
300 (58, 350) **  250 (120,375) **  220 (100,350) **  200 (150,330) **  250 (160,400) ** 
SBP 
(mmHg) 
130 (28) *  137 (27) *  130 (28) *  135 (28) *  145 (20) * 
DBP 
(mmHg) 
74 (16) *  73 (16) *  71 (17) *  73 (18) *  84 (12) * 
BMI 
(kg/m
2) 
27.2 (7.1) *  27.6 (6.6) *  26.6 (5.5) *  30.0 (6.5) *  28.2 (7.8) * 
Haemoglobin 
(g/dL) 
10.1 (1.9) *  9.6 (1.8) *  9.7 (2.0) *  9.2 (1.5) *  9.7 (1.8) * 
Platelet count 
(x10
9/L) 
240.5 (42,779) **  241 (8, 728) **  243 (21,592) **  226.5 (41,587) **  219 (163,419) ** 
Neutrophil count 
(x10
9/L) 
5.1 (1.0, 26.6) **  7.1 (0.8,30.6) **  7.1 (1.5,31.7) **  8.6 (3.9,18.5) **  5.9 (3.8,11.1) ** 
Lymphocyte count 
(x10
9/L) 
1.4 (0.3,3.9) **  1.1 (0.3,19.7) **  1 (0.2, 21.1) **  1.2 (0.4,17.6) **  1.3 (0.4,2.7) ** 
C-reactive protein 
(mg/L) 
27 (1,297) **  53 (1,487) **  64 (2,375) **  91 (3,282) **  23 (11,402) ** 
Albumin 
(g/L) 
29 (13,43) **  26.5 (10,45) **  27 (12,43) **  25.5 (11,38) **  29 (11,39) ** 
Calcium (Adjusted) 
(mmol/L) 
2.42 (0.18) *   2.31 (0.21) *  2.32 (0.24) *  2.26 (0.24) *  2.38 (0.16) * 
Phosphate  
(mmol/L) 
1.64 (0.56) *  1.83 (0.75) *  1.95 (0.73) *  1.67 (0.59) *  1.93 (0.61) * 
Calcium phosphate 
product 
3.98 (1.43) *  4.20 (1.77) *  4.49 (1.68) *  3.76 (1.35) *  4.58 (1.50) * 
Table 3.1 – Clinical and laboratory characteristics from the date of catheter insertion for each central venous catheter sub-
type.  Data values are expressed as value (%), *mean (SD) or **median (min, max). ‘TCVC’ = tunnelled central venous 
catheter. ‘NTCVC’ = non-tunnelled central venous catheter.  ‘IJug’ = internal jugular vein insertion site.  ‘Fem’ = femoral 
vein  insertion  site.    ‘(G)’  =  catheter  exchange  procedure  conducted  over  a  guidewire.    ‘CRB’  =  catheter-related 
bacteraemia.  ‘ARF’ = acute renal failure.  ‘A/CRF’ = acute on chronic renal failure.  ‘CRF’ = chronic renal failure.  
‘RRT’ = renal replacement therapy.  ‘Anticoagulation’ = warfarin or antiplatelet use.  ‘SBP’ = systolic blood pressure.  
‘DBP’ = diastolic blood pressure.  ‘BMI’ = body mass index.   91 
In  total,  301/823  (36.6%)  of  procedures  were  insertions  of  tunnelled  central  venous 
catheters (TCVC) whilst 522/823 (63.4%) were insertions of non-tunnelled central venous 
catheters (NTCVC).  Of the NTCVC insertions, 373/522 (71.5%) were inserted into the 
internal  jugular  veins  with  149/522  (28.5%)  inserted  into  the  femoral  veins.    73/522 
(14.0%)  of  NTCVC  insertions  were  conducted  as  catheter-exchange  procedures  over  a 
guidewire.  A total of 44,528 catheter days were accumulated over the study period during 
which time there were 115 cases of catheter-related bacteraemia (2.57 per 1000 catheter 
days) and 131 cases of catheter removal due to poor haemodialysis blood flow (2.94 per 
1000 catheter days).    
 
Bacteraemia 
 
115 cases of catheter-related bacteraemia occurred with 122 bacterial isolates identified on 
blood culture.  Staphylococcal sub-species accounted for the majority of cases with 47/122 
(38.5%)  isolates  of  staphylococcus  epidermidis,  29/122  (23.8%)  isolates  of  methicillin-
sensitive  staphylococcus  aureus  and  9/122  (7.4%)  isolates  of  methicillin-resistant 
staphylococcus aureus.  Gram negative bacilli accounted for 19/122 (15.6%) isolates, other 
gram positive cocci in 14/122 (11.5%) bacterial isolates and gram positive bacilli in 4/122 
(3.3%) isolates. 
 
Rates of catheter-related bacteraemia were 1.77 per 1000 catheter days in the TCVC group, 
6.3 per 1000 catheter days in the internal jugular vein NTCVC group and 13.5 per 1000 
catheter days in the femoral vein NTCVC group.  Internal Jugular and femoral NTCVCs 
exchanged over  a  guidewire demonstrated  catheter-related bacteraemia rates of 9.7 and   92 
21.5 per 1000 catheter days respectively.  Events occurred at median (range) of 54 (28, 
127) days in the TCVC group, 10 (5, 18) days in the internal jugular NTCVC group, 4 (4, 
5) days in the internal jugular guidewire exchange group, 6 (1, 8) days in the femoral 
NTCVC group and 8 days in the femoral guidewire exchange group. 
 
Using the TCVC group as a comparator, all types of NTCVC insertion procedure were 
significantly associated with catheter-related bacteraemia on univariate analysis (p<0.001).  
Other  variables  significantly  associated  with  the  subsequent  development  of  catheter-
related bacteraemia included higher haemodialysis blood flow (265mls/min v 250mls/min, 
p=0.002) and shorter durations of catheter lifespan (50 days v 83 days, p<0.001).  This, 
however, reflects our unitary practice of removing catheters once a diagnosis of catheter-
related bacteraemia has been made unless there is a strong clinical reason to try and salvage 
the catheter.  Trends towards a significant association with catheter-related bacteraemia on 
univariate testing included higher serum adjusted calcium levels (p=0.004), an elevated 
Modified Charlson comorbidity score (p=0.005), being on antibiotic at the time of catheter 
insertion  (p=0.008),  a  diagnosis  of  diabetes  (p=0.011)  and  a  longer  duration  on  renal 
replacement therapy (p=0.013).  All other variables were not significantly associated with 
outcome on univariate analysis. 
  
Multivariate analysis demonstrated hazard ratios (HR) for the development of bacteraemia 
in patients dialysing with internal jugular NTCVCs of 2.93 (p<0.001), femoral NTCVCs of 
5.97 (p<0.001), 6.42 (p<0.001) for internal jugular NTCVCs exchanged over a guidewire 
and 9.84 (p=0.002) for femoral NTCVCs exchanged over a guidewire (figure 3.1).  There 
was  also  a  significant  independent  association  between  an  elevated  modified  Charlson   93 
comorbidity  score  with  a  HR  of  1.102  (p=0.034).    All  other  variables  failed  to  reach 
statistical significance on multivariate testing (table 3.2).  
 
                
Figure 3.1 – Univariate Kaplan-Meier and Multivariate analysis adjusted catheter-related bacteraemia free 
survival plotted for each central venous catheter sub-type. 
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Variable  Univariate Analysis 
(p-value) 
Multivariate Analysis 
(Hazard Ratio) 
P-value 
 
NTCVC Femoral (Guidewire) 
 
 
p<0.001 
 
9.84 
 
p=0.002 
NTCVC Internal Jugular (Guidewire) 
 
p<0.001  6.42  p<0.001 
NTCVC Femoral 
 
p<0.001  5.97  p<0.001 
NTCVC Internal Jugular 
 
p<0.001  2.93  p<0.001 
Modified Charlson Comorbidity Score 
 
p=0.005  1.102  p=0.034 
Haemodialysis Blood Flow (mls/min) 
 
p=0.002  -  p=NS 
 
Table 3.2 – Variables entered into multivariate analysis and the associated risk of subsequent catheter-related 
bacteraemia. (Guidewire) refers to catheter exchange procedures over a guidewire. 
 
Poor Flow 
 
Rates of catheter removal due to poor flow were 0.98 per 1000 catheter days in the TCVC 
group, 12.3 per 1000 catheter days in the internal jugular vein NTCVC group, and 37.6 per 
1000  catheter  days  in  the  femoral  vein  NTCVC  group.    Internal  Jugular  and  femoral 
NTCVCs exchanged over a guidewire demonstrated failure rates of 20.2 and 32.3 per 1000 
catheter days respectively.   
 
Events occurred at median (range) of 57.5 (6, 337) days in the TCVC group, 6 (0, 22) days 
in  the  internal  jugular  NTCVC  group,  5  (1,  10)  days  in  the  internal  jugular  guidewire 
exchange group, 3 (1, 10) days in the femoral NTCVC group and 1 (0, 2) days in the 
femoral guidewire exchange group. 
   95 
Using  the  TCVC  group  as  a  reference  for  comparison,  all  types  of  NTCVC  insertion 
procedure  were  significantly  associated  with  catheter  removal  due  to  poor  flow  on 
univariate  analysis  (p<0.001).    Other  variables  significantly  associated  with  catheter 
removal due to poor haemodialysis blood flow were low haemodialysis blood flow during 
the  first  dialysis  following  catheter  insertion  (237mls/min  v  255mls/min,  p<0.001)  and 
elevated levels of CRP at the time of catheter insertion (61mg/dL v 40mg/dL, p<0.001).  
Patients who required catheter replacement due to poor flow were more likely to have their 
catheter removed earlier (36 days v 58 days, p<0.001). 
 
Trends towards a significant association with poor flow were seen with high platelet counts 
(p=0.067)  and lower levels of serum albumin  (p=0.087).   All other variables were not 
associated with outcome on univariate analysis. 
 
Multivariate analysis demonstrated hazard ratios (HR) for the removal of catheters due to 
poor haemodialysis blood flow in patients dialysing with internal jugular NTCVCs of 4.65 
(p<0.001),  femoral  NTCVCs  of  9.23  (p<0.001),  5.56  (p<0.001)  for  internal  jugular 
NTCVCs  exchanged  over  a  guidewire  and  11.73  (p<0.001)  for  femoral  NTCVCs 
exchanged over a guidewire (figure 3.2).   
   96 
    
            
Figure  3.2  –  Univariate  Kaplan-Meier  and  Multivariate  analysis  adjusted  catheter  survival  with  regard 
episodes of catheter removal due to insufficient haemodialysis blood flow.  Survival plotted for each central 
venous catheter sub-type. 
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There was also a significant independent association between an elevated CRP with a HR 
of 1.004 (p<0.001) per unit increase in CRP and HR=0.992 with haemodialysis blood flow 
immediately following catheterisation (p<0.001) to subsequent removal of catheter due to 
poor flow (table 3.3).  
 
Variable  Univariate Analysis 
(p-value) 
Multivariate Analysis 
(Hazard Ratio) 
P-value 
 
NTCVC Femoral (Guidewire) 
 
 
p<0.001 
 
11.73 
 
p<0.001 
NTCVC Femoral 
 
p<0.001  9.23  p<0.001 
NTCVC Internal Jugular (Guidewire) 
 
p<0.001  5.26  p<0.001 
NTCVC Internal Jugular 
 
p<0.001  4.65  p<0.001 
C-reactive Protein (mg/dL) 
 
p=0.002  1.004  p<0.001 
Haemodialysis Blood Flow (mls/min) 
 
p=0.002  0.992  p<0.001 
 
Table  3.3  –  Variables  entered  into  multivariate  analysis  and  the  associated  risk  of  subsequent  catheter 
removal due to poor haemodialysis blood flow.  (Guidewire) refers to catheter exchange procedures over a 
guidewire 
 
 
3.4 Discussion 
 
These data demonstrate the significant differences between tunnelled and non-tunnelled 
central venous haemodialysis catheter insertion procedures in terms of rates of catheter-
related  bacteraemia  and  catheter  failure  due  to  poor  haemodialysis  blood  flow.  
Importantly, they bring clarity to the debate of whether such adverse events develop as a   98 
function of the characteristics of the catheterisation procedure in terms of tunnelling and 
site of insertion, or the characteristics of the patient receiving the catheter.   
 
From these data, it can be concluded that the characteristics of the catheterisation procedure 
in terms of tunnelling and site of insertion, had the greatest independent effect on risk of 
developing  both  catheter-related  bacteraemia  and  catheter  failure  due  to  poor 
haemodialysis blood flow of all the variables studied.  The clear hierarchy of complication 
rates  across  different  types  of  catheter  insertion  procedure  were  demonstrated  as  being 
independent of established measures of comorbidity in haemodialysis patients, including 
haemoglobin, bone biochemistry, dialysis dose, markers of inflammatory burden, in the 
setting  of  acute  renal  failure,  diabetes  and  modified  Charlson  comorbidity  index  score 
(103-105).   
 
Of  the  variables  studied,  the  only  other  factor  independently  associated  with  catheter-
related bacteraemia was an elevated modified Charlson comorbidity index score at the time 
of catheter insertion.  The only other factor independently associated with catheter failure 
due to poor haemodialysis blood flow was elevated CRP at the time of catheter insertion. 
 
The wide range of clinical and laboratory variables included in the analysis allowed many 
of  the  potential  confounders  to  be  taken  into  account.    Not  all  potential  confounding 
variables were, however, included.  The number and type of vascular access procedures 
each patient had undergone prior to catheterisation was one variable that was not reliably 
recorded  in  the  EPR  and  as  such  was  not  recorded  during  data  collection.    It  can  be 
envisaged that patients with poor peripheral access or central venous stenosis may have a   99 
higher  turnover  catheter  insertions  and  thus  may  gradually  depend  more  heavily  on 
NTCVCs, use of insertion sites such as the femoral veins and/or use of guidewire catheter-
exchange procedures.  Such patients could account for the especially high hazard ratios 
found  with  these  procedures.    Whilst  the  large  number  of  procedures,  long  period  of 
follow-up and inclusion of variables such as the patient’s duration on RRT may partly 
adjust for this issue in study design, this study does not sufficiently address this potentially 
important risk factor.  Closer scrutiny of the complex vascular access patient could be 
achieved by future studies adjusting for variables such as the number of previous vascular 
access procedures, and reporting subsequent rates of conversion onto a functioning AVF or 
graft and subsequent sustainability of that AVF or graft.   
 
The use of a clinical definition of CRB may also be regarded as a limitation.  The most 
formal  definition  of  CRB  requires  concurrent  line  and  peripheral  blood  cultures,  both 
growing the same organism and with either 5 times as many colony forming units in the 
catheter culture or positive growth at least 2 hours before the peripheral culture.  For these 
criteria to be met requires the availability of dialysis unit nursing staff who are trained in 
peripheral venepuncture, patients with adequate peripheral veins to allow venepuncture to 
take place or in whom preservation of the peripheral veins for future arteriovenous fistula 
creation is not required, and suitable culture storage and analysis facilities on site.  Such 
requirements are a logistical hurdle in studies of simple observational design and thus may 
result in underreporting of clinically significant bacteraemia.  It was for these reasons that a 
clinical definition of CRB was used, albeit at the risk of over-reporting the rate of true 
bacteraemia arising from the catheter. 
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Another important limitation concerns the data on guidewire catheter-exchange procedures.  
The analysis was limited by not adjusting for the period of time spent with a catheter prior 
to it being exchanged via a guidewire.  In this regard, we cannot exclude that the higher 
event rates seen in this group do not simply reflect the effect of increased time with a 
catheter in-situ.  Whilst increased catheter lifespan was associated with a lower rate of 
CRB, this simply reflected the local unitary practice of removing a catheter once CRB had 
been diagnosed and as such does not help clarify this issue.  
 
How  does  catheter  insertion  site  contribute  to  bacteraemia  risk?    The  pattern  of  these 
results suggest that catheters inserted into a site which has been previously used (i.e. a 
previous catheter tunnel used with a catheter exchange procedure over a guidewire) or in 
skin folds such as the femoral creases may herald locations where pathogens are more 
likely to reside.  How does catheter tunnelling relate to bacteraemia risk?  Our data show 
that catheters entering the vein close to the skin surface without a period of subcutaneous 
tunnelling are more likely to become complicated by infection and/or thrombosis.  The 
shorter  physical  distance  between  skin  surface  and  vein,  and  thus  a  shorter  length  of 
exposure to innate immune defences may go some way to explain the better bacteraemia 
rates seen with subcutaneous tunnelling of the catheter.  With regard to the differences 
between catheter types due to poor haemodialysis flow, the tunnelled catheters used in this 
cohort were of greater diameter than their non-tunnelled counterparts and thus may account 
for the better thrombosis rates seen in this group.  Within the NTCVC groups, the main 
difference in flow rates was between catheters inserted into the internal jugular veins and 
the femoral veins.  This may simply reflect the different calibre, tortuosity and extrinsic 
compression of the venous tree in these locations.  Further study of these theories would be 
of benefit.   101 
 
Several organisations have drawn up clinical guidelines to address the issue of optimal 
catheter practice.  The UK Renal Association Guidelines, for instance, suggest that less 
than 20% of patients on long-term haemodialysis should use tunnelled or non-tunnelled 
central venous catheters as their mode of vascular access (48).  NKF-KDOQI cite the lower 
complication rate associated with tunnelled central venous catheters compared with non-
tunnelled catheters in their recommendation that tunnelled catheters are used where the 
period of catheter use is likely to be longer than 3 weeks.  In cases of suspected catheter 
thrombosis  or  low-grade  catheter-related  bacteraemia  in  the  absence  of  subcutaneous 
tunnel infection, NKF-KDOQI suggests that the catheter may be exchanged over a guide-
wire (47).  Our data suggest that future guidelines should give greater emphasis on early 
tunnelled central venous catheterisation where possible, minimising non-tunnelled central 
venous  catheter  use  and  limiting  guidewire  catheter-exchange  to  cases  where  re-
catheterisation at a separate site is unachievable. 
 
 
3.5 Conclusion 
 
In  conclusion,  our  data  suggest  that  tunnelled  central  venous  catheter  insertions  are 
associated  with  lower  complication  rates  than  non-tunnelled  central  venous  catheter 
insertions, independent of whether patients have acute or chronic renal failure, or high 
levels of comorbidity.  When considering central venous catheterisation, these data suggest 
that tunnelled catheter insertion be sought when patients have no pre-existing functioning 
arteriovenous  fistula  or  graft.    In  cases  where  tunnelled  central  venous  catheterisation   102 
cannot be performed, non-tunnelled catheterisation of the internal jugular veins should be 
sought.  Insertion of a non-tunnelled femoral venous catheter is associated with the next 
highest rates of bacteraemia and failure due to poor haemodialysis blood flow and therefore 
should be used in selected cases only.  The practice of catheter-exchange over a guidewire 
should be restricted to cases where primary catheterisation at a de novo site cannot be 
achieved.    
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Chapter 4 
A Prospective Randomised Controlled Trial Comparing the 
Effect of Heparinised Catheter Lock Solutions on Systemic 
Anticoagulation in Haemodialysis Patients   
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4.1 Background 
 
Haemodialysis catheter thrombosis is a common problem.  Thrombus formation on the 
catheter  surface  occurs  within  a  matter  of  hours  (106)
  and  this  may  extend  to  involve 
thrombosis of the central veins the longer the catheter remains in-situ (107).   A clear 
association between thrombus formation and subsequent catheter-related bacteraemia has 
been demonstrated (108). 
 
Presently  there  are  no  published  NKF-DOQI  guidelines  on  evidence-based  practice 
regarding the prevention of catheter thrombosis.  The majority of renal units simply rely on 
using  heparin  as  a  catheter-locking  solution,  where  filling  the  internal  lumens  of  the 
catheter  with  heparin  solutions  prevents  the  build  up  of  thrombus.    Evidence  to  date 
suggests that heparin lock solutions significantly decrease catheter thrombosis, decrease 
bacterial colonisation of the catheter and may decrease catheter-related bacteraemia (109).   
 
The benefits of maintaining catheter patency with heparin-locking are, however, balanced 
against  the  risk  of  systemic  heparinisation  and  subsequent  bleeding.    Haemodialysis 
patients  are  already  predisposed  to  bleeding  because  of  uraemia  or  associated 
coagulopathy.  Several renal units in the UK have observed major haemorrhagic events 
requiring blood transfusion following central venous catheter locking with heparin.  The 
balance of risk versus benefit is, however, uncertain and thus heparin-locking practice is 
found to vary widely among renal units (110, 111).   Several studies have been performed 
to  demonstrate  the  risks/benefits  of  different  heparin  locking  practices  however  the 
majority of studies have been observational, non-blinded and retrospective in design (56).   
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In this study an investigator-blinded randomised controlled trial of heparin catheter lock 
solutions  in  non-tunnelled  (temporary)  central  venous  catheters  was  undertaken.    The 
working  hypothesis  was  that  higher  concentrations  of  heparin  solution  would  lead  to 
significantly  greater disturbance of systemic  coagulation as measured by  the change in 
activated partial thromboplastin time (APTT) at 10 minutes post catheter locking.  The 
study was designed with a primary endpoint of change in APTT at 10 minutes following 
catheter  locking  with  heparin  1,000U/ml  and  5,000U/ml.    Secondary  study  endpoints 
included  subsequent  catheter  lifespan,  catheter  thrombosis  rates  and  rates  of  catheter-
related bacteraemia between groups.   
 
4.2 Methods 
 
Full approval was granted for this study from our local research and ethics committee.  34 
consecutive patients requiring insertion of a temporary non-tunnelled dual lumen central 
venous  haemodialysis  catheter  were  approached  of  which  28  patients  gave  informed 
consent and were recruited into the study. Patients were either starting haemodialysis for 
the  first  time  or  were  established  on  renal  replacement  therapy  (RRT)  and  required 
temporary central venous catheterisation because of vascular access failure.  Patients with 
exposure to heparin in the previous 24 hours were excluded from the study and thus were 
not asked to take part.  On entry to the study, patients underwent third party randomisation 
to either heparin 5000iu/mL or heparin 1000iu/mL as catheter lock solution.  All members 
of the investigating team were blind to the allocation of heparin solution.   
 
Standard  unitary  protocol  for  catheter  care  was  employed  throughout  the  observation 
period.  Specifically, this demanded complete sterile barrier precautions during catheter   106 
insertion and when manipulating the catheter hub.  Following catheter-hub manipulation, 
the skin surrounding the insertion site was soaked with chlorhexidine solution prior to a 
sterile dressing being applied.  
 
Once the catheter was inserted and sutured in-situ, a 5ml blood sample was taken from the 
catheter for measurement of the APTT.  Each lumen of the catheter was then flushed with 
20ml 0.9% Saline using a positive pressure technique to remove any blood from the lumen.  
Both lumens of the catheter were then slowly filled with a volume of the allocated heparin 
solution equal to the volume of each lumen as stated by the manufacturer.  A stop-clock 
was then started and at 10 minutes following catheter locking a peripheral venous blood 
sample taken for repeat measurement of the APTT.  The same concentration of heparin was 
used  to  lock  the  catheter  after  each  successive  dialysis  session  until  the  catheter  was 
removed.   
 
At the time of catheter insertion baseline clinical, demographic and laboratory variables for 
each patient were retrieved from the unitary electronic patient records and clinical case 
records.  Where multiple measurements of a single variable had been recorded, the most 
recent  value  was  used.    Clinical  variables  collected  were  age,  gender,  primary  renal 
diagnosis,  the  presence  or  absence  of  diabetes,  body  mass  index  (BMI),  systolic  and 
diastolic  blood  pressure,  anticoagulant  use,  statin  use,  immunosuppressant  medication, 
length  of  time  on  renal  replacement  therapy,  and  vascular  access  flow  rate  on 
haemodialysis.  Laboratory variables collected at study entry were haemoglobin, platelet 
count,  neutrophil  count,  lymphocyte  count,  serum  C-reactive  protein  (CRP),  serum 
albumin, serum adjusted calcium and phosphate product. 
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Outcomes 
 
Each patient was followed up for the period over which the catheter remained in-situ.  The 
primary outcome was the difference in APTT at 10 minutes following catheter locking 
between heparin 5000iu/mL and heparin 1000iu/mL.   Secondary outcomes included cases 
of catheter removal due to insufficient haemodialysis blood flow to maintain haemodialysis 
and cases of catheter-related bacteraemia (CRB).   
 
CRB events were determined by analysis of all positive blood culture results from the renal 
unit reported by the bacteriology laboratory during the period of study in conjunction with 
analysis  of  the  patient’s  clinical  notes  and  electronic  patient  record.    Bacteraemia  was 
deemed  significant  if  positive  blood  cultures  were  associated  with  a  raised  systemic 
inflammatory response (e.g. pyrexia, raised CRP, raised white-cell count).  This approach 
is  in  keeping  with  the  consensus  definition  of  clinically  significant  bacteraemia  and 
consistent with that used in routine clinical practice.   
 
Catheter removal due to poor flow was defined as removal of a central venous catheter in 
response  to  low  haemodialysis  blood  flows  that  consistently  impaired  effective 
haemodialysis delivery despite optimal anticoagulation and/or thrombolytic intervention.  
This  reflected  routine  clinical  practice  in  the  participating  renal  unit.    All  decisions 
regarding catheter removal were made by the clinical team responsible for each patient’s 
care and were made independently from the investigator. 
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Analysis & Study Protocol 
  
Statistical  analysis  was  performed  by  SPSS
TM  version  14.0  (SPSS  Inc,  IL,  USA).  
Normality testing was performed on all of the recorded continuous variables.  Student’s t-
testing and Mann-Whitney U testing were then used to assess differences between groups 
where appropriate.  The primary outcome sought was the difference in the APTT ratio 
between  groups  after  administration  of  the  heparin  lock  solutions  following  catheter 
insertion  as  determined  by  student’s  t-testing.    Bacteraemia-free  survival  and  catheter 
failure  secondary  to  poor  haemodialysis  blood  flow  survival  rates  for  each  group  was 
assessed  by  Kaplan-Meier  survival  analysis  and  Log  Rank  testing  with  p<0.05  being 
regarded as statistically significant.  A sample size of 12 participants in each group was 
determined as providing 80% power to detect a 25% difference in mean APTT from 28s to 
35s with standard deviation of 6s and significance level of p<0.05.  Randomisation was 
undertaken independently by the clinical trials pharmacy unit at Glasgow Royal Infirmary.  
Block  randomisation  was  used  with  the  aim  to  recruit  greater  numbers  than  those 
determined by the power calculation in an effort to pursue suitable numbers of secondary 
outcome events.   
 
All aspects of the clinical trial were conducted in accordance with national guidance from 
the UK Medical Research Council and the Department of Health.  Trial sponsorship was 
undertaken by NHS Greater Glasgow as the employer of the chief investigator, Dr Robert 
Mactier.  The Research and Development department of Glasgow Royal Infirmary were 
consulted where permission was sought and granted for the study to be conducted within 
NHS Greater Glasgow.  The study protocol was further developed by the Glasgow Royal 
Infirmary clinical trials pharmacy unit.  During this time consultation was made with the   109 
Medicines  and  Healthcare  products  Regulatory  Agency  where  it  was  determined  that 
studies  of  catheter  lock  solutions  are  regarded  as  studies  of  medical  devices  and  thus 
MHRA  approval  was  not  required.    Following  peer  review  the  study  protocol  was 
submitted to the local research ethics committee where permission for the study to proceed 
was granted.  The study protocol is detailed in figure 4.1 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Flow chart detailing the study design from recruitment to collation of results. 
Potential subjects identified by renal unit ward 
medical staff 
Subjects approached, given patient information sheet and 
left alone to contemplate participation 
Prior to catheter insertion, consent sought by investigator and 
pharmacy contacted where randomisation and assignation to a 
heparin group conducted.  Stock delivered to ward. 
1 x 5mL blood sample taken to measure APTT 
prior to catheter insertion 
Patient undergoes dialysis with heparin continued catheter 
locking with allocated heparin between sessions.  
 
Monitoring of safety, adverse events and clinical progress of 
participants conducted in real-time. 
Secondary outcome measures assessed over 
lifespan of catheter 
Catheter ‘locked’ with allocated heparin and APTT 
re-checked peripherally 10 minutes later. 
Catheter removed, results collated and prepared for 
statistical analysis   110 
4.3 Results 
 
28 patients who met the inclusion criteria provided informed consent to participate in the 
study.  16/28 (57.1%) patients were male.  Median age of the cohort was 68.0 years (range 
40.2 – 84.8).   
 
15/28 (53.6%) presented with acute renal failure, defined as a duration of renal replacement 
therapy (RRT) of less than 90 days with no known pre-existing renal disease.  7/28 (25.0%) 
presented with acute on chronic renal failure, defined as a duration of RRT less than 90 
days with known pre-existent renal disease.  6/28 (21.4%) patients had established renal 
failure with duration on RRT of median 737.5 days (range 329 - 7505 days).   
 
13  patients  were  randomised  to  the  heparin  1000iu/mL  group  whilst  15  patients  were 
randomised to the heparin 5000iu/mL group.  Details of all clinical and laboratory variables 
recorded  on  the  date  of  study  entry  for  each  group  are  listed  in  table  4.1  below.    No 
statistically  significant  differences  were  demonstrated  between  the  heparin  1000iu/mL 
group and the heparin 5000iu/mL group on univariate testing although trends towards a 
positive association were found when considering the proportion of patients known to have 
a diagnosis of diabetes with a greater proportion of such patients being demonstrated in the  
heparin 5000iu/mL group. 
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Variable 
 
Heparin 1000iu/mL  Heparin 5000iu/mL  P-value 
 
No. of Patients 
 
 
N=13 
 
N=15 
 
- 
Male:Female 
 
7:6  9:6  p=0.99 
ARF  
(N) 
7/13  8/15  p=0.99 
A/CRF  
(N) 
5/13  2/15  p=0.20 
CRF  
(N) 
1/13  5/15  p=0.17 
Diabetes   
(N) 
4/13  11/15  p=0.06 
Statin  
(N) 
6/13  8/15  p=0.99 
Aspirin 
(N) 
5/13  7/15  p=0.72 
Clopidogrel 
(N) 
0/13  2/15  p=0.48 
Immunosuppression 
(N) 
2/13  1/15  p=0.58 
Duration on RRT 
(days) 
0 (0, 460) **  9 (0, 7505) **  p=0.19 
SBP 
(mmHg) 
130 (24) *  133 (26) *  p=0.78 
DBP 
(mmHg) 
72 (22) *  74 (13) *  p=0.86 
BMI 
(kg/m
2) 
34.6 (6.7) *  28.3 (5.2) *  p=0.07 
Haemoglobin 
(g/dL) 
9.2 (1.2) *  9.2 (1.6) *  p=0.99 
Platelet count 
(x10
9/L) 
214 (37, 366) **  272 (73, 623) **  p=0.30 
Neutrophil count 
(x10
9/L) 
8.5 (4.4) *  8.4 (4.9) *  p=0.95 
Lymphocyte count 
(x10
9/L) 
1.2 (0.5) *  1.4 (0.7) *  p=0.35 
C-reactive protein 
(mg/L) 
52 (3, 220) **  29 (3, 74) **  p=0.17 
Albumin 
(g/L) 
23 (14, 37) **  29 (15, 42) **  p=0.27 
Calcium (Adjusted) 
(mmol/L) 
2.36 (0.17) *  2.29 (0.18) *  p=0.29 
Phosphate  
(mmol/L) 
1.48 (0.55) *  1.84 (0.62) *  p=0.11 
 
Table 4.1 – Clinical and laboratory characteristics of heparin 1000iu/mL and heparin 5000iu/mL groups.  
Data values are expressed as value (%), *mean (SD) or **median (min, max).  ‘ARF’ = acute renal failure.  
‘A/CRF’ = acute on chronic renal failure.  ‘CRF’ = chronic renal failure.  ‘RRT’ = renal replacement therapy.  
‘SBP’ = systolic blood pressure.  ‘DBP’ = diastolic blood pressure.  ‘BMI’ = body mass index.  Values 
recorded as mean (SD) or median (minimum, maximum). 
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The  measured  baseline  APTT  immediately  prior  to  catheter  heparin-locking  did  not 
significantly  differ  between  groups  with  mean  (SD)  APTT  of  28  (2.9)  in  the  heparin 
1000iu/mL group compared to mean (SD) APTT of 27.7 (5.9) in the heparin 5000iu/mL 
group (p=0.88).  The measured APTT at 10 minutes post catheter heparin-locking was 
significantly different between groups with mean APTT of 40.8 in the heparin 1000iu/mL 
group compared with mean APTT of 129.7 in the heparin 5000iu/mL group (p<0.001).  
When expressed as the percentage rise in APTT from baseline to 10 minutes, there was a 
statistically significant difference between groups of median +22.2% (range 0, 210) rise in 
APTT in the heparin 1000iu/mL group compared with +373.7% (range 133, 800) in the 
heparin 5000iu/mL group (p<0.001).  This is demonstrated in table 4.2. 
 
Average catheter lifespan was 7 days in both heparin 1000iu/mL and heparin 5000iu/mL 
groups  (p=0.90).    Catheter  failure  secondary  to  insufficient  haemodialysis  blood  flow 
occurred in 3/13 cases in the heparin 1000iu/mL group compared with 4/15 cases in the 
heparin 5000iu/mL group (p=0.88).  The rates of catheter-related bacteraemia were similar 
with 2/13 cases in the heparin 1000iu.ml group compared with 2/15 cases in the heparin 
5000iu/mL group (p=0.83).  This is demonstrated in table 4.2.  
 
Recorded mean haemodialysis blood flow for the lifespan of the catheter was similar in 
both groups at 235mls/min in the heparin 1000iu/mL group compared with 231mls/min in 
the  heparin  5000iu/mL  group  (p=0.77).    Median  c-reactive  protein  measured  over  the 
lifespan of the catheter was similar in both groups at 51mg/L in the heparin 1000iu/mL 
group versus 47mg/L in the heparin 5000iu/mL group (p=0.39).  This is demonstrated in 
table 4.2.   113 
Variable 
 
Heparin 1000iu/mL 
 
Heparin 5000iu/mL 
 
P-value 
 
APTT at 0mins 
(seconds) 
 
 
28 (2.9) * 
 
27.7 (5.9) * 
 
p=0.88 
APTT at 10mins 
(seconds) 
 
40.8 (18.6) *  129.7 (47) *  p<0.001 
Change in APTT at 10mins 
(% ) 
 
+22.1% (0, 210) **  +373.8% (133, 800) **  p<0.001 
Catheter Lifespan 
(days) 
 
7  7  p=0.90 
Catheter-Related Bacteraemia 
 
N=2/13  N=2/15  p=0.88 
Catheter Thrombosis 
 
N=3/13  N=4/15  p=0.83 
Haemodialysis blood flow 
(mls/min) 
 
235 (26) *  231 (30) *  p=0.77 
Mean c-reactive protein 
(mg/L) 
51 (6, 313) **  47 (11, 91) **  p=0.39 
 
Table 4.2 – Comparison of outcomes between heparin 1000iu/mL and heparin 5000iu/mL groups.  ‘APTT’ = 
activated partial thromboplastin time. Values recorded as *mean (SD) or **median (minimum, maximum). 
 
 
4.4 Discussion 
 
This  study  has  demonstrated  that  use  of  heparin  as  a  catheter-locking  agent  in 
haemodialysis patients is associated with a significant degree of systemic heparinisation as 
demonstrated  by  prolongation  of  the  activated  partial  thromboplastin  time  (APTT).  
Systemic heparinisation occurred in both groups despite only instilling a volume of heparin 
equal to the internal catheter luminal volume stated by the catheter manufacturer.  It is 
therefore likely that despite this method of heparin instillation, overspill of the injected 
heparin occurs.  As a result, patients in both groups were exposed to an increased risk of 
haemorrhage  in  the  hours  immediately  following  catheter  insertion  and  after  catheter-
locking following each haemodialysis treatment.  There were, however, no instances of   114 
haemorrhage in either group over the course of the study, albeit within a relatively small 
cohort with a relatively short duration of follow-up. 
 
We  found  that  the  use  of  heparin  1000iu/mL  conferred  a  significantly  lower  risk  of 
systemic heparinisation than heparin 5000iu/mL.  These findings were demonstrated in the 
setting  of  a  prospective,  investigator-blinded,  randomised  study  and  confirm  similar 
findings reported in non-randomised non-blinded observational studies (110, 111).  The 
lack of any significant difference between groups with regard to the secondary outcome 
measures of catheter-related bacteraemia and catheter failure due to poor haemodialysis 
blood flow is of limited value due to the small sample size, the lack of power to examine 
these  outcomes,  the  heterogeneity  of  non-tunnelled  catheter  insertion  sites  and  the 
relatively short duration of follow-up.  These limitations must also be considered when 
considering the primary outcome measure.  The mixture of acute and chronic renal failure 
patients, the presence of diabetes, concurrent comorbid conditions and anticoagulant and 
antiplatelet use could be accounted for more comprehensibly by greater numbers of study 
participants. 
  
These findings support  those suggested by  previous retrospective observational studies.  
The routine use of a 5,000U/ml heparin lock solution equal to the estimated catheter lumen 
volumes in 13 haemodialysis patients in an ICU setting in Scotland was associated with an 
APTT ratio >7 in 53% of the 32 paired samples available for analysis from these patients 
(111).  Several studies have observed good catheter patency rates when 1000iu/mL heparin 
lock solutions were used in the control group of prospective studies designed to examine 
the effect of antibiotic lock techniques on the incidence of catheter-related bacteraemia 
(112, 113).  Whether use of 1,000iu/mL heparin is a suitable alternative across a large   115 
population of haemodialysis patients is uncertain as there is some evidence uncovered in 
larger populations that catheter patency may be compromised.  In a Canadian longitudinal 
study of 6940 haemodialysis sessions the use of a 1000iu/mL heparin  lock solution in 
central venous haemodialysis catheters was not associated with higher rates of catheter 
malfunction compared with the use of 10,000iu/mL heparin solution but the 1000iu/mL 
group did require greater anti-thrombotic intervention with thrombolytic drugs (56).   
 
 
4.5 Conclusion 
 
The optimal method of heparin-locking dialysis catheters remains uncertain.  Balancing the 
risks of catheter-thrombosis and subsequent catheter failure due to under-anticoagulation 
against the risk of bleeding and haemorrhage associated with increasingly  concentrated 
heparin  catheter  lock  solutions  is  of  primary  importance.    By  demonstrating  the 
significantly higher risk of systemic heparinisation with heparin 5000iu/mL compared to 
heparin 1000iu/mL, this randomised, investigator-blinded controlled trial helps quantify the 
contribution heparin concentration makes to one side of this debate, that of increased risk 
of bleeding. This work also demonstrates the need for a large randomised controlled trial to 
determine the optimal concentration of heparin solution with regard to risk of catheter-
thrombosis, catheter-related bacteraemia and significant haemorrhage. 
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Chapter 5 
An In-Vitro Analysis of Vancomycin in Combination with 
Heparin as an Antimicrobial Haemodialysis Catheter Lock 
Solution 
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5.1 Background 
 
The work detailed in chapters 2 and 3 demonstrate staphylococcal sub-species to be the 
most  prevalent  of  pathogens  in  haemodialysis  patients  with  bacteraemia.    The  high 
prevalence  of  Staphylococcus  epidermidis  and  Staphylococcus  aureus  bacteraemia  in 
patients with catheter-related infection has been demonstrated in similar studies of patients 
with catheter related infection (114).   These bacteria are endemic on the skin surface and 
constitute normal skin flora.  If, however, a patient has an indwelling medical device such 
as  a  catheter  this  may  become  colonised  by  these  flora.    Initially  a  catheter  may  be 
colonised by only one single organism, for example, S. epidermidis, however, the longer a 
catheter remains in place, more diverse microbial communities may form and involve other 
organisms  such  as  klebsiella  pneumoniae  and  proteus  mirabilis  (115).    Many  of  these 
organisms have the ability to form biofilm which has been found to be the underlying 
substrate to catheter infection, bacteraemia and resultant systemic infection (116, 117). 
 
Biofilms were first identified in 1943 by Zobell however it was not until the 1970s that 
their  role  in  causing  infection  was  realised  (118).    Many  definitions  of  biofilms  have 
evolved  over  the  years  as  understanding  and  knowledge  of  biofilm  structures  has 
developed.  A biofilm is said to be a complex community of sessile cells that attach to a 
substratum  and  to  each  other.    They  are  embedded  within  a  matrix  of  self-producing 
polymeric substances and they have altered phenotypes due to differences in growth rates 
and gene transcription in comparison to their planktonic counterparts (115).  Some bacteria, 
such as certain types of staphylococci produce extracellular slime which may interfere with 
the phagocytic activity of macrophages and thus make bacteria within the biofilm more 
resistant  to  innate  immune  responses  such  as  killing  by  active  oxygen  species  in   118 
leukocytes.    These  mechanisms  allow  biofilms  to  develop  resistance  to  biocides, 
phagocytes and antimicrobials with the degree of resistance correlating with the maturity of 
the biofilm (119-121).  It is well recognised that successful treatment of CRB requires the 
successful eradication of biofilm (119). 
 
The  antibiotic  lock  technique  has  been  developed  as  a  method  of  preventing  and 
eradicating biofilm on the endoluminal surface of haemodialysis catheters.  This involves 
instillation of a concentrated antibiotic-anticoagulant into the catheter lumen that is left to 
dwell between haemodialysis sessions.  This method delivers a small absolute amount
 of 
antibiotic to the patient but achieves a high local concentration
 in the catheter lumen that is 
100 to  5,000 times  higher  than  the
  minimum  inhibitory  concentration  (MIC)  for  the 
infecting bacterium.  Use of antibiotic lock solutions as a primary prevention strategy has 
raised concerns regarding the risks of developing antimicrobial resistance with leakage of 
the  antibiotic-lock  solution  into  the  circulation.    Using  antibiotic-lock  solution  as  a 
secondary  adjunctive  measure  to  systemic  antibiotics  in  treating  catheter-related 
bacteraemia (CRB) is, however, less contentious.   
 
The antibiotic-lock technique requires the safe and efficacious combination of an antibiotic 
and  an  anticoagulant.    Heparin  is  a  well-established  anticoagulant  used  for  locking 
haemodialysis catheters.  It is stable in combination with antimicrobials (122) although 
does not demonstrate anti-microbial activity itself (123).  Several studies have used heparin 
in  conjunction  with  various  antibiotics  and  demonstrated  stability  in  combination  and 
positive in-vitro and in-vivo benefits in preventing and treating infection over the short 
term (122, 124, 125).  Whilst this area continues to evolve, our understanding of how   119 
combinations of anticoagulant and antimicrobial interact is limited.  In this study the effect 
of heparin on the bactericidal activity of the  glycopeptide vancomycin  on free floating 
planktonic and biofilm-associated staphylococci was examined.  The work was conducted 
with a null hypothesis of heparin having no significant effect on the ability of staphylococci 
to interact with vancomycin.  
 
 
5.2 Methods 
 
Bacterial Strains 
 
Six clinical isolates of S. aureus, obtained from the Scottish MRSA Reference Laboratory 
(SMRSARL)  (Stobhill  Hospital,  Glasgow,  UK),  were  selected  on  the  basis  of  their 
recognised capacity to form biofilm.  These isolates had been genotyped at the SMRSARL 
using either pulsed-field gel electrophoresis (PFGE) for methicillin resistance S. Aureus 
(MRSA) isolates using the Harmony method or a PCR-ribotyping technique for methicillin 
sensitive (MSSA) strains.  These genotyped isolates consisted of three MRSA isolates; 
MRSA1  (epidemic  MRSA-15),  MRSA100  (epidemic  MRSA-16),  MRSA546  (epidemic 
MRSA-15) and three MSSA isolates; MSSA51, MSSA55 MSSA62. S. epidermidis RP62A 
(ATCC 35984), a known biofilm-forming strain, was used as a positive control in biofilm 
assay and S. aureus National Collection of Type Cultures (NCTC) 6571 (Oxford strain) 
was used as a control for antibiotic susceptibility testing assays.  
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All isolates were stored in Microbank® storage vials (Pro-Lan Diagnostics) at -70°C and 
sub-cultured on brain heart infusion (BHI) agar (Oxoid, Basingstoke, UK) prior to each 
assay. Stock solutions were prepared by overnight incubation in BHI broth before 1ml of 
each bacterial suspension solution was centrifuged to create a pellet.  100µL of each pellet 
was diluted in BHI to a solution with an optical density (OD) of 0.03 for planktonic work. 
 
Biofilm Formation 
 
Biofilm formation was performed by the method described by Shanks et al (126).  Cultures 
of staphylococcal sub-species NCTC 1, 100, 546, 51, 55, 62 and RP62 were incubated 
overnight in BHI broth before 5ml of each bacterial suspension solution was centrifuged to 
create a bacterial pellet of each organism.  100µL of each pellet was diluted in BHI to a 
solution with OD of 0.07 at 590nm.  150µL of each bacterial suspension was then added to 
a row of 12 individual wells of a 96-well microtitre dish.  The final row of the 96-well 
microtitre  dish  was  filled  with  150µL  of  uninoculated  BHI  broth  as  a  control.    A 
corresponding  96-peg  lid  plate  was  then  placed  over  the  96-well  dish  with  each  peg 
‘dipped’ within its corresponding solution-filled well.  The peg lid and well dish was then 
sealed and incubated at 37.0
oC on a ‘rocking’ incubator tray for 48 hours.  On removal 
from the rocking incubator the 96-peg lid was then washed in phosphate buffered saline to 
remove adherent cells with only biofilm remaining adherent to each peg. 
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Preparation of Antibiotic and Anticoagulant Solutions 
 
A range of stock vancomycin solutions: 10,000mg/L, 1000mg/L, 100mg/L and 10mg/L, 
were  prepared  using  sterile  distilled  water  as  a  diluent,  in  accordance  with  the  British 
Society for Antimicrobial Chemotherapy guidelines (127).    
 
Using these stock solutions, each column of a 96-well microtitre dish was instilled with 
75µL vancomycin solution of increasing concentration. Each well in column 1 contained 
75µL 0.015mg/L vancomycin solution with the concentration of vancomycin doubled in 
each successive column up to a concentration of 16mg/L in column 11.  Each well in the 
column 12 of the microtitre plate was filled with 75µL sterile water to act as control.  These 
vancomycin-filled  96-well  microtitre  plates  were  used  as  the  basis  on  which  the 
experiments on planktonic bacteria were conducted. 
 
Stock heparin solutions: 1000iu/mL and 2000iu/mL, were prepared using heparin sodium 
1000iu/mL solution. 
 
Three separate incubation media were created.  Media A contained 80ml Mueller-Hinton 
(MH)  broth  and  20ml  heparin  5000iu/mL  solution,  creating  a  MH-heparin  1000iu/mL 
broth.  Media B contained 60ml MH broth and 40ml heparin 5000iu/mL solution, creating 
a MH-heparin 2000iu/mL broth.  Media C consisted of 100ml MH broth without heparin. 
When  conducting  the  analysis  of  combined  vancomycin-heparin  solutions,  75µL  of 
heparin-based media was added to each well of the vancomycin-primed 96-well microtitre 
plates described above.   122 
Planktonic MIC evaluation 
 
To demonstrate the MIC of vancomycin against planktonic microbes, stock solutions of 
MRSA 1, 100, 546 and MSSA 51, 55, 62 and Oxford 6571 were prepared in the method 
described above to an OD of 0.3 at 590nm in Mueller-Hinton (MH) broth.  These solutions 
were diluted by a factor of 1 in 10 and 75µL of this solution was added to each well of the 
pre-prepared vancomycin plates, thus equating with approximately 5x10
5 Colony Forming 
Units (CFU)/ml, the recommended inoculum for MIC assays (127).  The experiment was 
repeated on a separate, duplicate 96-well vancomycin-inoculated dish.  The dishes were 
then sealed and incubated overnight.  After a 16-hour incubation period the OD of the well 
plates was read to assess the degree of bacterial growth. 
 
To  demonstrate  the  MIC  of  vancomycin-heparin  against  planktonic  microbes,  stock 
solutions of MRSA 1, 100, 546 and MSSA 51, 55, 62 and Oxford 6571 were prepared to an 
OD of 0.03 at 590nm using the MH-heparin 1000iu/mL (Media A) stock broth solution.  
75µL of this solution was added to each well of the pre-prepared vancomycin plates.  The 
dishes were then sealed and incubated overnight.  After a 16-hour incubation period the 
OD of the well plates was read to assess the degree of bacterial growth.  The experiment 
was then repeated using MH-heparin 2000iu/mL (Media B) stock broth solution.  Both 
experiments were carried out in duplicate. 
 
To demonstrate the effect of heparin on planktonic microbial growth, stock solutions of 
MRSA 1, 100, 546 and MSSA 51, 55, 62 and Oxford 6571 were then prepared to an optical 
density of 0.3 at 590nm in Mueller-Hinton (MH) broth.  These solutions were diluted by a 
factor of 1 in 10 with 75µL of each solution then added to columns of eight duplicate wells   123 
of a 96-well microtitre dish prepared with 75µL control MH broth alone, 75µL heparin 
1000iu/mL  solution  (Media  A)  or  75µL  heparin  2000iu/mL  solution  (Media  B).    A 
duplicate  set  of  96-well  microtitre  dishes  were  prepared,  with  both  sets  incubated 
overnight.  After a 16-hour incubation period the optical density of the well plates was read 
to assess the degree of bacterial growth. 
 
Biofilm MIC evaluation 
 
Biofilm growth was conducted by the method described above using bacterial suspension 
of staphylococcal sub-species NCTC 1, 100, 546, 51, 55, 62, Oxford 6571 and the control 
strain RP62. 
 
Each column of a separate 96-well microtitre dish was instilled with 75µL vancomycin 
solution  in  the  method  described  above  with  each  well  in  column  1  containing  75µL 
0.25mg/L  vancomycin  solution  and  the  concentration  of  vancomycin  doubling  in  each 
successive  column up to a concentration of 256mg/L in column 11.   Each well in the 
column 12 of the microtitre plate was filled with 75µL sterile water to act as control.  Each 
well was then inoculated with 75µL Media A containing the MH-heparin 1000iu/mL broth.  
The biofilm-containing peg plate was then dipped into the well plates and incubated on a 
rocking incubator tray for 16 hours. 
 
To assess biofilm production, the prepared biofilm-impregnated 96-peg lids were dipped 
into 0.5% crystal violet solution with contact time of 2 minutes before gently washing with 
sterile water (figure 5.1). The 96-peg lid was then dipped into a 96-well plate, each well   124 
containing 150µL 70% ethanol solution so as to leach the absorbed crystal violet from the 
cells. The absorbance of the resultant solution was measured at 570 nm using a microtitre 
plate reader (BMG LUMIstar* plate reader, BMG, Germany).  
 
   
Figure 5.1 – An example of a biofilm-impregnated 96-peg lid having been dipped into 0.5% crystal violet 
solution for contact time of 2 minutes. 
 
The experiment was then repeated using MH-heparin 2000iu/mL (Media B) stock broth 
solution and the heparin free MH broth solution (Media C).  All experiments were carried 
out in duplicate.  
 
Statistical Analysis 
 
Statistical  analysis  was  performed  by  SPSS
TM  version  14.0  (SPSS  Inc,  IL,  USA). 
Parametric testing with student’s t-test and non-parametric testing with the Wilcoxon-sign   125 
rank  test  were  used  in  the  assessment  of  continuous  variables  where  appropriate.    All 
reported p-values were based on two-sided testing with a significance level set at α < 0.05. 
 
 
5.3 Results 
 
In all the planktonic studies the MIC for the reference strain S. aureus NCTC 6571 Oxford 
strain was demonstrated at 1mg/L and was thus within one well dilution of the accepted 
MIC as determined by Andrews et al (127) and hence a valid control.  In all the biofilm 
studies, the reference strain of S. epidermidis NCTC RP62 grew biofilm as demonstrated 
by a significantly greater OD than the MH control wells (see below).  
 
Demonstrating the MIC of Vancomycin against planktonic microbes (pMIC) 
 
With regard to the MRSA sub-species, the pMIC of vancomycin was found to be 2mg/L 
for NCTC 1 and 1mg/L for NCTC 100 and 546.  With regard to the MSSA sub-species the 
pMIC of vancomycin was found to be 1mg/L for NCTC 51 and 55, and 2mg for NCTC 62. 
 
Demonstrating the pMIC of Vancomycin-Heparin  
 
When  incubated  in  MH-heparin  500iu/mL  solution,  the  pMIC  of  vancomycin  was 
demonstrated at 0.5mg/L for MRSA NCTC 1, 100 and 546.  With regard to the MSSA sub-
species the pMIC of vancomycin was found to be 1mg/L for NCTC 51, 55 and 62. 
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Demonstrating the effect of Heparin on planktonic microbial growth 
 
There was no significant change in OD following the addition of heparin to culture media 
for isolates of MSSA NCTC 55, 51 and MRSA NCTC 100.   
 
There was a significant increase in OD of both heparin-containing culture media with S. 
aureus NCTC 6571 compared to the MH control (MH control OD=0.628 v MH-heparin 
500iu/mL OD=0.695, p=0.01; MH-heparin 1000iu/mL OD=0.718 p=0.001).   
 
MRSA NCTC 1 demonstrated a significant decrease in OD when incubated with MH-
heparin  1000iu/mL  culture  media  compared  to  MH-heparin  500iu/mL  and  MH  control 
(MH-heparin  1000iu/mL  OD=0.348  v  MH-heparin  500iu/mL  OD=0.419,  p<0.001;  MH 
control OD=0.408, p<0.001).  
 
MRSA NCTC 546 demonstrated a significant decrease in OD when incubated with MH-
heparin  1000iu/mL  culture  media  compared  to  MH-heparin  500iu/mL  and  MH  control 
(MH-heparin  1000iu/mL  OD=0.164  v  MH-heparin  500iu/mL  OD=0.244,  p<0.001;  MH 
control OD=0.235, p<0.001).  
 
MSSA NCTC 62 demonstrated a significant decrease in OD when incubated with MH-
heparin  1000iu/mL  culture  media  compared  to  MH-heparin  500iu/mL  and  MH  control 
(MH-heparin  1000iu/mL  OD=0.467  v  MH-heparin  500iu/mL  OD=0.646,  p<0.001;  MH 
control OD=0.597, p<0.001).    127 
 
The comparison of OD between culture media for each bacterial isolate is demonstrated 
and summarised below in table 5.1.   
 
 
Table 5.1 – Mean optical density at 590nm of suspensions incubated in MH, MH-heparin 500iu/mL and MH-
heparin 1000iu/mL broth.  P-values quoted refer to statistical comparison with MH control. *Significant 
difference in comparison with MH-heparin 500iu/mL group with p<0.001. 
 
Assessment of Biofilm Production 
 
Mean OD for the BHI broth control was 0.210.  When compared to the BHI control the 
mean OD for each of the MRSA isolates was 0.253 for NCTC 1 (p=0.09), 0.318 for NCTC 
100 (p<0.001) and 0.346 for NCTC 546 (p<0.001). For each of the MSSA isolates, the 
mean OD was 0.668 for NCTC 51 (p<0.001), 0.389 for NCTC 55 (p<0.001) and 0.920 for 
NCTC 62 (p<0.001).  The mean OD for S. epidermidis RP62 was 0.288 (p=0.01) when 
compared with the BHI control.  Full results are reported in table 5.2. 
 
 
 
Media 
 
MRSA 
1 
MRSA 
100 
MRSA 
546 
MSSA 
51 
MSSA 
55 
MSSA 
62 
Oxford 
6571 
 
MH 
 
 
0.408 
 
 
0.504 
 
 
0.235 
 
 
0.546 
 
 
0.684 
 
 
0.597 
 
 
0.628 
 
 
 
MH + Heparin 500iu/mL 
 
 
0.419 
 
 
0.495 
 
 
0.244 
 
 
0.587 
 
 
0.603 
 
 
0.646 
 
 
0.695 
(p=0.01) 
 
 
MH + Heparin 1000iu/mL 
 
 
0.348 
(p<0.001)* 
 
0.487 
 
 
 
0.164 
(p<0.001)* 
 
0.58 
 
 
0.688 
 
 
 
0.467 
(p<0.001)* 
 
 
0.718 
(p=0.001) 
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Table 5.2 – Optical density at 590nm recorded in each well of a 96-well microtitre dish to assess biofilm 
formation of each bacterial strain in comparison with a control of BHI broth. 
  
Demonstrating the MIC of Vancomycin-Heparin against microbes in biofilm (bMIC) 
 
Biofilm production was assessed in MH broth. When assessing the bMIC of vancomycin 
against staphylococcal biofilms only MRSA NCTC 1 and 546 grew sufficient biofilm in 
the control wells to be suitable for assessment.  The bMIC of vancomycin was determined 
at 4mg/L for MRSA NCTC 1 and 8mg/L for MRSA NCTC 546. 
 
Biofilm production was then assessed in MH-heparin 500iu/mL broth.  All staphylococcal 
strains  produced  biofilm  in  the  control  wells.    The  bMIC  of  vancomycin  decreased  to 
<0.25mg/L for MRSA NCTC 1 and decreased to 2mg/L for MRSA NCTC 546.  The bMIC 
of vancomycin was determined at less than 0.25mg/L for MRSA NCTC 100 and MSSA 
NCTC 51, 55 and 62. 
 
Bacterial 
Strain  1  2  3  4  5  6  7  8  9 
 
 
10 
 
 
11 
 
 
12 
 
Mean 
OD  
 
P-value 
Control 
  0.172  0.195  0.23  0.215  0.259  0.212  0.226  0.216  0.203  0.203  0.204  0.188  0.210 
 
- 
MRSA 1 
  0.167  0.205  0.392  0.397  0.199  0.234  0.156  0.263  0.268  0.188  0.244  0.327  0.253 
 
p=0.09 
MRSA 100 
  0.22  0.281  0.283  0.401  0.312  0.332  0.307  0.291  0.425  0.271  0.264  0.431  0.318 
 
p<0.001 
MRSA 546 
  0.251  0.358  0.33  0.249  0.516  0.345  0.328  0.252  0.461  0.385  0.31  0.363  0.346 
 
p<0.001 
MSSA 51 
  0.302  0.397  0.647  0.465  1.005  1.195  0.74  0.339  0.62  0.931  0.69  0.689  0.668 
 
p<0.001 
MSSA 62 
  0.885  0.87  0.465  1.716  2.545  0.801  1.075  0.617  0.544  0.537  0.72  0.262  0.920 
 
p<0.001 
MSSA 55 
  0.3  0.305  0.505  0.283  0.305  0.487  0.354  0.584  0.434  0.382  0.383  0.343  0.389 
 
p<0.001 
StaphRP62 
  0.208  0.22  0.248  0.445  0.267  0.448  0.198  0.206  0.24  0.38  0.245  0.354  0.288 
 
p =0.01   129 
Biofilm production was then assessed in MH-heparin 1000iu/mL broth.  All staphylococcal 
strains  produced  biofilm  in  the  control  wells.    The  bMIC  of  vancomycin  remained 
<0.25mg/L  for  MRSA  NCTC  1  and  at  4mg/L  for  MRSA  NCTC  546  was  within  one 
dilutional well of the MIC determined in MH-heparin 500iu/mL.  The MIC of vancomycin 
was determined at less than 0.25mg/L for MRSA NCTC 100 and MSSA NCTC 51, 55, 62.   
 
Full results for both pMIC and bMIC are demonstrated below in table 5.3. 
 
 
Table 5.3 – The minimum inhibitory concentration (MIC) of vancomycin to each staphylococcal sub-species 
in  the  presence  of  vancomycin  alone  or  heparin  in  combination  with  vancomycin.    ‘pMIC’  minimum 
inhibitory  concentration  against  planktonic  bacteria.    ‘bMIC’  minimum  inhibitory  concentration  against 
biofilm-embedded bacteria. 
 
Bacterial 
Strain 
 
pMIC 
Vanc alone 
(mg/L) 
pMIC 
Vanc/Hep 500iu/mL 
(mg/L) 
bMIC 
Vanc alone 
(mg/L) 
bMIC 
Vanc/Hep 500iu/mL 
(mg/L) 
bMIC 
Vanc/Hep 1000iu/mL 
(mg/L) 
 
MRSA 1 
 
2  0.5  4.0  <0.25  <0.25 
MRSA 100 
 
1  0.5  -  <0.25  <0.25 
MRSA 546 
 
1  0.5  8.0  2.0  4.0 
MSSA 51 
 
1  1  -  <0.25  <0.25 
MSSA 55 
 
1  1  -  <0.25  <0.25 
MSSA 62 
 
2  1  -  <0.25  <0.25   130 
5.4 Discussion 
 
Several  important  themes  arise  from  these  data  when  relating  them  to  the  study  of 
antibiotic lock solutions.   
 
Whilst  published  work  in  animal  models  suggests  that  heparin  has  minimal  impact  on 
antimicrobial activity against staphylococci (123).  These in-vitro data demonstrated some 
planktonic  staphylococci  to  have  decreased  suppression  of  growth  whilst  others 
demonstrate  heightened  suppression  of  growth  when  heparin  was  added  to  incubation 
solution.   
 
Interestingly when introducing a fixed concentration of heparin to a range of vancomycin 
concentrations, heparin appeared to lower the minimum inhibitory concentration (MIC) of 
vancomycin in several instances.  The accepted convention in experiments to establish the 
MIC of antimicrobial solutions, however, allows the MIC to be reproducibly within one 
well dilution.  Consequently, whilst a drop in MIC occurred in four out of six staphylococci 
examined,  only  MRSA  NCTC  1  developed  a  greater  than  2-well,  and  thus  significant, 
dilution drop in MIC. 
  
When considering biofilm MIC experiments, the addition of heparin again appeared to 
significantly lower the MIC of vancomycin in the cases of MRSA NCTC 1 and 564.  The 
effect of heparin on the MIC of vancomycin of the other staphylococcal sub-species was 
unable to be fully assessed in this short study.  When heparin 500iu/mL was compared with   131 
heparin 1000iu/mL, the MIC of vancomycin was unchanged.  This would suggest that if 
heparin does potentiate the efficacy of vancomycin, the effect would appear not necessarily 
to be dose dependent under these conditions. 
 
Consequently, it can be concluded that under these conditions, heparin may independently 
heighten  or  suppress  bacterial  growth  when  used  on  its  own,  depending  upon  the 
staphylococcus  studied.    Across  a  range  of  vancomycin  concentrations,  the  addition  of 
heparin appears to have the effect of lowering the MIC in certain instances.  This suggests 
that  heparin  could  modulate  bacterial  growth  when  combined  with  the  antimicrobial 
vancomycin.    This  hypothesis  could  be  proven  by  performing  viability  counts  when 
repeating these experiments, demonstrating whether there is an increased killing effect.   
 
The  second  significant  finding  of  interest  was  the  demonstration  of  the  absolute  MIC 
values  for  planktonic  staphylococci  exposed  to  vancomycin  being  lower  than  those 
determined for biofilm embedded staphylococci exposed to vancomycin.  Biofilm produces 
a  physical  barrier  between  antimicrobials  and  bacteria  and  thus  is  more  resistant  to 
eradication  than  planktonic  bacteria.    To  eradicate  biofilm  embedded  bacteria,  the 
antimicrobial must penetrate the glycoprotein calyx before binding with the bacteria.  The 
introduction of heparin appears to enhance the action of vancomycin.  This could arise 
from  either  increased  delivery  of  vancomycin  to  biofilm  embedded  bacteria,  possibly 
through heparin neutralising the electrical barriers to vancomycin penetration, or increased 
delivery  of  bacteria  to  vancomycin,  possibly  through  the  negatively  charged  heparin 
preventing further biofilm formation or increasing bacterial release from biofilm (128).   132 
All these findings, however, must be tempered by the methodological limitations of the 
study.  This was a small study of only seven laboratory-grown staphylococcal isolates, 
albeit  known  biofilm  producers  and  thus  potential  pathogens  for  catheter-related 
bacteraemia.    An  evaluation  of  staphylococcal  isolates  taken  from  cases  of  proven 
staphylococcal catheter-related bacteraemia would have greater clinical validity.  Another 
important point to be considered is the relatively small number of duplicate experiments to 
ensure accuracy of the results.  Whilst the model of biofilm colonisation on the 96-peg 
plates appeared effective and reproducible, in some instances the biofilm yield was poorer 
than expected and thus could be optimised by refinement of the technique with duplication 
of the experiments in greater numbers.   
 
The use of vancomycin as the antimicrobial under study may also be seen as a limitation.  
The  choice  of  vancomycin  was  primarily  driven  due  to  its  use  as  the  antimicrobial  of 
choice within the Glasgow Royal Infirmary Renal Unit when empirically treating catheter-
related  bacteraemia.    Since  this  study  was  designed,  the  development  of  vancomycin-
resistant enterococci has led to gentamicin becoming a more commonly used antimicrobial 
for constructing catheter lock solutions.  Our use of vancomycin may, therefore, be seen as 
being of lesser clinical relevance than initially intended. 
 
Nonetheless  the  clinical  relevance  of  these  findings  remains  of  interest.    When  using 
heparin  alone,  there  may  be  varied  degrees  of  infection  risk  depending  on  the  type  of 
staphylococcal pathogens expressed with a haemodialysis population.  When considering 
combined  antimicrobial-anticoagulant  solutions,  in  clinical  practice  the  catheter  lock 
solution may be 5mLs in volume and contain 500mg of vancomycin, making an especially   133 
high local concentration of antimicrobial targeted against the biofilm within the lumen of 
the catheter – several higher than the MICs of the organisms expected to be pathogenic.  
We now know, however, that these solutions leak into the systemic circulation where the 
volume of distribution may be as high as 5 litres, and bathes the outer portions of the 
catheter where biofilm may congregate.  There may therefore be a theoretical disadvantage 
of these solutions – excellent intraluminal suppression of biofilm but at the expense of poor 
suppression of planktonic bacterial grown in the blood stream and biofilm production on 
the outside of the catheter derived from increasingly resistant populations of organisms.  
These theoretical limitations merit scrutiny as part of randomised controlled trials using 
bacteraemia,  resistance  patterns,  adverse  events,  catheter  thrombosis  and  mortality  as 
outcomes over both short and long-term periods of follow-up. 
 
 
5.5 Conclusion 
 
Currently, the evaluation of potential antibiotic lock solutions in-vitro is widely applied but 
its  execution  variable.    There  is  great  heterogeneity  in  the  types  of  organism  studied, 
whether  they  are  studied  in  planktonic  or  biofilm  models,  the  type  and  dose  of 
antimicrobial and the type and dose of anticoagulant.  It is widely accepted that biofilm is 
the underlying substrate to catheter-related bacteria.  The results of this work suggest that 
there are differing magnitudes of response to vancomycin and heparin between planktonic 
and biofilm-embedded staphylococci.  Consequently, in-vitro assessment of antibiotic-lock 
solutions should be based uniformly on biofilm models, be centred on their response to 
combinations  of  the  antibiotic  and  anticoagulant  at  clinically  relevant  doses  and  be   134 
conducted against organisms commonly implicated in the pathogenesis of catheter-related 
bacteraemia.    It  should  be  on  this  platform  that  clinical  evaluation  of  successfully 
performing catheter-lock solutions should be carried forward into in-vivo work. 
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Chapter 6 
Contrast-Enhanced Magnetic Resonance Venography of 
Central Veins for Assessment of Haemodialysis Vascular Access 
– A Six-Year Case Series  
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6.1 Background 
 
Patients  with  established  renal  failure  (ERF)  may  undergo  a  large  number  of  vascular 
access procedures during the course of their time on renal replacement therapy (RRT).  One 
of the most frequently  complicated vascular  access procedures is insertion of a central 
venous  catheter  (CVC)  (54,  129-131).    CVCs  are  inserted  under  many  different 
circumstances.  Up to 40% of ERF patients present late and require urgent commencement 
on haemodialysis which may only be secured with the placement of a CVC.  Many patients 
established on RRT may rely on CVC insertion when vascular access, in the form of an 
arteriovenous fistula or graft, has failed, is yet to be established or is immature. 
 
Occult  central  venous  stenosis  and/or  thrombosis  may  complicate  what  was  initially 
thought a straightforward catheter insertion in up to 65% of patients (132) and in many 
cases leads to distortion of the central venous architecture.  Furthermore, ERF patients have 
a tendency towards a hypercoaguable state arising from intrinsic defects in both platelet 
function  and  plasma  factor  abnormalities
  (133)  which  may  contribute  to  limiting  the 
lifespan of a CVC.  In patients who have suffered from complications of CVC insertion, 
subsequent  vascular  access  provision  with  catheters,  fistulae  and  grafts  may  become 
technically more demanding.  
 
Clinicians have been using imaging techniques to assist in vascular access provision for 
many years.  One such technique, contrast-enhanced magnetic resonance venography (CE-
MRV)  using  gadolinium  chelates,  has  been  available  for  some  years  now  with  proven 
speed,  accuracy  and  reproducibility  in  the  detection  and  evaluation  of  central  venous 
thrombosis and stenosis (54, 134, 135).  Recently CE-MRV has come under close scrutiny   137 
following reports indicating an association between the administration of gadolinium-based 
contrast agents and the development of the rare condition nephrogenic systemic fibrosis 
(NSF) (55, 77, 136-138).  The exact nature of this association is studied and described in 
detail in Chapter 7 of this thesis.   
 
Current recommendations limit the use of gadolinium contrast agents to patients with a 
creatinine clearance of >30mls/min/1.73m
2 which has effectively prevented the use of CE-
MRV in the established renal failure (ERF) population.  The value of CE-MRV in these 
patients  is  acknowledged  and  thus  the  use  of  non-linear  gadolinium  chelates,  contrast 
removal strategies and non-contrast based MR imaging are now being explored as possible 
methods of delivering imaging of the vascular tree to this vulnerable patient group.  
 
Whilst the risk of developing NSF is now fully appreciated, the benefits CE-MRV has 
made to vascular access provision have yet to be formally quantified.  The aim of this 
report is to clarify the contribution that CE-MRV made to the management of ERF patients 
in Glasgow Royal Infirmary over a 6-year period ending when the association with NSF 
was reported.  The indications, findings and contributions made in a historical case series 
of CE-MRVs are described and the relationship between a number of routinely recorded 
parameters taken at the time of imaging and findings reported on CE-MRV is investigated.  
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6.2 Methods 
 
Patients 
 
A retrospective analysis of all patients who received haemodialysis for ERF and underwent 
gadolinium CE-MRV between 1
st January 2000 and 1
st January 2006 was performed.  This 
cohort was derived by searching our renal unit electronic patient record for details of all 
patients who had received haemodialysis for ERF during this time period and had a record 
of having undergone magnetic resonance imaging at any time in the past.  To ensure no 
eligible  patients  were  overlooked,  an  additional  search  of  the  hospital  Radiology 
Information System (RIS – CRIS3, Healthcare Software Systems, Mansfield Woodhouse, 
Nottinghamshire, UK) was conducted for all patients who had undergone CE-MRV and 
this list cross-referenced with the renal unit records of ERF patients.  
 
Clinical data from the date at which CE-MRV was undertaken was retrieved from the renal 
unit electronic patient record and recorded for each patient.  This included records of age, 
blood pressure, presence of diabetes mellitus, underlying cause of renal failure, duration of 
renal replacement therapy, haemodialysis blood flow, urea-reduction ratio and the number 
and type of vascular access procedures that had been undertaken prior to CE-MRV.  From 
review of both the radiology records of the CE-MRV studies and the electronic patient 
records,  the  initial  indications  for  requesting  CE-MRV  in  each  case  were  recorded  as 
either; 1) investigation of clinically suspected venous stenosis, thrombosis and/or venous   139 
occlusion, or 2) a search for suitable site for vascular access provision. 
 
CE-MRV 
 
All examinations were performed on a 1.5 T MRI system (Gyroscan ACS NT, Philips 
Medical Systems, Best, The Netherlands) with the patient supine using a 4-element phased 
array body coil for signal reception over the thorax and upper arms in anatomical position 
(a minority of patients underwent imaging of the abdomino-pelvic veins with coils over the 
abdomen and pelvis in a similar manner).  The exact details of the CE-MRV protocol 
evolved  over  the  course  of  the  study  period  consequent  upon  hardware  and  software 
upgrades.    CE-MRV  was  always  performed  using  a  breath-hold  coronal  multiphase 
gadolinium contrast-enhanced technique with first acquisition timed using bolus tracking to 
systemic arterial phase upon contrast arrival in the aortic arch for thoracic studies.  At least 
two  successive  breath-hold  acquisitions  were  subsequently  performed  for  equilibrium  / 
venous phases, the first as soon after the first arterial dynamic phase as repeat breath-
holding would allow and the last within 3 minutes of contrast agent injection.  In essence 
this is an indirect CE-MRV technique imaging the central veins in phases after vascular 
distribution. 
 
Consultant vascular radiologists with a specific interest in MR angiography interpreted all 
CE-MRV  studies  on  a  dedicated  MRI  workstation  (EasyVision  &  ViewForum,  Philips 
Medical Systems, Best, The Netherlands). 
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Outcomes 
 
Radiological  outcomes  were  derived  from  the  radiologist’s  report  of  the  images  and 
categorised as to whether there was evidence of venous thrombosis alone, venous stenosis 
alone,  venous  thrombosis  and  stenosis  in  combination  or  whether  the  scan  did  not 
demonstrate any such abnormality.  
 
Clinical outcomes were sought from the renal unit electronic patient record which was 
interrogated to determine what subsequent vascular access management had been instituted 
in the period following CE-MRV as derived from clinic letters, discharge summaries and 
records of vascular access intervention.  Findings were summarised and recorded on the 
basis of whether following CE-MRV there was an immediate change in vascular access 
management (defined as within 2 weeks of CE-MRV), a future change in vascular access 
management (greater than 2 weeks and less than 6 months post CE-MRV) or whether no 
change in management occurred within 6 months of CE-MRV.  
 
In light of the subsequently published association between gadolinium contrast agents and 
NSF in this group of patients (55, 77, 136-138) any instances of NSF were deliberately 
sought in this cohort by review of all case records and related pathology reports.   
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Interpretation of Outcomes 
 
Tests of association between the outcomes of venous stenosis and venous thrombosis and 
the clinical and laboratory variables recorded at the time of CE-MRV were conducted by 
parametric  and  non-parametric  testing  as  appropriate.    Students  t-testing  and  Mann-
Whitney U testing were used in the analysis of continuous variables and Chi-square testing 
of categorical variables.  For all statistical analyses the reported p-values were based on 
two-sided testing with a significance level set at α < 0.05. 
 
 
6.3 Results 
 
Patient Data 
 
During the period 2000-2006 the renal unit and associated satellite haemodialysis units 
referred 62 patients in whom a total of 78 CE-MRVs were performed.  All CE-MRVs were 
requested to assess the central veins and aid in management of haemodialysis vascular 
access.  A total of 29/62 (46.8%) patients were male and 33/62 (53.2%) female with mean 
age 58.9yrs (16.14 SD). 18/62 (29.0%) patients were known diabetics.  Median length of 
time on renal replacement therapy was 804 days (range 26, 5982) (table 6.1).  
 
All patients had chronic renal failure requiring RRT with 12/62 (19.4%) having a primary 
glomerulonephritis, 17/62 (27.4%) an interstitial nephritis, 8/62 (12.9%) renal failure as   142 
part of a multi-system disease, 10/62 (16.1%) with diabetic nephropathy and 15/62 (24.2%) 
with a non-specified or unclassifiable cause for their renal failure.  
 
 
 
 
 
 
 
   
 
 
 
 
Table 6.1 – Baseline characteristics of the cohort immediately prior to undergoing CE-MRV. MABP = mean 
arterial blood pressure, AVF = arteriovenous fistula, CVC = central venous catheter. *Median (min, max). 
 
Of the patients studied, arteriovenous fistula or graft surgery had been undertaken on a 
median of 2 (range 0 to 8) occasions per patient prior to CE-MRV (figure 6.1).  Successful 
central  venous  catheterisation  had  been  undertaken  on  a  median  of  5  (range  0  to  22) 
occasions prior to CE-MRV (figure 6.2). 
Variable 
 
Mean (SD) 
Age (years) 
 
58.9 (16.1) 
Male / Female 
 
29/62 (46.8%) / 33/62 (53.2%) 
Diabetes 
 
18/62 (29%) 
Duration of RRT (days) 
 
804 (26, 5982)* 
Haemodialysis blood flow (ml/min) 
 
255.8 (59.9) 
Urea reduction ratio (%) 
 
67.5 (7.3) 
MABP (mmHg) 
 
96.6 (14) 
AVF / Graft creations 
 
2 (0,8)* 
CVC insertions 
 
5 (0, 22)*   143 
  
    
Figure  6.1  –  Frequency  plot  of  arteriovenous  (AV)  fistula  and  arteriovenous  graft  creation  procedures 
undertaken prior to CE- MRV. 
 
 
 
 Figure 6.2 - Frequency plot of number of central venous catheters inserted per patient prior to CE-MRV. 
   144 
Indications for CE-MRV 
 
Of the 78 CE-MRVs undertaken, the majority (72/78, 92.3%) were for assessment of the 
central veins of the neck and thorax with only a minority (6/78, 7.7%) studying the femoral 
and iliac veins plus inferior vena cava.  In a total of 46/78 (59.0%) investigations CE-MRV 
was requested in patients in whom there was clinical suspicion of veno-occlusive disease 
secondary  to  previously  established  vascular  access.  32/78  (41.0%)  CE-MRVs  were 
performed in order to establish suitable sites for future vascular access provision. 
  
Radiological Outcomes 
 
Of the 78 CE-MRVs undertaken 32/78 (41.0%) demonstrated venous stenosis alone, 6/78 
(7.7%) demonstrated venous thrombosis alone, 20/78 (25.6%) demonstrated both localised 
venous  stenosis  and  venous  thrombosis  within  the  large  veins  and  20/78  (25.6%) 
demonstrated no abnormalities of the central venous system. 
 
In patients where CE-MRV confirmed venous stenosis, univariate testing demonstrated a 
significant  association  with  increased  incidence  of  surgery  for  arteriovenous  fistulae  or 
synthetic arteriovenous grafts (stenosis=2.0 v no stenosis=1.0, p=0.040) and central venous 
catheterisation  (stenosis=6.0  v  no  stenosis=4.5,  p=0.034).    There  was  no  association 
between venous stenosis and patient age, gender, urea-reduction ratio, haemodialysis flow, 
mean arterial blood pressure, duration on renal replacement therapy or the presence or 
absence of diabetes mellitus.   145 
In patients where CE-MRV confirmed venous thrombosis, univariate testing demonstrated 
significantly lower haemodialysis flow rates (thrombosis 217.5mls/min v no thrombosis 
275mls/min,  p=0.002)  and  a  higher  mean  monthly  arterial  blood  pressure  (thrombosis 
101.5mmHg  v  no  thrombosis  94.2mmHg,  p=0.046).    There  was  no  association 
demonstrated  between  venous  thrombosis  on  CE-MRV  and  the  number  of  previous 
arteriovenous fistulae or grafts, the number of previous central venous catheters, patient 
age, gender, urea reduction ratio, duration on renal replacement therapy or the presence or 
absence of diabetes mellitus. 
 
Clinical Outcomes 
 
In 36/78 (46.2%) of cases changes to vascular access management occurred within a two 
week period of CE-MRV.  In nearly 30 cases this was achieved through the insertion of a 
tunnelled  central  venous  haemodialysis  catheter,  in  3  cases  through  percutaneous 
angioplasty/stenting of the central veins, in 2 cases patients were anticoagulated and in 1 
patient  previously  scheduled  endovascular  intervention  was  prevented  from  being 
unnecessarily attempted. 
 
In 27/78 (34.6%) of cases changes to vascular access management occurred within the 
period from two weeks to six months following CE-MRV.   
 
In 15/78 (19.2%) cases there was no documented evidence from the patient records that 
CE-MRV had directly influenced subsequent patient management.   146 
Patients  who  had  abnormalities  on  MRV  were  more  likely  to  undergo  vascular  access 
intervention  in  the  6  months  following  imaging  than  those  with  a  normal  CE-MRV 
(Abnormal MRV 50/58 (86.2%) v Normal MRV 12/20 (60%), p=0.031). 
 
From the whole cohort of 62 patients 4 were identified as having developed suspected NSF 
(51, 70, 128-130), each had received 30 ml gadodiamide for their CE-MRV studies or other 
MRI investigations (in one patient on 3 occasions in total) prior to the onset of symptoms 
attributed  to  NSF.    No  patients  in  our  series  receiving  gadobenate  dimeglumine 
(Multihance) alone are suspected of having developed this condition to date.  These cases 
are analysed in detail as part of a case-control study described in Chapter 7 (55). 
 
 
6.4 Discussion 
 
Arteriovenous  fistulae  are  widely  recognised  as  the  gold  standard  in  haemodialysis 
vascular access due to their lower rate of infective and thrombotic complications when 
compared to central venous haemodialysis catheters (139).  However, in settings where 
interim haemodialysis is required the advantage conferred by central venous catheterisation 
as  a  means  of  gaining  quick,  durable  and  reliable  access  to  the  vascular  tree  often 
outweighs  these  relative  disadvantages.    Consequently  central  venous  catheterisation 
remains a cornerstone in the maintenance of patients on haemodialysis.  Central venous 
catheterisation, however, may give rise to structural complications which may impact on 
the provision of future vascular access.  The demographics of this cohort describe such a   147 
group. In general, the majority of patients studied had been on renal replacement therapy 
for many months or years, had been exposed to multiple vascular access procedures and in 
whom the maintenance of vascular access had become actively problematic.  In the vast 
majority of cases CE-MRV gave a definitive assessment of venous patency that had proven 
difficult to quantify by clinical or other radiological means. 
 
The  methodology  used  was  observational,  retrospective  and  in  a  select  group  of 
problematic patients and thus has to be taken carefully in this context.  No control group 
was  studied  and  thus  these  findings  are  purely  observational  and  without  any  direct 
comparator.    Patient  selection,  the  pattern  of  vascular  access  usage,  the  threshold  for 
imaging  and  the  availability  of  CE-MRV  are  features  that  will  vary  across  different 
haemodialysis patient populations.  As such, MRV findings reported in this group may not 
be directly transferable to other haemodialysis populations and have to be observed within 
these limitations.  Despite these issues several important themes have been demonstrated.   
 
A total of 74% of CE-MRVs demonstrated abnormalities in the form of venous thrombosis, 
venous stenosis or both.  Patients with an abnormal CE-MRV were significantly more 
likely to have successful vascular access establishment in the 6 months following scanning 
than those with a normal CE-MRV.  This included instances where CE-MRV demonstrated 
positive findings that led to percutaneous venous angioplasty and stent insertion in three 
cases.  In another instance a patient was spared previously planned percutaneous venous 
angioplasty  and  stent  insertion  after  CE-MRV  failed  to  demonstrate  a  suitable  central 
venous anatomical abnormality.  Negative findings on CE-MRV for the central veins also 
proved useful with several patients who would have been considered for anticoagulation   148 
being  spared  unnecessary  treatment.    These  findings  suggest  that  the  anatomical  data 
generated by CE-MRV was an important contributor in the management of vascular access 
in this patient group.  
 
This case series also studied trends of association between baseline clinical variables and 
the vascular access complications found on CE-MRV.  The findings were consistent with 
the published literature to date, albeit in patient populations without ERF.  The association 
between low haemodialysis blood flow and central venous thrombosis is to be expected in 
an analysis such as this with low haemodialysis blood flow likely to be both a cause and 
effect of localised central venous thrombosis.  What is more difficult to explain is the 
positive association between an increased mean arterial pressure and venous thrombosis.  A 
potential  explanation  is  that  elevated  mean  arterial  pressure  is  a  marker  of  underlying 
cardiovascular disease and is hence associated with both vascular endothelial dysfunction 
and  an  underlying  thrombogenic  state.    This  is  an  area  that  is  not  addressed  by  this 
particular study design but would merit future investigation.  
 
A  further  interesting  finding  is  a  positive  association  between  the  number  of  previous 
arteriovenous fistulae or synthetic graft procedures and the development of central venous 
stenosis.  These methods of vascular access often deliver high velocities of turbulent blood 
flow back into the venous tree that could theoretically give rise to local vascular endothelial 
dysfunction and create a predisposition to an increased thrombogenic state.  A prospective 
examination of the relationship between arteriovenous fistulae or synthetic grafts, markers 
of vascular endothelial function and the development of mechanical complications such as 
venous thrombosis and stenosis would be required to investigate this.  Such work would 
help build a definition of the ‘at-risk’ patient and therefore identify those most likely to   149 
derive benefit from vascular access planning and targeted intervention. 
 
Several reports have compared the utility of CE-MRV with venography and ultrasound in 
patients who have required vascular access to administer fluid, chemotherapeutic drugs or 
nutrition or who have been clinically suspected of having central vein thrombosis (140-
145).  These reports indicated CE-MRV to be superior in demonstrating differing degrees 
of  venous  stenosis,  thrombosis  and  anatomical  variation  when  compared  to  ultrasound 
(140-142).    In  comparison  with  traditional  venography,  CE-MRV  was  found  to  be 
equivalent in assessing venous patency and better at demonstrating venous anatomy and 
blood  flow  whilst  being  less  invasive,  avoiding  radiation  and  avoiding  exposure  to 
potentially nephrotoxic iodinated contrast (141-145).  The finding of venous stenosis in 
66.6%  of  the  study  population  is  approximately  equitable  to  the  prevalence  of  venous 
stenosis seen in similar patient populations who have used venography (132).  Differing 
prevalence of stenosis and thrombosis in such studies may be accounted for by patient 
selection, different patterns of vascular access usage, differing thresholds for imaging and 
variability in access to imaging. 
 
CE-MRV  was  however  found  to  be  associated  with  significant  health  risk  with  four 
patients  within  the  cohort  being  subsequently  found  to  have  developed  NSF.    These 
patients underwent gadolinium contrast-enhanced studies prior to the issuing of the FDA 
and ACR guidelines on the use of gadolinium-based contrast agents in patients with renal 
dysfunction  (146,  147).    The  association  between  the  administration  of  different 
gadolinium contrast agents in patients with ERF and the development of NSF was clearly 
of concern and was investigated further, the details of which are described in the next 
chapter.     150 
 
Clearly, however, CE-MRV would appear to have been of value in the majority of patients 
in this cohort.  Alternatives to traditional gadolinium CE-MRV where the risk of NSF is 
minimised and the quality of anatomical data  generated preserved, should be explored.  
This may be achieved by focussing on the use of non-linear gadolinium chelates, contrast 
removal strategies and non-contrast based MRI.  These methods are now being explored as 
possible means of imaging the vascular tree to this vulnerable patient group.  
 
 
6.5 Conclusion 
 
These data have demonstrated that CE-MRV has been an effective imaging modality in the 
assessment,  planning  and  maintenance  of  haemodialysis  vascular  access  with  central 
venous  catheters.  Use  of  CE-MRV  has  been  shown  to  be  associated  with  significant 
changes to vascular access management and clinical decision-making whilst offering what 
appeared until recently to be a more acceptable side-effect profile than the previous gold-
standard technique of contrast venography in patients with renal failure.  These advantages, 
however,  must  now  be  considered  against  the  risk  association  with  the  use  of  specific 
gadolinium-based contrast agents in ERF.  Only once the NSF issue is resolved can CE-
MRV have an effective role in patients with problematic vascular access. 
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Chapter 7 
Gadolinium-Enhanced Magnetic Resonance Imaging and 
Nephrogenic Systemic Fibrosis – A Retrospective Study of a 
Renal Replacement Therapy Cohort 
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7.1 Background 
 
Nephrogenic  systemic  fibrosis  (NSF)  (previously  labelled  nephrogenic  fibrosing 
dermopathy)  was  first  described  in  2000.    The  earliest  published  cases  described  a 
scleromyxoedema-like  condition  affecting  patients  with  advanced  kidney  disease.  
Typically,  the  condition  presents  cutaneously  with  thickening,  oedema,  induration  or 
discolouration of the skin of the limbs and trunk, although most commonly with facial 
sparing.  Progressive disease may result in joint contractures and subsequent loss of limb 
function.  Fibrosis of other organ systems may occur with resultant end-organ dysfunction 
(148-150).  Mortality has been noted to be high although anecdotal improvement in both 
morbidity  and  mortality  has  been  reported  following  recovery  of  renal  function,  either 
spontaneously  or  after  renal  transplantation,  or  with  immunomodulatory  treatments 
including extracorporeal photophoresis and phototherapy (151-154). 
 
The diagnosis of NSF was made initially on clinical grounds alone although histological 
features  which  may  support  the  diagnosis  are  now  widely  accepted.    Skin  lesions 
demonstrate dermal thickening, which stains positive for mucin, and with collagen bundles 
which  traverse  down  into  the  superficial  fascia  (155).    Fibrous  bundles  contain 
CD34/procollagen  expressing  fibroblast-like  cells  and  CD68/FactorVIIIa  expressing 
dendritic-like cells.  The combination of these typical pathological and laboratory features 
distinguishes NSF from similar conditions including systemic sclerosis, scleromyxoedema 
and eosinophilic vasculitis. Indeed, to fully confirm a diagnosis of NSF, the absence of 
scl70 and anti-centromere antibodies as well as a normal serum electrophoresis (136, 156) 
should be obtained.   153 
To date, 304 patients have been reported to the NSF registry (155, 157).  Demographically, 
these patients have been found to be similar to the general established renal failure (ERF) 
population although mean age is lower (136, 158).  Vascular disease, thrombotic events, 
chronic liver disease and the presence of anti-phospholipid antibodies have been associated 
with NSF, although not directly implicated in its pathogenesis (156, 159-163).  
 
Since 1998 the increasing use of gadolinium-enhanced magnetic resonance imaging (MRI) 
in ERF to avoid iodinated contrast exposure has paralleled the description of patients with 
NSF.  Several case series have since explored the association between NSF and exposure to 
gadolinium containing contrast agents, reporting a relatively high frequency of gadolinium-
enhanced MRI in patients prior to developing NSF (77, 164-168).   
 
This  retrospective  study  was  designed  to  compare  the  frequency  of  administration  and 
cumulative dose of gadolinium contrast agent in a cohort of dialysis dependent patients 
who did and did not develop NSF.   
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7.2 Methods  
 
Patients 
 
A retrospective analysis of all patients who received renal replacement therapy (RRT) for 
established  chronic  renal  failure  (Stage  V  Chronic  Kidney  Disease,  eGFR<15mls/min) 
within the renal units of two city teaching hospitals and associated satellite units in the 
West of Scotland, between 1
st January 2000 and 1
st July 2006 was conducted.  Patients 
were analysed as to whether they had a diagnosis of NSF and with regards their previous 
exposure to  gadolinium contrast-enhanced MRI.  The local ethics  committee granted  a 
waiver of review for the study and also waived the need for informed consent. 
 
The patient cohort was obtained through a search of the unitary electronic patient record 
(EPR),  a  computerised  database  containing  details  of  all  patients  who  have  ever  been 
referred to either of the two units.  An EPR search was conducted to determine all patients 
within the two hospitals who had undergone RRT for stage V CKD between 1
st January 
2000 and 1
st July 2006.  Patients who had functioning renal grafts throughout the study 
period and thus did not receive dialysis and all patients who received RRT for acute renal 
failure for less than 90 days were excluded.  Age, gender, underlying renal diagnosis, time 
on RRT, mode of RRT and mortality were recorded from the EPR for each patient in the 
cohort.  
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Database Interrogation 
 
Diagnosis  entries  on  the  EPR  for  all  patients  on  RRT  with  stage  V  CKD  were  then 
searched for the terms “nephrogenic”, “systemic”, “fibrosis”, “fibrosing”, “dermopathy”, 
“scleroderma”, “scleromyxoedema” and “sclerosis”.  All patients with a positive match for 
any of these search terms were reviewed thoroughly with respect to the clinical history and 
histopathological records to determine those patients with a diagnosis of NSF.  Where the 
original biopsy specimens were available they underwent further review by a pathologist to 
ensure the validity of the original diagnosis.  Age at starting RRT, age at diagnosis, sex, 
cause of renal failure, dialysis modality, time on RRT, the presence of a confirmatory skin 
biopsy,  serum  bicarbonate  (mmol/l)  at  time  of  MRI,  weight  (kg)  at  time  of  MRI, 
subsequent treatment, whether they recovered renal function, clinical outcome, duration of 
follow-up and the time period between imaging and a subsequent diagnosis of NSF were 
recorded for each NSF patient.  
 
The EPR was then interrogated with regard to the cohort’s previous exposure to MRI.  The 
type  of  MRI  scanner  used,  number  and  type  of  gadolinium-enhanced  MRI  studies, 
cumulative gadolinium dosage (mls), cumulative gadolinium dosage adjusted for weight 
(mmol/kg),  average  dose  per  scan  (mmol/kg/scan)  and  type  of  gadolinium  chelate  was 
recorded for each patient.  Where complete data was not provided in the radiology reports 
held on the EPR, hand searching of the radiology departmental records was conducted.  
Gadolinium exposure was calculated over the six and a half-year period for all non-NSF 
patients and for the period 1
st January 2000 until the first presentation of disease for all 
patients in the NSF group.  Weight adjusted dose was calculated by using the dry weight at   156 
the time of imaging in the case of haemodialysis patients or recorded weight within six 
weeks  of  imaging.    The  number  of  MRI  scans  undertaken  prior  to  and  following  the 
diagnosis  of  NSF  was  recorded  for  each  NSF  patient.    The  cumulative  frequency  of 
gadolinium-enhanced MRI and NSF cases was recorded for the study period. 
 
Statistical Analysis 
 
Statistical analysis was performed by SPSS
TM version 14.0 (SPSS Inc, IL, USA).  Shapiro-
Wilk testing for normality was performed on continuous variables with rejection of the null 
hypothesis  of  normality  at  a  significance  level  of  α  <  0.05.    Testing  for  equality  or 
homogeneity of variance was conducted using Levene's tests.   
 
Difference in mean age between NSF and non-NSF patients was assessed by Students’ t-
test.    Prevalence  of  gadolinium-enhanced  MRI  exposure  between  NSF  and  non-NSF 
groups  was  assessed  by  Chi-square  testing.    Differences  between  median  number  of 
gadolinium-enhanced  MRI,  median  cumulative  dose  of  gadolinium  contrast  (mls  and 
mmol/kg) and median dose of  gadolinium contrast (mls/kg/scan) in NSF and non-NSF 
groups were assessed by Wilcoxon rank sum testing.  Differences in gender and mortality 
were assessed by Chi-square testing.  All reported p-values were based on two-sided testing 
with a significance level set at α < 0.05.   157 
7.3 Results 
 
Patients 
 
1826 stage V chronic kidney disease patients who had received RRT for ERF in North 
Glasgow Renal Units during the study period were identified.  The mean age at starting 
RRT  was  58.8  years  and  1053/1826  (57.7%)  patients  were  male.    In  total,  253/1826 
(13.9%) commenced RRT due to ERF as a result of a primary glomerulopathy, 374/1826 
(20.5%) with an interstitial nephropathy, 336/1826 (18.4%) with a multi-system disease, 
281/1826 (15.4%) with diabetic nephropathy and 582/1826 (31.9%) with an unknown or 
unclassifiable cause of their renal failure. 
 
MRI characteristics  
 
Over the 6 and a half-year period, 421/1826 (23.1%) patients underwent a total of 542 
gadolinium-enhanced  MRI.    Examinations  performed  using  contrast-enhanced  MRI 
included  angiography  (430/542,  79.3%),  cardiac  studies  (90/542,  16.6%)  and  central 
nervous system imaging (22/542, 4.1%).  A total of 379/542 (69.9%) contrast enhanced 
MRI  examinations  were  performed  on  1.5T  superconducting  systems  whilst  163/542 
(30.1%)  were  performed  on  1.0T  superconducting  systems.    Most  examinations  were 
assigned 30-minute appointments except for cardiac studies, which were usually scheduled 
1.5 hours.  However, the exact time duration for static RF field and pulse sequence varying 
fields would have been variable and was not recorded.  480/542 (88.6%) MRI scans were   158 
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performed with gadodiamide (Omniscan, GE Healthcare, Chalfont St Giles, UK) with a 
median dose volume of 30ml, reflecting the predominant use of this agent in the West of 
Scotland  since  1998.    62/542  (11.4%)  scans  were  performed  using  other  gadolinium-
containing contrast agents as follows: 41/542 (7.6%) MRI used gadobenate dimeglumine 
(Multihance, Bracco S.p.A., Milan, Italy) as the contrast agent with median dose volume of 
15ml.  13/542 used gadopentetate dimeglumine with a median dose of 15mls (Magnevist, 
Berlex, Canada), 6/542 gadobutrol with a median dose of 15mls (Gadovist, Schering, West 
Sussex, UK) and 2/542 gadofosvest trisodium with a median dose of 10mls (Vasovist, 
Schering, West Sussex, UK).  The annual incidence of gadolinium-enhanced MRI among 
the  cohort  steadily  increased  until  2004  with  fewer  scans  undertaken  in  2005  and  a 
subsequent reduction in contrast-enhanced MRI in patients on RRT in response to the FDA 
warning issued in June 2006.  The incidence of NSF parallels the rise in MRI imaging in 
the RRT cohort and is demonstrated in figure 7.1. 
 
 
 
 
 
 
 
   
 
Figure 7.1 - Frequency of MRI and NSF incidence from January 2000 to July 2006 (x-axis), number of 
gadolinium-enhanced MRIs (line) and incidence of NSF (square dots). The increasing use of MRI parallels 
the identification/development of patients with NSF.   159 
NSF versus non-NSF cases  
 
The clinical and laboratory characteristics of the patients with NSF are demonstrated below 
in table 7.1 
Patients  1  2  3  4  5  6  7  8  9  10  11  12  13  14 
Sex  M  F  M  F  M  F  F  M  F  F  M  F  F  F 
Primary 
diagnosis 
U  P  DM  GN  DM  GN  U  AP  DM  P  DM  P  GN  GN 
Skin biopsy  Y  Y  Y  Y  Y  Y  Y  N  Y  Y  Y  Y  N  Y 
Age (years)  63.2  61.0  43.5  54.3  67.1  49.0  63.7  43.7  37.7  20.5  60.4  58.5  59.8  73.2 
Age starting 
RRT (years) 
61.6  56.6  42.4  22.2  67.0  49.0  56.7  38.9  35.1  17.0  59.9  51.7  59.1  66.2 
Time on RRT 
(years) 
1.6  4.4  1.1  32.1  0.1  0.0  7.0  4.8  2.6  3.5  0.5  6.8  0.7  7.0 
RRT mode  PD  HD  HD  HD  HD  HD  HD  HD  HD  HD  HD  HD  PD  HD 
HCO3 
(mmol/l) 
22  24  26  25  18  28  18  36  17  25  23  26  29  21 
Photophoresis    Y      Y                   
Renal function  -  -  -  -  -  Sp  -  -  -  -  -  Tx  -  - 
Follow up 
(days) 
691  2006  72  105  80  1863  178  252  30  460  257  799  533  50 
Outcome  S  I  D  D  S  I  D  D  na  D  D  S  S  na 
 
Table 7.1 - Baseline characteristics of NSF patients.  M, male; F, female; U, unknown; P, pyelonephritis; 
DM, diabetes mellitus; GN, glomerulonephritis; AP, adult polycystic kidney disease; Y, yes; N, no; Time on 
RRT,  at  diagnosis  with  NSF;  RRT  mode,  at  the  time  of  NSF  diagnosis;  PD,  peritoneal  dialysis;  HD, 
haemodialysis;  HCO3,  serum  bicarbonate  level  within  30  days  of  MRI;  -,  no  change;  Sp,  spontaneous 
improvement;  Tx,  renal  transplant;  Outcome,  of  NSF;  S,  stable;  I,  improved;  D,  dead;  na,  not 
applicable/follow up time too short for comment. 
 
From the full cohort, a total of 14/1826 (0.77%) patients had an established diagnosis of 
NSF as evident by clinical and pathological findings noted within the clinical records and 
on further review of the biopsy material where available.  Despite skin biopsy not being   160 
performed in two patients the clinical picture, based on examination and laboratory tests, 
was  considered  consistent  with  the  diagnosis  of  NSF  by  both  a  dermatologist  and 
nephrologist.    With  the  caveat  that  the  NSF  group  were  relatively  few  in  number  in 
comparison to the non-NSF group, the mean age at starting RRT was significantly lower 
for NSF patients at 48.3yrs (p=0.022) and the median time on RRT at diagnosis was 3 
years.    A  comparison  of  the  characteristics  of  patients  with  NSF  and  without-NSF  is 
detailed in table 7.2 below. 
 
Table 7.2 - Clinical characteristics of the complete RRT cohort comparing those with a diagnosis of NSF to 
those without.  All variables expressed as value (%). *Variable expressed as mean (SD). 
 
 
  
 
Characteristic  NON-NSF   NSF   Significance 
Level 
 
Number of patients 
 
n=1812  n=14  - 
Age  58.8yrs (16.9)* 
 
48.3yrs (15.1)*  p=0.022 
Prevalence of Gadolinium MRI  408/1812 (22.5%)  13/14 (92.9%)  p<0.001 
EDTA Diagnosis  
     Primary Glomerulonephritis 
     Interstitial Nephropathy 
 
     Multisystem Disease 
 
     Diabetic Nephropathy 
 
     Unknown/Unclassifiable 
 
n=249/1812 (13.7%) 
 
n=370/1812 (20.4%) 
 
n=336/1812 (18.5%) 
 
n=277/1812 (15.3%) 
 
n=580/1812 (32.0%) 
 
 
n=4/14 (28.6%) 
 
n=4/14 (28.6%) 
 
n=0/14 
 
n=4/14 (28.6%) 
 
n=2/14 (14.3%) 
 
- 
 
- 
 
- 
 
- 
 
- 
Proportion Male:Female 
 
1.37  0.55   p=0.095 
Mortality at end of study period  707/1812 (39.0%)  6/14 (42.9 %)  p=0.77 
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The prevalence of and relative dosing of gadolinium-enhanced MRI within the cohort and 
amongst NSF patients is described in tables 7.3 and 7.4 respectively. 
 
Characteristic 
 
NON-NSF  NSF  Significance Level 
Prevalence of Gadolinium-MR  n=408  n=13  P<0.001 
Gadodiamide Dose (ml)  30  45  P<0.001 
Gadodiamide Dose (mmol/kg)  0.23  0.39  P=0.008 
Gadodiamide Dose (mmol/kg/scan)  0.21  0.20  P=0.83 
Scan Number  1 (1, 6)  2 (1, 3)  P=0.009 
MRA/V  323/455 (71.0%)  16/25 (64.0%)  P=0.46 
 
Table 7.3 - Pattern of MRI and gadodiamide dosage for the complete RRT cohort.  Gadodiamide doses and 
scan number are given as medians. MRA/V, proportion of MRI performed for angiography. 
 
Patient  1  2  3  4  5  6  7  8  9  10  11  12  13  14 
MRI Imaging  Y  Y  Y  N  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y 
Total Dose (ml)  90  90  40  na  30  30  90  45  45  60  45  40  58  75 
Total Dose 
(mmol/kg) 
0.60  0.47  0.20  na  0.16  0.30  0.61  0.41  0.39  0.90  0.27  0.21  0.39  0.65 
Dose 
(mmol/kg/scan) 
0.20  0.16  0.20  na  0.16  0.30  0.20  0.41  0.39  0.45  0.27  0.21  0.19  0.13 
MRI-NSF time 
(days) 
76  83  477  na  2395  35  2  4  16  52  64  289  99  441 
MRI pre NSF  3  3  1  0  1  1  3  1  1  2  1  1  2  5 
MRI post NSF  1  2  0  0  1  1  1  1  0  3  0  0  1  0 
 
Table 7.4 - Pattern of MRI and gadodiamide dosage within NSF patients.  Y, yes; N, no.  Total median dose 
of gadodiamide administered prior to onset of NSF is given in ml and mmol/kg.  Median gadodiamide dose 
per scan is given in mmol/kg/scan.  MRI-NSF time is the time interval between gadolinium-enhanced MRI 
and NSF onset; MRI pre NSF is the total number of MRI scans prior to NSF diagnosis; MRI post NSF is the 
number of MRI scans performed after a diagnosis of NSF.   162 
13/14 patients with NSF had undergone gadolinium-enhanced MRI, all having been dosed 
with gadodiamide (tables 7.3 and 7.4).  None of the NSF patients had been exposed to any 
of  the  other  gadolinium-based  contrast  agents.    One  patient  (patient  4)  in  our  study 
developed biopsy proven NSF without prior exposure to gadolinium.  This patient had been 
on  renal  replacement  therapy  for  32  years,  had  previous  thrombotic  vascular  disease 
(diagnosed  by  conventional  angiography)  and  was  known  to  have  chronic  hepatitis  C 
infection.  An extensive review of her past medical history was undertaken to ensure no 
gadolinium-enhanced MRI had been undertaken.  This patient died within 3 months of the 
diagnosis of NSF and thus direct questioning of the patient could not be performed.  
 
Analysis  of  the  full  cohort  demonstrated  a  strongly  significant  association  between 
undergoing gadolinium-enhanced MRI and the subsequent development of NSF (table 7.3, 
non-NSF 408/1812, 22.5% v NSF 13/14, 92.9%, p<0.001).  The relative risk of developing 
NSF following gadolinium–enhanced MRI was 43.38 ({13/421/{1/1405}).  13/421 (3.1%) 
of the ERF population exposed to gadodiamide developed NSF with 14/1826 (0.77%) of 
the RRT population having developed NSF.  When considering the 421 patients who had 
undergone gadolinium-enhanced MR, patients with a diagnosis of NSF were exposed to a 
significantly higher total dose of gadodiamide than their non-NSF counterparts (median 
45ml v 30ml, p<0.001).  This was supported by weight-adjusted data (median 0.39mmol/kg 
v 0.23mmol/kg, p=0.008).  Weight data was incomplete for 19 patients, all within the non-
NSF group, which were excluded.  Patients underwent a median of 1 scan per patient in 
both groups, however the distribution of scanning events demonstrated a greater proportion 
of gadolinium scans within the NSF group (p=0.009).  No difference was found in the 
average dose of gadodiamide per scan between the groups (median 0.20mmol/kg NSF v   163 
0.21mmol/kg non-NSF, p=0.83) nor in the proportion of gadodiamide scans undertaken for 
angiography (16/25, 64% NSF v 323/455, 71% Non-NSF) (table 7.3). 
 
The time between gadolinium exposure and presentation with NSF ranged from 2 to 2395 
days  (median  time  76  days).    Five  patients  developed  NSF  greater  than  90  days  after 
receiving gadodiamide.  Of these, three had a time of onset greater than one year.  Six 
patients within the NSF group had undergone previous gadolinium-enhanced MRI without 
apparent complication and eight went on to receive further exposure after presentation with 
NSF. 
 
Outcome of NSF Patients 
 
Within the full cohort no significant difference between NSF and non-NSF groups was 
found with regard to mortality (p=0.77).  At the end of the study period 6/14 (42.9%) of 
patients with NSF had died however, the follow-up period for four of the remaining eight 
patients was less than three months.  The median time to death following diagnosis of NSF 
was 215 days.  In three patients the cause of death was recorded as sepsis-related occurring 
in  hospital,  two  patients  suffered  an  in-hospital  cardiac  arrest  (one  in  the  context  of 
hyperkalaemia) and one patient died suddenly at home, all without subsequent post-mortem 
examinations.    Two  patients  demonstrated  mild  functional  improvement  determined  by 
regular review at dialysis out patient clinics and patient self-reporting of symptoms: Patient 
2  started  extracorporeal  photophoresis  in  January  2005  and  patient  6  had  spontaneous 
improvement of renal function to an eGFR of 49ml/min.  Patient 5 started extracorporeal 
photophoresis in June 2006 and patient 12 received a functioning renal transplant in June   164 
2006 but there was no detectable clinical improvement in their NSF at the end of the study 
period.  
 
 
7.4 Discussion  
 
A link between gadolinium-based contrast agents, in particular gadodiamide, and NSF was 
first postulated in January 2006, (77, 165) with further reports emerging thereafter (164, 
166-169).  At the time this study was completed there was no other case-control series 
examining  this  association  or  determining  if  there  was  a  cumulative  gadolinium  dose-
related relationship with the subsequent development of NSF.  
 
These  data  align  closely  with  those  which  have  reported  an  association  between 
gadolinium-enhanced MRI and the development of NSF in patients with ERF.  These data 
suggest the association to be dose-dependent.  No patient exposed to only a single standard 
dose of contrast agent (15 ml of 0.5 mol/l agent, approximately 0.1 mmol/kg) developed 
NSF.  1 in 130 (0.77%) of the overall ERF population developed NSF, however 1 in 32 
(3.1%)  of  the  ERF  population  exposed  to  gadolinium-enhanced  MRI  developed  the 
condition.  Mortality did not appear to differ significantly from that of the regular RRT 
population during this follow-up period. 
 
When considering the international NSF registry, more than 95% of reported cases are said 
to  have  evidence  of  gadolinium  exposure  (170).    Indeed,  one  patient  in  this  study 
developed biopsy proven NSF without evidence of prior exposure to gadolinium.  A clear   165 
explanation of this remains elusive but such cases suggest that exposure to gadolinium may 
not be the sole causative feature to developing NSF.  Similarly, in patients exposed to 
gadolinium, although the median time from gadolinium administration to the onset of NSF 
symptoms  was  76  days,  in  four  there  was  a  period  of  months  to  years  before  clinical 
features developed.  This lag time is longer than that reported by some other groups (77, 
164-166, 171).  Such findings suggest that gadolinium, although causally implicated, is not 
the only factor involved in NSF.   
 
The  combination  of  renal  dysfunction  and  gadolinium  exposure  heighten  the  risk  of 
developing NSF.  Why these conditions predispose to NSF is uncertain.  What we do know 
is that gadodiamide is distributed in the extracellular fluid and excreted unchanged by the 
kidneys  with  an  elimination  half-life  in  normal  renal  function  of  80–100  minutes.  
Consequently 72 hours following gadolinium administration up to 95% has been excreted 
in  individuals  with  normal  renal  function  (176).    The  pharmacokinetics  of  gadolinium 
handling  in  established  renal  failure  is  poorly  understood  however,  in  patients  with  a 
glomerular  filtration  rate  of  2-10  ml/min,  not  on  dialysis,  the  elimination  half-life  of 
gadodiamide intravenous injection has been found to be approximately 34 hours.  It follows 
that the lower excretion rate of gadolinium in established renal failure leads to a longer 
period of cumulative gadolinium exposure.   
 
The type of gadolinium chelate used in contrast studies may also impact on the degree of 
free gadolinium exposure. Different gadolinium chelates demonstrate varying properties in 
terms of their structure (linear versus macrocyclic), electrochemistry (ionic versus non-
ionic)  and  affinity  towards  binding  proteins.    Gadolinium-based  contrast  agents  differ   166 
significantly  with  respect  to  their  propensity  to  transmetallate  (release  toxic  free 
gadolinium from the chelate) and in terms of their kinetic and thermodynamic stability. 
Gadodiamide  has  a  lower  conditional  stability  constant  compared  to  other  gadolinium 
chelates  despite  the  addition  of  excess  chelate  (169,  170,  173-175).    This  could  be  a 
plausible explanation for the especially pronounced association gadodiamide has with the 
development of NSF compared with other chelates.  This remains a theoretical concept and 
the  transmetallation  theory  has  yet  to  be  observed  in  pharmacokinetic  studies  of  ERF 
patients.  Indeed, it is not clear if alternative gadolinium-based agents are safer or if the 
preponderance of patients with NSF related to gadodiamide simply reflect its pattern of 
use. 
 
Acidosis, anaemia and hypoalbuminaemia at the time of MRI exposure have been cited as 
potential cofactors in the development of NSF (77, 165, 169, 171).  In this work no such 
associations  were  seen.    Such  data  are  very  difficult  to  interpret  in  a  study  of  this 
methodology as patients may undergo MR imaging to investigate co-morbid conditions 
including vascular disease or sepsis, which may be responsible for these abnormalities and 
potentially confound any association demonstrated.  
 
How does gadolinium exposure relate to the development of NSF?  Several recent studies 
using spectroscopy have demonstrated the presence of gadolinium in the skin of some, but 
not  all,  patients  with  NSF  (169,  176-179).    One  autopsy  study  has  demonstrated  the 
deposition of gadolinium in the heart and vasculature of patients who died following a 
pathological diagnosis of NSF (180).  A pathological study of biopsy  proven NSF has 
demonstrated  deposition  of  gadolinium  in  irregular  small  aggregates  that  adhered  to 
collagen fibres within connective tissue in the dermis (179).  Fibrocytes extracted from   167 
these  deposits  in  NSF  patients  have  been  demonstrated  to  synthesise  excess  levels  of 
hyaluronan  and  collagen  (181).    These  findings  have  led  researchers  to  speculate  that 
gadolinium deposited within the dermis is phagocytosed by tissue macrophages, triggering 
a localised cytokine cascade that promotes the release of pro-fibrotic mediators.  These in-
vitro  studies,  along  with  in-vivo  studies  such  as  this,  may  strengthen  the  association 
between gadolinium-based contrast agents and development of NSF; however have yet to 
prove causation.  
 
Once NSF develops the clinical course appears varied.  Some reports suggest a proportion 
of  patients  undergo  gradual  improvement  in  symptoms  over  time.    This  appears  most 
pronounced  in  those  who  have  subsequently  undergone  renal  transplantation  and  thus 
gained a degree renal function.  Complete recovery of NSF symptoms with ongoing stage 
V  kidney  disease  has  yet  to  be  described.    The  majority  appear  to  suffer  heightened 
morbidity and impaired quality of life arising from musculoskeletal and other end-organ 
dysfunction.    Reports  to  date  suggest  that  approximately  5%  of  NSF  patients  have 
especially aggressive disease that may progress and rapidly result in premature death (138).  
Within  this  study  follow-up  times  were  short  although  mortality  was  not  increased  in 
patients with NSF when compared to their non-NSF counterparts. 
 
No  consistently  successful  treatment  for  NSF  has  emerged  but  extracorporeal 
photophoresis (ECP) has been advocated (151, 152, 182).  ECP involves extracorporeal 
exposure  of  blood  cells  to  photoactivated  8-methoxypsoralen,  which  are  subsequently 
reinfused.  How this exposure translates into a reduction in symptom burden is unknown.  
Some have postulated a role for ECP in modulating the activity of circulating fibrocytes 
however this has yet to be demonstrated in-vitro or in-vivo and thus remains a speculative   168 
explanation (151).  One patient in this cohort had undergone ECP with some improvement 
and a second commenced treatment just prior to the end of the study period.  Randomised 
controlled trials of ECP treatment have yet to be performed in NSF patients.   
 
The restoration of renal function, whether by treatment of the underlying renal disease or 
by renal transplantation, anecdotally appears to confer a degree of symptomatic relief.  Up 
to 65% of injected gadodiamide may be eliminated during a single haemodialysis session 
whilst approximately 69% may be excreted over a 22-day period in patients on regular 
peritoneal dialysis (183).  A more aggressive regime of peritoneal dialysis involving 10 to 
15 exchanges per day has been shown to cause a 90% reduction in circulating gadolinium 
(182).  Whilst these data suggest that an aggressive dialysis strategy following gadolinium 
exposure may be beneficial, one study describes three patients in whom NSF developed 
despite daily haemodialysis on each of the three days immediately following gadodiamide 
exposure (164).  These data suggest such a strategy is therefore of limited benefit.   
 
This  report  has  several  limitations,  predominately  arising  through  its  retrospective 
observational design.  Thorough patient review was conducted in an attempt to control for 
this although some issues could not be adequately addressed.  The duration of each MRI 
scan was not recorded and examinations were performed on separate scanners, hence no 
comment can be made on the relationship between scan duration, magnetic field strength or 
MRI system type and development of NSF.  The study population was restricted to those 
with CKD Stage V with no analysis of patients with acute renal failure or earlier stages of 
CKD.  These populations are considerably greater in size than the stage V CKD population 
and  thus  establishing  the  risk  of  developing  NSF  in  these  groups  is  of  considerable 
importance.    As  stipulated  earlier,  pathological  confirmation  of  NSF  is  becoming   169 
increasing important.  Two patients in this study did not undergo skin biopsy and thus 
histological confirmation of the diagnosis could not be made.  Conversely, the possibility 
that  other  patients  with  NSF  were  not  diagnosed  cannot  be  excluded,  especially  as 
awareness of the disease was limited 6 years ago.  In comparison with the RRT population 
studied the NSF caseload was small in number and this limited the use of more detailed 
statistical analyses that could examine independence of association alongside other clinical, 
laboratory and demographic variables.   
 
 
7.5 Conclusion 
 
This  study  confirms  the  association  between  gadodiamide-enhanced  MRI  and  the 
development of NSF in patients with Stage V CKD and undergoing RRT.  These findings, 
together  with  those  of  other  studies,  suggest  that  gadodiamide  should  no  longer  be 
considered  as  without  risk  for  use  in  patients  with  advanced  renal  failure  (glomerular 
filtration rate < 15ml/min) and undergoing RRT.    170 
 
 
 
 
 
 
 
 
 
Chapter 8 
 
Discussion and Conclusions 
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8.1 Independent Risk Factors for Adverse Clinical Outcomes 
   
The primary aim of this thesis was to perform a detailed evaluation of the risks to health 
conferred by  aspects pertaining to the  establishment and maintenance  of haemodialysis 
vascular access in patients with renal failure.   
 
The work detailed in chapter 2 was a retrospective analysis of bacteraemia and mortality in 
a cohort of haemodialysis patients with established renal failure that was representative of a 
typical  UK  chronic  haemodialysis  population.    Despite  a  retrospective  methodology  in 
which a ‘snapshot’ of vascular access was related to outcomes over a subsequent 18-month 
period, use of a synthetic vascular access catheter was found to have an especially strong 
independent  association  with  risk  of  bacteraemia  and  death  compared  with  use  of  an 
arteriovenous  fistula.    These  effects  were  found  to  be  independent  of  known  adverse 
prognostic factors such as advanced age, sex, diabetes, anaemia, and the other clinical and 
laboratory variables that were studied.  The demonstration of such a relationship despite a 
methodology that was not sensitive to changes in vascular access type suggested that use of 
central venous catheters may have an especially strong association with adverse outcomes 
compared with other clinical and laboratory variables. 
 
Both  the  non-tunnelled  and  tunnelled  central  venous  catheter  groups  in  this  study 
demonstrated  poorer  outcomes  than  their  arteriovenous  fistula  counterparts.    Closer 
scrutiny  of  the  two  groups  demonstrated  those  patients  using  tunnelled  central  venous 
catheters (TCVCs) to have been on renal replacement therapy (RRT) for a longer period of 
time  compared  to  patients  with  non-tunnelled  central  venous  catheters  (NTCVCs).  
Analysis  of  the  individual  case-mix  suggested  this  to  be  a  product  of  patients  whose   172 
peripheral vasculature had been exhausted of attempts to create an arteriovenous fistula or 
graft.  Indeed, the demographics and co-morbidities of the TCVC group and arteriovenous 
fistula (AVF) group were found to be very similar and thus the conclusion that adverse 
outcomes are independently associated with TCVC use when compared to AVFs would 
appear to be valid.  When considering the NTCVC group, it was evident that this consisted 
of a higher proportion of patients who had commenced RRT for established renal failure 
within three months of study entry and in this setting the co-morbidities that often arise 
during this period may have contributed to the difference in clinical outcomes seen in this 
particular group when compared to the TCVC and AVF groups.   
 
Whilst this study suggested that central venous catheter use was associated with poorest 
outcomes, the different characteristics expressed by the TCVC and NTCVC groups made 
direct comparison limited.  What was not clear was the degree to which the different event 
rates  expressed  between  groups  was  a  function  of  the  clinical  characteristics  of  those 
undergoing  a  specific  type  of  catheter  insertion,  or  a  function  of  the  type  of  catheter 
insertion procedure itself.  The lack of detailed data on comorbidity, other than the data we 
included regarding age, duration on RRT and diabetes compounded this problem. 
 
To  address  these  limitations,  a  prospective  study  of  catheter  insertion  procedures  was 
designed.    This  methodology  allowed  real-time  measurement  of  a  broader  number  of 
comorbidity markers including Charlson score – a validated means of comorbidity scoring 
– and was sensitive to real-time changes in vascular access method.  The ensuing data, 
presented in chapter 3, demonstrate the significant differences between tunnelled and non-
tunnelled central venous haemodialysis catheter insertion procedures in terms of rates of 
catheter-related  bacteraemia  and  another  clinically  significant  outcome  in  catheter  use,   173 
catheter failure due to poor and unsustainable haemodialysis blood flow.  Patients with 
TCVCs demonstrated consistently better outcomes than those using NTCVCs, independent 
of the wide range of clinical and laboratory characteristics that were recorded.  Within the 
NTCVC groups a clear hierarchy of independent risk association was seen with de-novo 
internal jugular catheterisation being the best performing NTCVC procedure and guidewire 
catheter exchange in the femoral veins being the poorest performing NTCVC procedure.  
Again,  these  outcomes  were  independent  of  other  important  clinical  and  laboratory 
variables.   
 
These data bring greater clarity to the interesting debate of whether such adverse events 
develop  as  a  function  of  the  characteristics  of  the  catheterisation  procedure  or  the 
characteristics  of  the  patient  receiving  the  catheter.    It  appears  that  the  catheterisation 
procedure, in terms of tunnelling and site of insertion, contributes independently and most 
significantly  to  these  important  clinical  outcomes.    The  demonstrated  hierarchy  of  risk 
association within NTCVC insertion procedures is of considerable clinical relevance; this 
should help guide clinical practice and could even be used as an evidence-based foundation 
on which clinical guidelines for central venous catheterisation for haemodialysis may be 
built. 
 
Whilst the study provided as detailed an account of independent risk association that most 
prospective observational studies could offer, the definitive answer to these questions can 
still only be achieved by randomised controlled trials.  Until such studies are conducted and 
designed  to  account  for  variables  such  as  the  number  of  previous  vascular  access 
procedures and standard baseline clinical and laboratory demographics, our understanding   174 
of vascular access will remain limited to such observational work.  Furthermore, this study 
was limited to outcomes that relate to infection and thrombosis, other outcomes such as 
mortality, subsequent rates of conversion onto a functioning AVF or graft and subsequent 
sustainability of that AVF or graft remain of considerable interest.  Mapping the vascular 
access  journey  for  a  population  of  haemodialysis  patients  and  relating  this  to  these 
outcomes may identify the key junctures in which haemodialysis patients either follow a 
path of optimally safe, long-term, vascular access establishment, or may deviate down a 
route of repeated short lifespan vascular access methods, high complication rates and early 
death.  By identifying these points on a population level, interventions designed to prevent 
adverse outcome could be applied and outcomes improved.  It is these areas in which there 
remains a pressing need for further in-depth study. 
 
 
8.2 Optimising Catheter Performance with Lock Solutions 
 
Once  established,  the  successful  maintenance  of  patent  central  venous  catheters  for 
haemodialysis is of critical importance.  Historically the most common complication that 
limited  catheter  lifespan  was  catheter  thrombosis.    Unfractionated  heparin  has  become 
almost  universal  in  its  use  across  the  world  as  a  catheter-locking  agent  by  preventing 
intraluminal catheter thrombosis due to its proven anticoagulant effect.  Catheter-locking 
practices have, however, evolved over recent years with an increase in the use of combined 
solutions  that  both  limit  thrombosis  and  lower  risk  of  catheter-related  bacteraemia  by 
preventing and reducing bacterial biofilm.  Whilst the benefits of catheter-locking with 
combined  anticoagulant  and  antimicrobial  solutions  are  becoming  increasingly  well   175 
documented, the potential limitations or pitfalls of these techniques have not been fully 
explored.  The work described in chapters 4 and 5 examine the potential for catheter lock 
solutions to leak into the systemic circulation in patients, and examine how combinations 
of anti-coagulant and antimicrobial may alter their antimicrobial properties in vitro. 
 
The  work  described  in  chapter  4  successfully  demonstrated  that  use  of  heparin  as  a 
catheter-locking agent in haemodialysis patients is associated with a significant degree of 
systemic  heparinisation  as  demonstrated  by  prolongation  of  the  activated  partial 
thromboplastin  time  (APTT).    Systemic  heparinisation  occurred  in  both  of  the  groups 
studied,  either  heparin  1000iu/mL  or  5000iu/mL,  despite  only  instilling  a  volume  of 
heparin equal to the internal catheter luminal volume stated by the catheter manufacturer.  
Use of heparin 1000iu/mL conferred a significantly lower risk of systemic heparinisation 
than  heparin  5000iu/mL.    There  were,  however,  no  instances  of  haemorrhage  in  either 
group over the course of the study, albeit within a relatively small cohort with a relatively 
short duration of follow-up.  The lack of any significant difference between groups with 
regard  to  the  secondary  outcome  measures  of  catheter-related  bacteraemia  and  catheter 
failure due to poor haemodialysis blood flow is of limited value due to the small sample 
size,  the  lack  of  power  to  examine  these  outcomes,  the  heterogeneity  of  non-tunnelled 
catheter insertion sites and the relatively short duration of follow-up.   
 
Whilst these findings are of particular clinical interest routine clinical practice cannot be 
greatly shaped by this study.   In specific instances however, such  as when performing 
haemodialysis in patients with a significant bleeding risk, use of a lower concentration of 
heparin  solution  may  be  conducted  knowing  that  this  will  lead  to  less  systemic   176 
heparinisation  between  dialysis  sessions  and  thus  would  be  an  appropriate  additional 
measure to undertake. 
  
This study does raise other important clinical points, especially when considering the utility 
of combined anticoagulant-antimicrobial catheter lock solutions.  The concept of occult 
leakage of catheter lock solution into the systemic circulation may promote an environment 
in which antimicrobial resistance could be allowed to flourish.  Within the catheter lumen 
the  concentration  of  antimicrobial  is  invariably  very  high  and  contained  within  a  low 
volume of only a few millilitres – few, if any, susceptible microbes could survive in such 
an  environment  let  alone  develop  antibiotic  resistance.    If  the  solution  leaks  into  the 
systemic  circulation  the  volume  of  distribution  for  that  antimicrobial  increases 
considerably.    This  dilution  may  produce  systemic  levels  of  antimicrobial  that  are  of 
sufficiently low concentration to promote the preferential growth of antimicrobial-resistant 
microbes.    When  considering  a  population  of  haemodialysis  patients  the  emergence  of 
antimicrobial resistance could lead to significant morbidity and mortality.  Through the 
same mechanism other adverse effects, such as ototoxicity with gentamicin, may become 
increasingly expressed by a dialysis population through continuous cumulative exposure to 
an antimicrobial.  It must be emphasised, however, that such limitations only realistically 
apply to those in whom concurrent systemic delivery of the antimicrobial is not taking 
place.  As such, these limitations would only appear relevant to those undergoing primary 
prevention of bacteraemia as opposed to those with a catheter-related bacteraemia who are 
reliant  upon  catheter  salvage  i.e.  use  of  catheter  locking  as  an  adjunctive  secondary 
prevention  strategy.    Indeed,  how  the  addition  of  catheter  lock  solutions  to  standard 
catheter salvage practice may affect outcome is another important question which remains 
to be fully evaluated.   177 
This study highlights both the need for detailed outcome data when evaluating combined 
catheter lock solutions, and the need for long-term follow-up of the patient populations in 
which  these  techniques  are  trialled.    Whilst  these  uncertainties  persist  there  remains  a 
pressing need for a means of maintaining catheter patency and limiting bacteraemic events 
in  haemodialysis  patients  with  the  minimum  of  adverse  events.    Optimal  catheter  lock 
solution composition, technique of delivery and circumstances of use remain to be fully 
clarified and shall require continued study. 
 
It is also important to determine whether any interaction between constituent anticoagulant 
and antimicrobial solutions may exist and, if so, how this may affect overall performance.  
The work detailed in chapter 5 aimed to elicit whether any such interaction occurs between 
heparin and vancomycin on planktonic and biofilm embedded staphylococci.  
 
These  in-vitro  data  demonstrated  that  heparin  alone  may  independently  heighten  or 
suppress bacterial growth, depending upon the staphylococcus studied.  Across a range of 
vancomycin concentrations, the addition of heparin appeared to have the effect of lowering 
the MIC.  Similar patterns were seen when considering biofilm embedded staphylococci.  
This  suggests  that  heparin  could  modulate  bacterial  growth  when  combined  with  the 
antimicrobial vancomycin.  Repeating these analyses with viability counts would be a way 
of testing this hypothesis by demonstrating the killing effect of the lock solution.  
 
Whilst of pharmacokinetic interest, these in-vitro findings were elicited in a small study of 
seven laboratory-grown staphylococcal isolates, albeit known biofilm producers and thus 
potential  pathogens  for  catheter-related  bacteraemia.    An  evaluation  of  staphylococcal   178 
isolates taken from cases of proven staphylococcal catheter-related bacteraemia would have 
greater clinical validity.  The relatively small number of duplicate experiments and sub-
optimal quality of the biofilm modelling are all aspects of the methodology that would 
require further refinement before these conclusions could be meaningfully advanced.   
 
These findings are, however, of significant clinical interest.  Standard catheter practice in 
many renal units involves catheter locking with heparin alone.  Whilst this may suppress 
growth of staphylococcal sub-species, others may experience heightened growth.  When 
considering  combined  antimicrobial-anticoagulant  solutions  excellent  intraluminal 
suppression of biofilm may be achieved but, with occult leakage, may occur at the expense 
of  poor  suppression  of  planktonic  bacterial  grown  in  the  bloodstream  and  biofilm 
production on the outside of the catheter containing increasingly resistant populations of 
organisms and perhaps accelerated by the presence of heparin.   
 
These theoretical limitations merit scrutiny.  This may be achieved by further laboratory 
study  looking  at  intraluminal  and  extraluminal  biofilm  growth  under  differing 
antimicrobial-anticoagulant  conditions.    On  a  clinical  level,  the  role  of  extraluminal 
catheter  biofilm  versus  intraluminal  catheter  biofilm  with  regard  to  risk  of  metastatic 
bacterial  infection  such  as  endocarditis  and  osteomyelitis  remains  unclarified  and  the 
presence  of  secondary  metastatic  infection  would  be  a  useful  clinical  endpoint  when 
considering  the  clinical  utility  of  combined  antimicrobial-anticoagulant  catheter  lock 
solutions  in  vivo.    Randomised  controlled  evaluation  of  combined  antimicrobial-
anticoagulant  solutions  using  bacteraemia,  resistance  patterns,  adverse  events,  catheter 
thrombosis and mortality as outcomes over both short and long-term periods of follow-up   179 
could further tease out the relative advantages and disadvantages of these practices.  By 
performing such studies optimal catheter-locking practice with  combined antimicrobial-
anticoagulant solutions may be determined.  
 
 
8.3 Vascular Imaging in Haemodialysis Patients 
 
Patients  on  RRT  for  many  months  or  years  are  exposed  to  multiple  vascular  access 
procedures.  As time on RRT progresses vascular access complications may accumulate, 
impairing the function of existing access and limiting the availability of sites for future 
access.    It  is  under  these  circumstances  that  imaging  of  the  central  veins  is  used  to 
determine appropriate access points to the vascular tree with the aim of linking suitable 
venous architecture with optimal access function.  Contrast enhanced magnetic resonance 
venography (CE-MRV) had become increased used over recent years due to its proven 
speed,  accuracy  and  reproducibility  in  the  detection  and  evaluation  of  central  venous 
thrombus  and  stenosis  (54).    Few  had,  however,  formally  quantified  its  clinical 
applicability and thus the work detailed in Chapter 6 was designed, studying all CE-MRV 
examinations undertaken in haemodialysis patients within Glasgow Royal Infirmary Renal 
Unit. 
 
This  work  described  the  abnormalities  found  on  CE-MRV  and  the  subsequent  clinical 
course  followed  by  the  patients  in  whom  CE-MRV  imaging  was  undertaken.    The 
methodology used was observational, retrospective and in a select group of problematic 
patients and thus has to be taken carefully in this context.  Despite these limitations several   180 
important themes were demonstrated.  CE-MRV gave a definitive assessment of venous 
patency  that  had  proven  difficult  to  quantify  by  clinical  or  other  radiological  means.  
Abnormalities were found in 74% of CE-MRVs with patients in whom an abnormality was 
found being significantly more likely to have successful vascular access establishment in 
the  6  months  following  scanning  than  those  with  a  normal  CE-MRV.    A  positive 
association  between  the  number  of  previous  arteriovenous  fistulae  or  synthetic  graft 
procedures and the development of central venous stenosis was demonstrated.  Negative 
findings on CE-MRV also proved useful with several patients.  
 
These advantages however have had to be tempered with the emergent finding that four 
patients within the cohort developed nephrogenic systemic fibrosis (NSF) following CE-
MRV.  This coincided with the emergence of gadolinium contrast agents as a potential 
causative agent in the pathogenesis of NSF in published literature (77).  The serious nature 
of the condition effectively ended the mainstream usage of CE-MRV in RRT patients and 
highlighted  the  benefit  of  post-marketing  surveillance  when  considering  the  use  of 
medicines/contrast  media  extending  into  specific  patient  sub-groups.    Given  the 
uncertainties surrounding the aetiology and pathogenesis of NSF, the work described in 
chapter 7 was designed.  On completion of this study there was no other case-control series 
examining  this  association  or  determining  if  there  was  a  cumulative  gadolinium  dose-
related relationship with the subsequent development of NSF. 
 
The findings of this study supported the reported association between gadolinium-enhanced 
MRI  and  development  of  NSF  in  patients  with  ERF.    The  relationship  appeared  dose 
related although mortality appeared to be unaffected when compared with the non-NSF 
cohort studied.  One patient in the study developed biopsy proven NSF without exposure to   181 
gadolinium and in several instances the median time from gadolinium administration to the 
onset of NSF symptoms was relatively prolonged.  These findings suggest that gadolinium, 
although causally implicated, was not the only factor involved in the development of NSF.  
 
This  study  provided  a  significant  step  forward  in  our  understanding  of  the  association 
between  gadolinium  and  NSF  development.    Importantly,  however,  this  study  reported 
association,  not  causation  and  thus  only  provides  a  basis  on  which  pathogenetic 
mechanisms can be hypothesised before being tested by in-vitro and in-vivo assessment.  
Several key areas require scrutiny. 
 
Firstly,  the  sequence  of  events  linking  gadolinium  exposure,  renal  dysfunction  and  the 
development of a pro-fibrotic response requires elucidation.  A number of in-vitro studies 
have highlighted the prolonged excretion of gadolinium in renal failure, the deposition of 
gadolinium in the dermis and the pro-fibrotic responses that arise from local tissue injury in 
association with gadolinium deposition.  These in-vitro data need to be pursued further 
before  a  solid,  tangible  pathogenetic  mechanism  can  be  put  forward.    Secondly,  can 
modulation of these variables be undertaken that not-only reduces but obviates the risk of 
developing NSF?  The comparison of cyclic versus linear gadolinium chelates, effective 
renal replacement strategies that limit exposure/heighten excretion of the chelate and the 
generation of antifibrotic targets all merit detailed study.  Thirdly, what treatment strategies 
are  effective  in  limiting  the  morbidity,  progression  and  mortality  associated  with 
established NSF?  Few, if any of the therapeutic options reported have more than anecdotal 
support to their use.  Given the rarity of the condition and the assumption that the case 
incidence will decline following the withdrawal of CE-MRV in stage V CKD, this question 
may never be fully answered.  Whilst these issues remain unresolved the benefits that CE-  182 
MRV provided cannot go unrecognised and thus there remains a significant need to pursue 
other methods of imaging the vascular tree in which such reproducible image quality is 
obtained without any resultant adverse effect.  
 
 
8.4 Conclusions 
 
Successful vascular access provision is the bedrock on which successful haemodialysis is 
built.    The  considerable  expansion  of  haemodialysis  worldwide  has  been  built  on  a 
template of simple vascular access rules – fistula first, catheters when in crisis.  Within 
these  rules  it  is  clear  that  no  method  of  vascular  access  remains  risk  free.    With  the 
increasing provision of haemodialysis to aging, comorbid populations these rules require 
refinement and each facet of access provision requires close scrutiny. 
 
This thesis has provided a detailed evaluation of the risks to health conferred by some of 
the key elements of haemodialysis vascular access provision and maintenance.  The clear 
hierarchy of adverse risk across vascular access types, the spectrum of independent risk 
association  expressed  across  the  range  of  catheter  insertion  procedures,  the  varied 
considerations required when assessing catheter locking strategies and the advantages and 
disadvantages of imaging the vascular tree are important themes which have been explored, 
developed and clarified within this thesis.  Many questions have been answered and yet in 
many  instances  another  set  of  important  questions  have  arisen.    It  is  of  considerable 
importance  that  many  of  the  issues  described  in  this  thesis  continue  to  be  explored, 
solutions  developed  and  outcomes  improved  in  this  especially  large  population  of   183 
vulnerable patients.  Small changes applied across a large, vulnerable, population can make 
a  considerable  change  to  outcome.    The  safe  and  effective  provision  of  haemodialysis 
vascular access therefore remains an area in which considerable improvements in the health 
of renal patients may be made in the future. 
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